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Historical background 
 
The tragic beauty of retinal disorders has captivated ophthalmologists ever since the 
introduction of the ophthalmoscope by von Helmholtz in 1851.1 His “Augenspiegel” was 
accepted quickly by nearly every prominent European ophthalmologist. However, some 
remained sceptic, as recounted by von Helmholtz in his lecture “Das Denken in der Medicin” 
in 1877:2     
 
“Mit bezug auf den Augenspiegel sagte mir ein hochberühmter 
chirurgischer Kollege, er werde das Instrument nie anwenden, es sei zu 
gefährlich, das grelle Licht in kranke Augen fallen zu lassen, ein anderer 
erklärte, der Spiegel möge für Ärzte mit schlechten Augen nützlich sein, er 
selbst habe sehr gute Augen und bedürfe seiner nicht.” 
 
Following the discovery of the ophthalmoscope, knowledge and understanding of many eye 
conditions increased rapidly in what became known as “the golden age of ophthalmology”. In 
less than a decade, a variety of disorders were described, including retinal detachment 
(Coccius 1853), the cupped disc in glaucoma (Von Graefe 1855) and diabetic retinopathy 
(Jaeger 1856). The first description of retinitis pigmentosa is generally ascribed to the Dutch 
ophthalmologist Donders in 1855,3 although earlier reports, indicative of the same disorder, 
date as far back as 1744. At that time, Ovelgün described a familiar form of night blindness 
that closely resembled the disorder that would become known as retinitis pigmentosa.4 In 
addition, both Schon in 1828 and Ammon in 1838 mentioned the unusual combination of 
poor vision and pigmentary abnormalities of the retina.4 Although the term “retinitis” is a 
misnomer, the attempts of many authors to rename the disorder remained unsuccessful, 
perhaps with the exception of Leber who suggested the term 
“tapeto-retinal degeneration” in 1916.  
 In 1909, the German ophthalmologist Karl Stargardt 
(Fig. 1) described a macular dystrophy in seven patients from 
two families with visual loss beginning in the first two decades 
of life. These patients often revealed a normal fundus, but over 
time he observed the development of macular atrophy with 
yellowish retinal flecks.5 This typical form of juvenile macular 
degeneration was soon named Stargardt(‘s) dystrophy. The term 
fundus flavimaculatus was introduced half a century later, when 
Franceschetti described a similar disorder with a larger number 
of flecks that extended into the peripheral retina.6 Despite the 
typical ophthalmoscopic findings and the, seemingly, milder 
clinical course with a later age of onset, many were convinced 
that this was actually a variant of Stargardt disease and 
considered these terms interchangable.7,8 In fact, the original 
illustrations of two of Stargardt’s patients revealed that their 
flecks were also present in the midperiphery, but Stargardt published only the central fundus 
of another patient. Rosehr later published the drawing of the second patient, which showed 
widespread flecks.7,9 
 Over the years, a number of tests were devised to assess the specific functional 
abnormalities in inherited retinal disorders. These include the psychophysical tests aimed to 
evaluate colour vision, visual fields and dark adaptation, but most importantly, the 
electroretinogram (ERG) and, to a lesser extent, the electro-oculogram (EOG).  The fact that 
the electroretinogram (ERG) is abnormal or even nonrecordable in patients with retinitis 
Figure 1.  
Karl  Stargardt (1875-1927). 
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pigmentosa was demonstrated by Karpe in 1945.10 Following the introduction of setting 
conditions in ERG testing that enabled separate evaluation of rod and cone photoreceptor 
function, many patients with retinitis pigmentosa were shown to exhibit more severely 
affected scotopic (rod) tracings than photopic (cone) tracings.4,11 In fact, the diagnosis rod-
cone dystrophy came to be synonymous with retinitis pigmentosa, to the point where, for 
some clinicians, only a nonrecordable or abnormal ERG in a rod-cone pattern was considered 
consistent with the diagnosis retinitis pigmentosa.4 Around that time, Berson and colleagues 
published an article on patients with progressive cone-rod dystrophy whose ERG patterns and 
clinical features were generally not regarded as being related to retinitis pigmentosa.12 The 
issue became complicated when Heckenlively reported 20 cases who met most of the criteria 
of retinitis pigmentosa but with cone-rod patterns on the ERG.13 Nevertheless, it became 
generally accepted that the psychophysical schemes correlate with the “rod-cone” and “cone-
rod” types of photoreceptor dysfunction on the ERG, although exceptions may occur.  
 
More than a decade after the invention of the ophthalmoscope, Gregor Mendel published the 
results of his breeding experiments on garden peas. With these results, the Austrian monk was 
the first to demonstrate the existence of genes and the way they are inherited. In the 
subsequent development of human genetics, ophthalmology has played an important role. In 
1911, the noted cytologist Wilson deduced that the gene involved in colour vision deficiency 
was located on the X-chromosome and was thereby the first to map a disease to a specific 
chromosome.14 Another example, although many more may be given, concerns the first 
textbook on human genetics, which was written by the ophthalmologist and geneticist 
Waardenburg in 1932.15  
The age of molecular genetics in retinal disease was heralded by Bhattacharya and co-workers 
when they mapped an X-linked retinitis pigmentosa gene on the short arm of the X-
chromosome in 1984.16 Six years later, mutations in the rhodopsin gene were implicated in an 
autosomal dominant form of retinitis pigmentosa.17 Since then, extraordinary progress has 
been made in the identification of ophthalmic disease genes. To date, more than 100 genes 
responsible for human retinal dystrophies have been identified (RetNet, 
http://www.sph.uth.tmc.edu/RetNet/), and for many of these genes we have gained significant 
insights into their role in inherited retinal disease.  
 
 
Structure and function of the retina 
 
The complex neurosensory layer of the retina contains both the light-sensitive photoreceptors 
(rods and cones) and a specialized circuit of neural cells. Much of the construction of a visual 
image takes place in the retina itself, through the use of these intricate neural circuits. In this 
respect, the retina is a true nervous centre. This is not surprising, since the retina develops 
from a pouch of the embryonic forebrain and must therefore be considered part of the brain.  
 
Anatomical and functional aspects 
It would take many pages to even begin to explain the complex anatomical and functional 
aspects of the human retina. This discussion will therefore be limited to the essentials.  
 From an anatomical perspective, three distinct cell layers can be recognized in the 
neural tissue (Fig. 2). The outer nuclear layer (ONL) is composed of the bodies of 
photoreceptor cells. The inner nuclear layer (INL) consists of second and third-order neurons, 
such as 11 types of bipolar cells, as well as horizontal and amacrine cells. The ganglion cell 
layer (GCL) is the third layer and consists of approximately 20 types of ganglion cells. The 
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axons of these cells form the nerve fibre layer (NFL) and give rise to more than a million 
optic nerve fibers.18  
These cellular layers are separated by two regions that are virtually empty of cell bodies, but 
are rich in sites of contact between neurons. In the outer plexiform layer (OPL), also referred 
to as the outer synaptic layer, the photoreceptors make contact with the bipolar and horizontal 
cells. In the thicker inner plexiform layer (IPL), or inner synaptic layer, the bipolar cells, 
ganglion cells and other cell classes make synaptic contacts.  
 
 
 
 
Figure 2. Radial section 
of the human retina. The 
pigment epithelium (RPE) 
is the lightly pigmented 
band at the bottom of the 
picture. The microvilli of 
the pigment epithelium 
connect with the 
photoreceptor outer 
segments (POS). These are 
parallel to each other, but 
bent at an angle (artefact). 
The outer nuclear layer 
(ONL) is composed of the 
bodies of rods and cones. 
This photograph shows 
four very pale nuclei of 
cone cells (*); the rest of 
the nuclei, the dark ones, 
are rod nuclei. Few 
ganglion cells are visible 
in the ganglion cell layer 
(GCL), but four bundles of 
axons (†) can be observed 
in the nerve fibre layer 
(NFL). The cellular layers 
are separated by the outer 
and inner plexiform layers 
(OPL and IPL). 
 
 
   
 Functionally, the so-called vertical pathway may be separated from the laterally 
integrating interneurons. The vertical pathway generates primarily excitatory signals which 
are eventually transmitted to the brain. This pathway consists of photoreceptors, bipolar cells 
and ganglion cells. The laterally integrating interneurons may be divided into two major 
classes, according to the layer of the retina where their synaptic connections are located. The 
first type is composed of horizontal cells, which have their terminals in the outer synaptic 
layer. These cells provide lateral inhibition, which causes the activation of the bipolar cells to 
depend more on differences in light intensity within the image, such as the borders of objects, 
than on the overall level of light intensity. The second class is formed by the amacrine cells. 
These cells connect exclusively in the inner synaptic layer. There are many types of amacrine 
cells, which vary greatly in morphology and function, but with few exceptions, their specific 
roles remain uncertain.19 
NFL
GCL
IPL
INL
OPL
ONL
POS
RPE
* * * *
† †††
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 Intuitively, one might expect the photoreceptors to be at the surface of the retina, but 
in fact, light has to pass through the entire neurosensory retina before reaching the rods and 
cones. This has the advantage that the photoreceptor cells are able to directly contact the 
underlying monolayer of supportive pigment cells: the retinal pigment epithelium (RPE). 
These layers, the photoreceptors and the RPE, and especially their functional relation are 
highly relevant to this thesis.  
 
Photoreceptors and retinal pigment epithelium 
Rods and cones are found in every vertebrate retina. In humans, only 5% of the 
photoreceptors are cones, the remaining 95% being rods. Whereas most mammals have only 
two types of cones, primates have three different cone types. These three cone types possess 
different spectral sensitivities. S-cones are most sensitive to photons at the high (short 
frequency) end of the visible spectrum. M-cones and L-cones are most sensitive to medium 
and low frequencies of visible light, respectively.  
Cones and rods are not equally distributed throughout the retina (Fig. 3). The fovea contains 
only cones; in this area, the inner and outer segments of the cones are thinner than elsewhere 
in the retina. In the peripheral retina there are many more rods than cones, but because the 
diameter of the inner segments of the cones increases, they still cover 20-25% of the area.   
Rods have the capacity to register the capture of even a single photon, which makes them 
perfectly suited to operate in dim light. Under dark circumstances, where the human eye can 
barely detect different objects, the rate at which each rod is catching photons is about once 
every 85 minutes.20 Cones, on the other hand, are adapted to operate in the brighter conditions 
of daylight. A patch of snow in sunlight at high elevations is, other than direct reflections 
from the sun, about the brightest thing we can see. In those circumstances, each of the foveal 
cones is catching about 300.000 photons per second.20 
Figure 3. The spatial density of rods and cones in the retina. In the human eye there are 4-6 
million cone photoreceptors with high concentration in the central retina. Rod photoreceptors are 
more numerous, 78-110 million rods are found throughout the retina, with the exception of the 
very central region. 
 
 
 Photoreceptor cells contain an inner and an outer segment. The inner segment holds 
the cell organelles necessary for the metabolism of the cell, whereas the outer segment is 
specialized in the conversion of light into an electric signal. In rod photoreceptors, the outer 
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segment is stacked with flattened membranous discs (Fig. 4).  These discs are derived from 
the surface membrane but are no longer continuous with the surface membrane or with each 
other. In cones, the outer segment discs are actually infoldings of the surface membrane of the 
cell (Fig. 4).  
 
 
 
 
 
 
 
 
Figure 4. Schematic representation of 
rod (left) and cone (right) photoreceptor 
(not in scale). In this diagram, the 
pigment epithelium is located near the 
top and light reaches the outer segments 
from below. Contrary to cones, the disc 
membranes of the rod photoreceptors 
are not continuous with the plasma 
membrane. 
The inner segment consists of a 
prominent mitochondria-rich region 
called the ellipsoid, and an area 
between the ellipsoid and nucleus, the 
myoid, that contains the Golgi 
apparatus and the endoplasmatic 
reticulum.  
 
 
 
 
The photoreceptor disc membranes contain a number of unique proteins. The structural 
proteins peripherin/RDS and ROM-1, located at the disc rim, are important in stabilizing the 
structure of the disc. The ABCR or rim protein is involved in the transport of all-trans-retinal. 
The majority of remaining disc proteins, notably rhodopsin in rod photoreceptors, is involved 
in photon catching and subsequent amplification of this signal. In both rods and cones, the 
visual pigment in the membrane discs consists of an apoprotein, opsin, linked to a 
chromophore, 11-cis-retinal. The spectral characteristics of a particular pigment are 
determined by its specific opsin. Upon absorption of a photon, 11-cis-retinal isomerizes to the 
all-trans-retinal form (photoactivation). This is the first step in the excitation phase of 
phototransduction, which, through several steps, leads to membrane hyperpolarisation and 
neurotransmitter release at the photoreceptor terminal synapse. The recovery phase of 
phototransduction involves active turnoff and recycling of the transduction components.21,22 
An important aspect is the re-isomerization of all-trans-retinal to 11-cis-retinal, a process that 
is commonly referred to as the visual pigment cycle (Fig. 5). For rod photoreceptors, an 
important part of this chromophore regeneration takes place in the RPE. After release  by the 
activated rhodopsin molecule, all-trans-retinal is actively removed from the interior of the rod 
disc membrane by the ABCR protein, although free diffusion might also occur.23-25 In the 
cytoplasmic space all-trans-retinal is reduced to all-trans-retinol and subsequently transported 
to the RPE. In several steps all-trans-retinol is then converted to the 11-cis-retinal 
chromophore, which is recombined in the photoreceptor outer segment with opsin to yield a 
light sensitive rhodopsin molecule. 
Outer segment
Nucleus
Inner segment
Ellipsoid
Myoid
Synaptic terminal
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Analysis of the retinoid turnover, however, reveals that this visual cycle may be too slow to 
keep up with chromophore demand under daylight conditions. Recently, a novel pathway for 
visual pigment regeneration was suggested for cone photoreceptors that involves the all-trans 
to 11-cis re-isomerization in the Müller cells of the retina.26,27  
all-trans-retinol
all-trans-retinal
CH2OH
CH3
CH3
CH3CH3CH3
rhodopsin 
(11-cis-retinal + opsin)
Rod outer segment
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Figure 5. The visual cycle of retinoids in rod photoreceptors and retinal pigment 
epithelium (RPE). Vision begins when light induces the isomerization of the 11-cis–retinal 
chromophore. Rhodopsin is transformed into metarhodopsin II (not shown), which decays 
into opsin (apo-rhodopsin) and all-trans-retinal after several seconds. The ABCR protein 
subsequently acts as an outward directed flippase for all-trans-retinal. Once in the 
cytoplasm, all-trans-retinal is reduced to all-trans-retinol (vitamin A). This substance is 
released from the photoreceptor and taken up by the RPE where it is esterified to an all-
trans-retinylester. Through various intermediates 11-cis-retinal is formed which is 
recombined in the outer segment with opsin to yield a light sensitive rhodopsin molecule. 
 
 
 Like the neuroretina, the RPE is a derivative of the central nervous system and lies in 
close approximation to the photoreceptor outer segments. The RPE has a variety of functions; 
with regard to this thesis, only two will be considered here. The critical role of the RPE in 
visual pigment regeneration has been discussed above. The second function involves the 
phagocytosis of rod outer segments. Photoreceptor outer segments are renewed at a constant 
rate. The older membrane discs are shed in a circadian rhythm and gradually replaced by new 
discs originating form the base of the outer segment. Every 24 hours the RPE engulfs and 
digests the distal 10% of the rod outer segments. Since each RPE cell contacts approximately 
45 outer segments, this amounts to several average sized cells every day, which makes the 
RPE cell the most active phagocytic cell in the human body.22 The shed outer segments are 
internalized in phagosomes, which merge with lysosomes, where the discs are digested. 
Undigested portions of outer segment material remain within RPE cells and accumulate to 
form lipofuscin granules, which collect as RPE cells age. 
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Functional assessment of inherited photoreceptor dystrophies 
 
In the 19th and early 20th century the diagnosis of inherited retinal receptor dystrophies was 
mainly based on a thorough clinical examination. A visual field test confirmed the diagnosis 
and was used for follow-up of the patient. With the advent of clinical ERG testing, a more 
detailed analysis of functional loss became possible. Currently, the visual acuity, 
ophthalmoscopic findings, the visual field and the ERG, supplemented with pedigree analysis, 
are the main tools in the management of inherited retinal dystrophies. Additional tests, 
however, may provide important information on the nature of the disorder. These tests include 
the electro-oculogram (EOG), dark adaptation, colour vision tests, and fluorescein 
angiography. In selected cases molecular genetic analysis may also be utilized. 
  
 
 
 
  
Figure 6. Dark 
adaptation curve. The 
initial phase is 
determined by the 
cones as they recover 
their sensitivity. A 
characteristic rod-
cone break can be 
seen at 9-11 minutes 
when rod sensitivity 
becomes more 
prominent. At 30-40 
minutes maximal 
dark adaptation is 
achieved. 
 
 
  
By definition, psychophysical testing relies on a behavioural response to a stimulus. Besides 
assessment of the visual acuity, the visual psychophysics include visual field testing, dark 
adaptation and colour vision tests. Investigation of the visual field may be performed with 
either static or kinetic stimuli. It is used to locate regions in the visual field that show absent 
or decreased sensitivity. Dark adaptation tests measure the threshold of sensitivity of the 
retina to a spot of light after the patient is placed in the dark. A degree of standardization can 
be attained by initially giving a light bleach and by using cycloplegia to eliminate potential 
variability caused by accommodation. The test spot is commonly 12º above fixation. Every 1 
or 2 minutes the spot is varied until the value is identified where the patients can just perceive 
the light. In a typical dark-adaptation curve (Fig. 6), the greater sensitivity of the rods 
becomes apparent after 9-11 minutes (the cone-rod break). After approximately 30 to 40 
minutes the rods have reached their maximum sensitivity. This test is time consuming and 
may be difficult for the patient. An alternative is to measure the final dark-adapted threshold. 
Colour vision tests can demonstrate abnormalities in many retinal disorders that affect cone 
photoreceptors. Protanomaly, deutanomaly and tritanomaly indicate abnormalities in 
respectively the red, green and blue cones. Receptor anomalies in the macular area often lead 
to colour disturbances resembling protan abnormalities, whereas abnormalities elsewhere in 
the retina may result in acquired tritan-like abnormalities. However, since colour vision is not 
fully understood, the interpretation of the test results may prove to be difficult. 
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Figure 7. Impressions of ERG recordings in normal subjects according to ISCEV standard protocol. 
A. Maximal response to standard achromatic flash (2.0 log phot td-s) in dark-adapted state. B. 
Scotopic ERG, rod response to weak blue flash (-0.1 log scot td-s). C. Photopic ERG, light-adapted 
(background 1.5 log cd/m2) cone response to standard achromatic flash. D. 30-Hz flicker response 
to standard achromatic flash.  
 
 
 The ERG and EOG are electrophysiologic tests. The ERG is a response evoked from 
the retina by a flash of light. By varying the stimulus conditions the function of cone and rod 
photoreceptor systems may be evaluated separately. A typical full-field ERG response (bright 
flash dark-adapted) is biphasic, with the first negative peak called the “a-wave” and the next 
positive peak called the “b wave” (Fig. 7-A) The “a-wave” represents repolarization of the 
photoreceptor cells; while the “b-wave” is derived form the cells in the bipolar region of the 
middle retinal layers. 
The ERG is highly responsive to minor changes in test conditions. For this reason, the 
International Society for Clinical Electrophysiology of Vision (ISCEV) has developed a 
standard for clinical electrophysiology.28 The ISCEV standard specifies four responses of 
particular relevance to inherited photoreceptor dystrophies. Both rod and cone systems can be 
stimulated by using a bright flash in a dark-adapted state (Fig. 7-A). In a normal subject, 
approximately 70% of the amplitude is generated by rods. This maximal response may be 
used in follow-up, especially when the scotopic ERG is nonrecordable.29  To measure the rod 
system response, the patient is dark-adapted for 45 minutes and a dim blue or white light is 
utilized that is below the threshold for eliciting a cone response (Fig. 7-B). The photopic ERG 
is obtained in a light adapted state. This causes the rods to be bleached out, leaving only the 
cones to respond to the flash stimulus (Fig. 7-C). In addition, cones can be stimulated by an 
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achromatic stimulus flickering at 30 Hz, which exceeds the flicker fusion frequency of rods 
(Fig. 7-D). It is important to realize that the ERG represents a mass response of the outer and 
middle retinal layers and does not correlate with the visual acuity or localized retinal 
pathology. 
 The EOG measures the standing potential, which exists between the front and back of 
the eye. It originates in the RPE and the signal changes with light adaptation. In general, the 
amplitude in the light adapted state is about twice as high as in the dark. The test results are 
reported as the light peak/ dark trough ratio, also referred to as the Arden ratio. These values 
typically range from 1.75 to 2.20, although each laboratory has to establish its own reference 
values.30,31 The EOG is useful in a number of conditions with pathology of the RPE, notably 
Best disease, but in retinitis pigmentosa and allied disorders it tends to duplicate information 
obtained from the ERG and dark adaptation tests.29 
 In selected cases, fluorescein angiography may be used, although this is not really a 
functional test. Its primary use in the evaluation of retinal photoreceptor dystrophies lies in 
the evaluation of the location and extent of RPE atrophy. In addition, specific abnormalities 
may be evaluated, such as cystoid macular edema in retinitis pigmentosa and blocking of 
choroidal background fluorescence in Stargardt disease and other ABCA4-associated 
disorders.    
 
 
Classification of inherited photoreceptor dystrophies 
 
Most systems of classification separate stationary retinal disease (such as congenital 
stationary night blindness (CSNB) and rod monochromatism) from progressive photoreceptor 
dystrophies. The latter category may be subdivided into peripheral degenerations, in which 
the rods seem to be the primary target of disease, and central degenerations, in which the cone 
photoreceptors seem initially affected. The majority of retinal disorders that primarily affect 
the rod system are known collectively as retinitis pigmentosa, also called rod-cone dystrophy. 
Central degenerations may be further divided into disorders that remain confined to the 
posterior pole, the macular dystrophies, and those that also affect the peripheral retina in the 
course of the disease, such as cone and cone-rod dystrophy.  
 Attractive as this may seem, there are inherent problems with such a system of 
classification. It is recognized that both rod and cone photoreceptor systems are compromised 
in most, if not all, retinal photoreceptor dystrophies.32 These disorders comprise a spectrum of 
diseases ranging from predominantly cone-mediated disorders to predominantly rod-mediated 
disorders. Clinical studies have shown that many intermediate disorders exist, in which there 
is varying involvement of both systems. This complicates classifications that use selective 
photoreceptor involvement as a major criterion. In addition, in many macular dystrophies, 
there is evidence of a more widespread retinal involvement. Finally, since broad criteria are 
applied, this inherently results in heterogeneous patient groups. This does not only apply to 
the clinical features, but also to the genetic defects and pathophysiologic mechanisms, as 
molecular genetic research has clearly demonstrated.   
 It is evident that clinical research alone has not achieved a satisfactory system of 
classification. The main obstacle seems to be a lack of understanding of the pathophysiology 
of retinal photoreceptor dystrophies. For this reason, a classification based on molecular 
genetic findings may be preferable. Identification of the causative gene alone, however, may 
not suffice, because different mutations in a single gene may result in remarkably different 
forms of retinal disorders. This may be illustrated by the striking variation in phenotypes 
ensuing from mutations in genes such as RDS/peripherin and ABCA4. In addition, as yet 
unidentified genetic or environmental modifying factors may be of influence on the final 
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phenotypic outcome. A better understanding of all the factors involved is essential before a 
classification solely based on the genotype will become useful. Until that time, a clinical 
diagnosis that includes the underlying genetic defects seems the best alternative.    
 
 
Clinical features of inherited photoreceptor dystrophies 
 
Inherited photoreceptor dystrophies may be grouped in several ways. We will distinguish 
three main categories as outlined above: 1. rod-cone dystrophies (primarily retinitis 
pigmentosa); 2. cone dystrophies and cone-rod dystrophies; 3. macular dystrophies.  
 
Rod-cone dystrophies 
Patients with retinitis pigmentosa comprise the most widely recognized group of patients with 
inherited retinal disorders. It should be regarded as a phenotypic description of several related 
dystrophies of the photoreceptors and the pigment epithelium. All Mendelian patterns of 
inheritance have been found in these disorders.  
By definition, retinitis pigmentosa is a progressive disorder. Both rod and, in most types, cone 
photoreceptors are affected early in the course of this disease. Eventually, loss of 
photoreceptor elements leads to widespread atrophy of most of the retinal layers. Although 
the clinical findings may be highly variable, these patients typically demonstrate night 
blindness and progressive loss of the peripheral visual field early in the course of their 
disease. The typical ophthalmoscopic features of this dystrophy include hyperpigmentation of 
the RPE in the form of “bone spicules” that alternate with atrophic regions, attenuation of the 
retinal arterioles, and waxy pallor of the optic nerve head. The ERG is the most critical 
diagnostic test for retinitis pigmentosa because it provides an objective measure of rod and 
cone function across the retina. The full-field ERG typically shows a marked reduction of 
both rod- and cone-mediated responses, although rod loss generally predominates. In the later 
stages of the disorder, cone and rod tracings often become nonrecordable. Visual field testing 
is useful for follow-up care of patients with retinitis pigmentosa and typically shows midzonal 
defects (ringscotomas) in the early stages of the disorder. The dark adaptation is generally 
disturbed.4,33-36 
Retinitis pigmentosa may be encountered either in isolated form or in association with 
systemic abnormalities. Systemic conditions associated with pigmentary retinopathy are 
numerous. Some of the well-known syndromes include: Usher, neuronal ceroid lipofuscinosis 
(a group of recessive lysosomal storage disorders, including Vogt-Spielmeyer-Batten 
disease), abetalipoproteinemia (Bassen-Kornzweig syndrome), peroxisomal disorders (such as 
Zellweger syndrome and Refsum disease) and mitochondrial disorders (Kearn-Sayre).  
 Besides the large group that is referred to as retinitis pigmentosa, a few other 
peripheral retinal degenerations with primarily or initial involvement of rod photoreceptors 
have been discerned. These disorders, such as Bietti crystalline dystrophy, gyrate atrophy and 
choroideremia, all display a unique fundus appearance that enables a separate clinical 
classification.   
 
Cone and cone-rod dystrophies 
Progressive cone dystrophy usually present in adolescence or early adult life. Predominant 
symptoms are progressive loss of visual acuity, pronounced photophobia and day blindness. 
In addition, a fine nystagmus may be found in these patients.  In contrast with other macular 
disorders, colour vision abnormalities, usually of the red-green type, are present early in the 
course of the disease. The aforementioned symptoms often precede the fundus abnormalities, 
which include a bull’s eye maculopathy or, less frequently, granular pigment alterations in the 
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posterior pole. Rarely, a central atrophy of RPE with exposure of the larger choroidal vessels 
may be found. Visual field testing shows central scotomas, sometimes with relative central 
sparing; the peripheral visual field remains unaffected. The ERG shows loss of the cone-
mediated responses with normal rod-mediated responses.37 A substantial number of patients 
that are initially diagnosed with progressive cone dystrophy will eventually progress to a 
cone-rod dystrophy, with abnormalities in the rod mediated ERG recordings and sometimes 
night blindness. 
Many cases of progressive cone dystrophy are sporadic. In patients with a family history, 
autosomal dominant inheritance is most common, although autosomal recessive and X-linked 
forms have been described.37-39 
 In patients with cone-rod dystrophy, the rod photoreceptors are also affected, but their 
symptoms are overshadowed by the abnormalities of the cones, especially in the early stages 
of the disorder. The initial symptoms therefore resemble progressive cone dystrophy and most 
patients do not develop night blindness until the later stages of the disease. In addition to the 
macular abnormalities described in cone dystrophy, midperipheral fundus abnormalities may 
be observed, indicative of a more widespread retinal degeneration. These abnormalities 
include mild attenuation of the retinal vessels, and mild bone spicules or dust-like 
pigmentations. Atrophy of the RPE may occur in the macula, but may extent beyond the 
vascular arcades. Initially, the visual field demonstrates a central scotoma; eventually, partial 
ringscotomas and large paracentral scotomas may be found, as well as mild peripheral 
constriction. The ERG is crucial in the diagnosis and typically demonstrates a more severe 
reduction in cone-mediated responses compared with rod-mediated responses. Nevertheless, 
some patients demonstrate equally reduced cone and rod ERG recordings, despite an 
otherwise typical presentation. Most cases with cone-rod dystrophy are either isolated or 
inherited in an autosomal recessive fashion, but all inheritance patterns have been 
demonstrated.12,38,40-42 
 
Macular dystrophies 
A variety of dystrophies, principally located at the macula, can be distinguished according to 
fundus appearance and inheritance pattern.43,44 Despite the term “macular dystrophies”, which 
suggests localized pathology, many of these disorders are at a molecular level panretinal 
disorders, in which the macular region shows greater susceptibility to the degeneration. This 
can be argued for Stargardt disease, as demonstrated in Appendix 6, as well as for Best 
disease, where the EOG abnormalities also indicate a more widespread retinal dysfunction.45 
Age-related macular degeneration (AMD) may be considered the most prominent of these 
disorders, since this is the leading cause of severe visual loss in patients over 65 years of age 
in the western world. There is strong evidence that this is a complex disorder in which a 
variety of genetic and environmental factors influence the final phenotypic outcome.46 Like 
Stargardt disease, AMD will be discussed in Chapter 2.  
The majority of the macular dystrophies demonstrate an autosomal dominant inheritance 
pattern, with AMD, X-linked juvenile retinoschisis and autosomal recessive Stargardt disease 
as the most important exceptions.47,48 Among the most renowned autosomal dominant 
macular dystrophies are Best disease (vitelliform macular dystrophy), adult-onset vitelliform 
macular dystrophy, the pattern dystrophies, autosomal dominant drusen, central areolar 
choroidal dystrophy and Sorsby fundus dystrophy. Although these disorders are all 
characterized by a loss of central vision and atrophy of the macula and underlying RPE, they 
are highly heterogeneous with regard to the clinical findings and the underlying genetic cause. 
They will not be discussed here in greater detail; for additional information on both the 
clinical and genetic aspects, the reader may consult references 43, 44, 46 and 47. 
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Introduction to molecular genetics 
 
Basic principles of human genetics 
The genome is defined as an organism’s complete set of DNA (deoxyribonucleic acid). 
Genomes vary widely in size: the smallest known genome for a free-living organism (a 
bacterium) contains about 600.000 base pairs, while haploid genomes of higher developed 
organisms such as humans and mice, have some three billion base pairs. Almost all DNA in 
the human genome is arranged in 22 pairs of autosomes and two sex chromosomes (X and Y). 
The pairs of autosomes are homologous, meaning that they carry almost identical DNA 
sequences. The two sex chromosomes may be fully homologous (XX) or partially 
homologous (XY). A small amount of DNA is also present in mitochondria. Human 
mitochondrial DNA is 16.569 base pairs in length and contains 13 recognizable genes that 
code for polypeptides.  
Each chromosome ranges in length from about 50 million to 250 million base pairs. In the 
chromosomes, DNA is organized in a double-stranded helix containing two longs chains of 
nucleotides (an organic base, a pentose and a phosphorus group). Nucleotides contain one of 
four different organic bases: adenine (A), thymine (T), guanine (G) and cytosine (C). The two 
DNA chains of the double helix are held together by the weak hydrogen bonds between the 
base pairs of the opposite strands. Since A only pairs with T and G only with C, the two 
strands have complementary sequences.  
 Genes are specific sequences of nucleotides that encode instructions on how to make 
proteins (or RNA). All twenty different amino acids that are found in proteins are encoded in 
the nucleotide sequence. It takes three bases to specify an amino acid; the specific relation 
between these triplets of bases and specific amino acids is known as the genetic code. 
Latest estimates from gene-prediction programs suggest that there might be 24.500 protein-
coding human genes.49 The distribution of genes is not random; each gene has a specific 
location, a locus, within the chromosome. In eukaryotic organisms most structural genes 
consist of a set of coding regions (the exons) separated by noncoding regions (the intervening 
sequences (IVS) or introns). In contrast to simple organisms such as bacteria, genes in 
humans show enormous variation in size and internal organisation. The size may vary in 
length from hundreds to several millions of bases (megabases), which is often, but not always, 
reflected in the size of their product. In larger genes, the size of an intron tends to be 
proportionally large. The average exon size, however, is about 170 base pairs and, although 
very large exons are known, exon size is comparatively independent of gene size. 
The symbols assigned to human genes consist of up to four letters that reflect a feature of the 
condition that is determined by the gene. 
 The first step in the creation of the protein that is encoded in a strand of DNA is the 
transcription of DNA in messenger RNA (mRNA), as depicted in Figure 8. Apart from 
structural differences, such as the replacement of thymine by uracil (U) and ribose as sugar 
component, the information in a single strand of mRNA is an exact copy of the coding DNA 
strand. This primary RNA, however, still contains both introns and exons. In mRNA splicing, 
the noncoding introns are removed and the exons are spliced together to form the final, edited 
mRNA. The splice sites form the boundaries between introns and exons and demonstrate 
certain invariable features: intronic regions almost always begin with the dinucleotide GT (the 
splice donor site) and end with AG (the splice acceptor site). 
Once in the cytoplasm, the strand of mRNA forms the template for producing a specific 
sequence of amino acids. This translation process takes place in the ribosomes and requires 
another form of RNA called transfer RNA (tRNA). As mentioned, a triplet of nucleotide 
bases in the mRNA encodes a specific amino acid. The order of these triplets, or codons, is 
known as the translational reading frame. Termination of the translation of RNA is signalled 
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by the presence of one of three stop codons. As a final step, the long chain of amino acids 
often undergoes post-translational modification, such as glycosylation, hydroxylation or the 
proteolytic cleavage of polypeptides, to attain the functional protein structure.50-53 
 
 
 
 
 
 
 
Figure 8. From DNA to 
protein. The first step 
involves transcription of DNA 
into primary RNA. Removal 
of the non-coding introns 
from the primary RNA and 
splicing of the remaining 
exons result in the formation 
of mRNA. Newly processed 
mRNA is transported from the 
nucleus to the ribosomes in 
the cytoplasm, where the 
protein is synthesized. 
 
 
 
 
 
Inherited disorders 
By definition, genetic disorders are caused by abnormalities in the genetic material. Four 
types may be distinguished: monogenic, multifactorial, chromosomal and mitochondrial. 
Monogenic (also called single-gene or Mendelian) disorders are caused by mutations in the 
DNA sequence of one gene. There are more than 6000 known monogenic disorders, which 
occur in about 1 out of every 200 births. These disorders are inherited in the characteristic 
Mendelian modes of inheritance: autosomal dominant, autosomal recessive and X-linked. 
Multifactorial (also called complex or polygenic) disorders are caused by a combination of 
mutations in multiple genes as well as environmental factors. These mutation are not always 
present from conception but may also be acquired during life. Multifactorial disorders are the 
major causes of morbidity and include diabetes mellitus, diabetes mellitus, cancer, and 
Alzheimer disease. Chromosomal disorders are characterized by gross abnormalities in the 
chromosomal structure, such as missing or extra copies, large breaks, and rejoinings 
(translocations). Finally, a rare type of genetic disorder involves mutations in the 
nonchromosomal DNA of the mitochondria. Leber hereditary optic neuropathy is a well-
known example of such a disease. Mitochondrial disorders are transmitted exclusively from 
the mother, but may affect both men and women. 
 
Mutations 
Any change in the genetic material may be considered a mutation. This change leads to a 
variation in the nucleotide sequence of a gene and these alternative forms of a gene are called 
alleles. The most common (“normal”) allele at a gene locus is addressed as the “wild-type” 
allele. Some genes have more allelic forms. These so called multiple alleles may be dominant 
or recessive to the normal allele. For example, different alleles may be involved the colour of 
the iris, and this is also the case in the ABO blood group system.   
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Although the term mutation is often used for those allelic variations that cause disease, it is 
more appropriate to name these variants “pathogenic” or “disease-causing mutations.” 
Alternatively, if an allele is not associated with disease, and is relative frequent (1%, or 
more), it is referred to as a polymorphism. If the frequency is lower, then the term rare variant 
is applied. 
 Mutations may occur anywhere in the genome of an organism. Since most of our DNA 
does not encode gene products, many mutations will have no impact on cellular functions. 
However, mutations in exons of a structural gene may alter the gene product and lead to a 
pronounced change in the phenotype. 
Mutations can be divided into several classes. Base pairs may be deleted, inserted or, most 
commonly, substituted by another base pair. Besides these stable or fixed mutations, a new 
class of mutations have been identified: the unstable or dynamic mutations. These consist of 
an increased number of triplet repeat sequences, which has been identified as the mutational 
basis for a number of different single gene disorders. 
Mutations may also be subdivided according to their structural effect on proteins. Single base 
pair substitutions may lead to the replacement of the original amino acid by another amino 
acid, a so-called missense mutation. In nonsense mutations, the amino acid codon is replaced 
by a stop codon and the protein will be prematurely terminated. Nonsense mutations are 
usually associated with severe phenotypic abnormalities. In splice site mutations a conserved 
splice site is destroyed or a new, alternative, splice site is created, resulting in altered exons or 
exon skipping. Often, these mutations occur in the highly conserved GT and AG nucleotides, 
located at respectively the splice donor and splice acceptor site. Finally, deletions, insertions 
and abnormal splicing may all cause a frameshift. Such mutations involve the insertion or 
deletion of nucleotides that are not a multiple of three and thereby cause a shift in the 
translational reading frame. This results in a complete novel sequence of amino acids bearing 
absolutely no resemblance to the original protein.52,53 
   
Mutation screening and detection assays 
Mutation testing methods can be divided into two groups: mutation screening and mutation 
detection.   
 In mutation screening tests, a sample is screened for any deviation from the standard 
sequence. Single strand conformational polymorphism analysis (SSCP) is one of the most 
widely used screening tests. It is based on the principle that each denaturated single-stranded 
DNA molecule assumes a three dimensional conformation upon renaturation that is dependent 
on the primary nucleotide sequence. In SSCP, the exons and their flanking regions, and 
perhaps other areas of interest of a cloned gene, are amplified by PCR (polymerase chain 
reaction).  Samples of these DNA fragments from affected and some unaffected individuals 
are denaturated and electrophoresed. If two DNA molecules, representing the same genetic 
region, differ by a single nucleotide pair, this will influence the conformation of these strands, 
resulting in a different migration pattern during gel electrophoresis. Side-by-side comparison 
of affected and unaffected individuals will quickly reveal nucleotide alterations in a specific 
exon or region of a gene.  
Other conventional mutation screening tests are denaturing gradient gel electrophoresis 
(DGGE) and heteroduplex analysis (HA). Like SSCP, these tests are PCR based and rely on 
the difference in the nucleotide sequence in the genes of affected individuals compared with 
the same genetic region of individuals with a normal phenotype.54 
Once a mutation is detected with one of the screening assays, the segment with the mutation 
can be analyzed. Direct DNA sequencing determines the individual nucleotides of the specific 
DNA fragment, which can then be compared with the nucleotide sequence in the DNA 
segment without the mutation. 
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Figure 9. Principle of the ABCR400 microarray. Normal: ACGTGCGTAT; mutant: 
ACGTGCATAT A. Probe DNA molecules arrayed on the glass matrix. These oligonucleotides are 
designed with the 3’ immediately adjacent to the variable site (the GA transition; arrow). B. PCR 
prepared and fragmented sample DNA molecules are annealed to the DNA probes. The variable site 
in the mutant sample is encircled. C.  Nucleotide analogs (dideoxynucleotides) with fluorescent 
labels are used to tag the sample DNA. Four fluorophores are used, one for each type of nucleotide. 
D. Sample DNA and unused dye-labelled nucleotide analogs are washed off followed by signal 
detection (adapted from Jaakson et al.).55  
 
 
 Mutation detection methods test a DNA sample for the presence or absence of a 
specific mutation. A number of tests allow easy testing for a specified DNA sequence change, 
but a relative new technique that allows fast, cheap and reliable screening, is the DNA 
microarray (gene chip).  In principle, every DNA microarray analysis depends on the 
hybridization (the process of base pairing of two complementary single-strand DNA 
molecules) between bound DNA molecules (probes) and sample DNA. The gene chip 
currently employed in the screening for ABCA4 mutations, is the ABCR400 chip and contains 
over 400 mutations. This chip utilizes arrayed primed extension (APEX) technology (Fig. 9). 
In a recent study it was demonstrated that this microarray was more than 98% effective in 
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determining known ABCA4 gene variations.55 Again, it must be emphasized that these 
microarrays are not designed to detect new mutations.54,55 
 
Animal models of human disease 
Several animals may be used to study human genetic disease, including primates, rats and 
zebrafish, but the mouse model is most widely used. Transgenic mouse models may be 
divided into two broad categories.  In the first, structural genes (transgenes) are introduced 
into the mouse genome, where they will come to expression. In the second category, mouse 
genes are knocked out or a specific mutation is introduced (knocked in). A homozygous or 
heterozygous mutation is thus created, which provides the opportunity to study the 
consequences of the loss or the altered function of a specific mouse gene.  It must be kept in 
mind, though, that mouse models of human disease may develop phenotypes that are 
considerably different than the corresponding human phenotypes. For instance, the fact that 
mouse retina does not contain the equivalent of a macula, as well as differences in the lifespan 
between humans and mice, complicates the creation of a mouse model for macular disorders 
that occur later in life.     
 
 
Molecular genetics in inherited photoreceptors dystrophies 
 
In the past 15 years, genetic linkage and mutation detection analysis have been successfully 
used to identify the genes that are responsible for a number of eye diseases. Although most of 
these genes are retina specific, some are expressed in organs other than the eye and will often 
lead to syndromic forms of retinal degeneration.   
It soon became clear, as already suspected from clinical observations, that many retinal 
disorders demonstrate a remarkable genetic heterogeneity. This means that mutations in many 
different genes may result in phenotypically identical disorders. This is perhaps best 
illustrated by retinitis pigmentosa: for each of the Mendelian inheritance patterns of this 
disorder, a host of genes and loci have been reported.  
The converse of genetic heterogeneity is clinical heterogeneity, the finding that the type and 
location of mutations in a specific gene may result in dramatically different phenotypes. It 
may be difficult to predict the rate and extent of disease progression in a certain patient, even 
when other patients with abnormalities in the same gene have been studied. Rarely, different 
phenotypes are even encountered among family members with identical mutations.56 This, of 
course, suggests the existence of modifying factors, either in the genetic background or in the 
environment that influence the severity of the phenotype. A number of retinal disease genes 
display clinical heterogeneity. Mutations in the peripherin/RDS gene have been associated 
with digenic (with ROM-1) and autosomal dominant forms of retinitis pigmentosa, as well as 
macular dystrophies, such as pattern dystrophy, central areolar choroidal dystrophy and 
subtypes of autosomal dominant drusen.56-58 Other examples include the ABCA4 gene 
(Stargardt disease and autosomal recessive forms of cone-rod dystrophy and retinitis 
pigmentosa) and the arrestin gene (Oguchi disease and autosomal recessive retinitis 
pigmentosa).22  
 
The relevance of genotype-phenotype correlation 
A significant part of this work is dedicated to the comparison of the genomic sequence 
(genotype) with the clinical appearance (phenotype). Establishing more precise genotype-
phenotype relationships may improve our understanding of inherited photoreceptor 
dystrophies in several ways.59  
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1. Studying the effects of pathologic alterations in genes helps us to understand not only the 
disease mechanisms, but also the normal physiology of the retina. This may be illustrated by 
the pathophysiologic mechanism in Stargardt disease, which involves accumulation of 
lipofuscin.60 The new insights that were gained through the animal model of this disorder also 
seem to apply to AMD and the aging eye in general.60 
2. Currently, with very few exceptions, treatment options are nonexistent for patients with 
inherited retinal disorders.61,62 Our newly gained insights in genetic and biochemical 
mechanisms may be used to devise therapeutic interventions. Once developed, these treatment 
modalities may be tested in animal or in vitro models, designed with the specific genetic 
information acquired earlier. 
3. The identification of genetic abnormalities that lead to retinal disease may be used to 
improve diagnosis. Rapid and specific diagnostic tests, such as the microarray (Appendix 5) 
have been developed that enable the identification of disease-associated mutations.55,63 When 
the genotype-phenotype correlations are well defined, we may predict outcomes with a high 
degree of accuracy, years before those outcomes occur. In addition, we are able to make an 
early diagnosis in patients at risk; treatment or screening may then be instituted before the 
manifestation of symptoms. 
4. A more specific classification that includes the underlying genetic defect enables the 
definition of genotypically homogeneous patient populations. The benefits are obvious when 
specific retinal disorders are studied from a clinical point of view. Furthermore, genotypically 
homogeneous patient populations are essential in the rational evaluation of therapies. This 
may be illustrated by a large study in 1993, demonstrating a modest beneficial effect of 
vitamin A supplements in 601 retinitis pigmentosa patients.64 Since a variety of 
pathophysiological pathways lead to the retinitis pigmentosa phenotype, it is likely that a 
positive effect of vitamin A would be more obvious when tested in genotypically 
homogeneous populations of retinitis pigmentosa patients. Alternatively, potentially negative 
effects on genotypical subgroups, which may have been missed with the current study design, 
may become apparent.        
 
The molecular basis of photoreceptor dystrophies 
For many inherited photoreceptor dystrophies the responsible gene has been identified. 
Mechanistic studies, often involving transgenic animal models, have significantly improved 
our understanding of the pathophysiology in these disorders. A complete review of the 
underlying molecular mechanisms is beyond the scope of this general introduction. We will 
therefore limit the discussion to a broad overview, supplemented with relevant examples.  
The majority of proteins encoded by photoreceptor dystrophy genes can be assigned to one of 
the four following categories: 
 
1. Proteins of the phototransduction cascade.  
Vision begins when light induces the isomerization of 11-cis-retinal, leading to the 
dissociation of opsin and all-trans-retinal. At the same time, a conformational change in opsin 
permits the binding of the G-protein transducin. This is the first step in an amplification 
process that eventually results in hyperpolarisation of the photoreceptor plasma membrane. 
Mutations responsible for human retinal disease have been identified in virtually every protein 
that participates in the visual transduction cascade or the recovery process. One of the best-
known examples is rhodopsin. Mutations in the rhodopsin gene are the major cause (20-30%) 
of autosomal dominant retinitis pigmentosa, but a limited number of specific mutations have 
also been implicated in patients with congenital stationary night blindness.65 Although in vitro 
studies classified the functional aspects of rhodopsin mutations, these findings did not 
correlate well with the phenotype. Other examples of proteins in this category are transducin 
Chapter 1 
28 
(mutations in GNAT1 encoding the -subunit of transducin), phosphodiesterase, the cGMP-
gated cation channels, guanylate cyclase (RetGC-1 and 2) and guanylate cyclase activation 
protein (GCAP-1 and 2).66 
 
2. Proteins involved in the metabolic processes concerning photoreceptors and retinal 
pigment epithelium (mainly the visual pigment cycle).  
The RPE65 gene is specifically expressed in the RPE and is an example of a protein with a 
crucial role in the visual pigment cycle. Mutations in this gene have been found in patients 
with early-onset retinitis pigmentosa as well as Leber congenital amaurosis (LCA), the most 
severe type of photoreceptor dystrophy characterized by blindness or severe visual 
impairment at birth.67,68 In Rpe65-deficient (Rpe-/-) mice, the isomerization process of all-
trans-retinol to 11-cis-retinol is blocked (Fig. 5). The molecular defect in these mice leads to 
absence of 11-cis-retinal and rhodopsin, accumulation of all-trans-retinyl esters and 
eventually photoreceptors death.69 Abnormalities in the ABCR protein, 11-cis-retinol 
dehydrogenase (c-RDH) and cellular retinaldehyde binding protein (CRALBP) may also lead 
to various forms of hereditary retinal disease.66 
 
3. Photoreceptor structural proteins.  
An abundant transmembrane protein involved in structural integrity is peripherin/RDS. In rod 
outer segments it forms a heterotetrameric complex with another structural protein: rod outer 
segment protein 1 (ROM-1). They may act as an adhesion molecule involved in stabilisation 
of the outer segment discs or in maintenance of the curvature of the rim. As mentioned above, 
mutations in peripherin/RDS have been implicated in a variety of autosomal dominant 
phenotypes, as well as digenic retinitis pigmentosa (in combination with null mutations in 
ROM-1).70 Besides peripherin/RDS and ROM-1, rhodopsin may also be considered a 
structural protein, since it accounts for nearly 80% of the proteins in the disc membrane of the 
rod outer segment.71  
 
4. Transcription factors that regulate gene expression.  
The cone rod homeobox gene is an example of a gene encoding a transcriptional regulatory 
protein (CRX) involved in the differentiation of photoreceptor cells.72 Besides its role in 
retinal development, CRX acts synergistically with neural retinal leucine zipper (NRL) to 
control the expression of photoreceptor specific genes such as rhodopsin.73 Several clinical 
phenotypes have been associated with CRX mutations, including Leber congenital amaurosis 
and autosomal dominant cone-rod dystrophy.74,75 Mutations in NRL have been implicated in 
autosomal dominant retinitis pigmentosa.76 
 
Some of the recently identified genes encode proteins of unknown function. This applies to 
bestrophin, the protein product of the Best macular dystrophy gene (VMD-2), and the 
EFEMP1 gene, which is mutated in Malattia Leventinese/Doyne honeycomb retinal 
dystrophy.66 
 Although a large number of pathophysiologic models exist, the precise mechanisms 
that lead to photoreceptor death in inherited photoreceptor dystrophies are far from 
understood. There are many indications that cell death does not occur as the direct result of a 
specific mutation.77 This is illustrated by the loss of cone photoreceptors as result of 
mutations in rhodopsin that is only present in rod photoreceptors.77 Analysis of the 
degeneration of normal and transgenic photoreceptors in a chimeric mouse model also 
revealed a uniform degeneration that was independent of the genotype and similar to 
photoreceptor degeneration in transgenic mice.78 The deleterious effect of proximity to 
defective and/or dying cells is presumably responsible for the death of genetically normal 
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cells. Thus, both the genetic defect and cellular interactions are involved in photoreceptor cell 
death.79 Although the precise nature of these cellular interactions have not been defined, 
ultimately, the cells die by apoptosis as determined by analysis of DNA fragments and the 
absence of an inflammatory respons.22 Although abnormalities in proteins of great functional 
diversity lead to photoreceptor cell death, it is unlikely that a private preapoptotic pathway 
exists for each of these disorders. More likely, a smaller number of preapoptotic pathways 
exist that are shared by many of these disorders.80 
Insights in the molecular bases underlying inherited retinal disorders have clinical 
relevance. This may be illustrated by the treatment strategies that have been developed in 
animal models of Leber congenital amaurosis caused by RPE65 mutations. Recently, the 
visual cycle block in Rpe-/- mice has been successfully targeted by bypassing the biochemical 
defect. Since 11-cis-retinal is not formed, the investigators introduced 9-cis-retinal, which 
forms the visual component isorhodopsin, in Rpe-/- mice. This study demonstrated, both 
morphologically and electrophysiologically, that an alternative rod photopigment was formed 
with restoration of retinal function.81 Even more impressive are the results of gene therapy in 
RPE-/- dogs. In this study, recombinant adeno-associated virus, carrying wild-type RPE65, 
was delivered subretinally to RPE65-/- dogs. Electrophysiologic evaluations demonstrated 
improved retinal functions and behavioural tests indicated near to normal vision under 
photopic conditions. Interestingly, persistence of transferred DNA was restricted to the 
injected quadrant. This was the first study to show that gene therapy can restore vision in a 
large animal model of human retinopathy.82  
 
 
Aim and outline of the thesis 
 
This work is focussed on the clinical features and genetic abnormalities of the retinal 
disorders associated with mutations in the photoreceptor specific ABCA4 gene. Three main 
topics will be addressed. First, the types of inherited photoreceptor dystrophies that are 
associated with mutations in the ABCA4 gene. Second, the extent to which the ABCA4 gene is 
involved in cone-rod dystrophy and retinitis pigmentosa, since both disorders display 
considerable genetic heterogeneity. Third, the determination of the specific clinical 
characteristics of these disorders. In addition, an attempt is made to integrate these findings 
and describe a larger continuum of ABCA4-associated phenotypes.  
 Chapter 1 serves as a general introduction and familiarizes the reader with the clinical 
aspects of inherited photoreceptor disorders and some basic principles of molecular genetics. 
It also briefly reviews the impact of molecular genetics aspects on hereditary retinal disease. 
Chapter 2 offers a comprehensive overview of the current status and future prospects in 
ABCA4-associated retinal dystrophies. The results of our clinical studies and mutation 
analyses of ABCA4-associated retinal disease are discussed and correlated with other clinical 
and mutation analysis studies, as well as with the current pathophysiological models. Chapter 
3 is a colour atlas of ABCA4-associated retinal disease and gives an overview of the spectrum 
of phenotypes. It includes both new patients, as well as a number of patients that are discussed 
in the various appendices. 
Appendix 1 contains the first detailed clinical description of ABCA4-associated cone-rod 
dystrophy and retinitis pigmentosa. In Appendix 2, the results of the first ABCA4 mutation 
analysis in a cohort of 20 autosomal recessive or isolated cone-rod dystrophy patients are 
described. Appendix 3 is dedicated to the remarkable variation in clinical characteristics 
among patients with ABCA4-associated cone-rod dystrophy. Appendix 4 demonstrates three 
families, where different mutations in the ABCA4 gene lead to the occurrence of Stargardt 
disease and retinitis pigmentosa or cone-rod dystrophy within a single family. In Appendix 5, 
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the recently developed genotyping microarray is used to search for known ABCA4 mutations 
in cohorts of patients with autosomal recessive CRD and autosomal recessive retinitis 
pigmentosa. Appendix 6 illustrates the continuum of phenotypes associated with ABCA4 
mutations. Nine, well-documented patients are described, with a special interest in 
intermediate and overlapping forms. 
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Introduction 
 
Inherited retinal disease 
Retinal photoreceptor dystrophies comprise a variety of disparate, genetically determined 
conditions that differ from one to another in their mode of inheritance, their pattern of visual 
loss and their ophthalmoscopic appearances.1 Affecting about 1:2000, they are the most 
important cause of visual loss in the young.2 
Until recently, our classification and understanding of these disorders was solely based on 
clinical observations, such as the ophthalmoscopically observed abnormalities, supplemented 
with a number of functional tests. In most cases this approach has not lead to the fundamental 
cause of a disease and its pathogenesis. Consequently, therapeutic options to modify the 
course of the disease are available to us only for a few inherited retinal disorders.3  
With the advent of molecular genetics in modern medicine it has now become possible to 
analyze a disease from the “inside out”. The identification of the underlying genetic defect is 
the first step in understanding the fundamental causes of disease. Animal models, such as 
transgenic mice, often prove to be invaluable tools, not only in our present search to 
understand normal and abnormal gene expression, but also in the evaluation of future 
therapeutic strategies. Besides more conventional means of intervention, such as dietary 
supplementation, pharmacotherapy or surgery, gene therapy is being actively explored for a 
wide range of Mendelian inherited disorders.  
 At the moment more that 100 genes and 50 chromosomal loci have been implicated in 
a variety of retinal disorders (RetNet, http://www.sph.uth.tmc.edu/RetNet/). Only a few 
retinal disorders turn out to be genetically homogeneous. More often, these disorders display 
a considerable genetic heterogeneity, meaning that mutations in different genes result in 
clinically similar phenotypes. Retinitis pigmentosa (RP), for instance, exhibits an 
unprecedented genetic heterogeneity: genes encoding protein products involved in the 
phototransduction cascade, the visual pigment cycle, structural integrity, as well as 
transcription and splicing, have all been implicated in this disease.4 Apparently, all these 
genetic defects lead to the final common pathway of photoreceptor death and the phenotypic 
characteristics of RP. On the other hand, different mutations in the same gene may also lead 
to a variety of disorders. Mutations in the RDS/peripherin gene have been linked to dominant 
and digenic RP (in combination with the ROM1 gene), dominant forms of macular 
degeneration and adult vitelliform macular degeneration (RetNet). Another important gene 
associated with a variety of retinal disorders, and the only gene identified in autosomal 
recessive forms of macular dystrophy, is the ABCA4 gene, the focus of the present review. 
 
The role of the ABCA4 gene in inherited eye disease 
In the search for the gene underlying autosomal recessive Stargardt disease (STGD1), linkage 
studies first mapped this retinal dystrophy to chromosome 1p21-p13, which was later refined 
to a 2-centiMorgan region.5-9 Besides demonstrating a high degree of genetic homogeneity for 
STGD1, these linkage studies also provided further evidence for the longstanding clinical 
suspicion that fundus flavimaculatus (FFM) actually represented a variant of STGD1.10,11  
In 1997 the photoreceptor-specific ATP-binding cassette transporter (ABCR) gene, one of 21 
newly discovered ATP-binding cassette transporter (ABC) genes, mapped to the same 
cytogenetic region as STGD1.12,13 Subsequent molecular genetic analysis confirmed that the 
ABCR gene (later renamed ABCA4) was mutated in patients with STGD1.14 In addition, 
ABCA4 sequence variations were found in a statistically higher percentage of age-related 
macular degeneration (AMD) patients compared with control subjects.13 This putative role of 
ABCA4 in the development of AMD has been disputed by subsequent reports and remains a 
topic of ongoing debate. In 1998, mutations in the ABCA4 gene were also implicated in 
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autosomal recessive retinitis pigmentosa (arRP)15 and autosomal recessive cone-rod dystrophy 
(arCRD).16 The importance of this gene in the field of inherited retinal disorders increased 
when mutation analysis studies demonstrated that ABCA4 gene mutations were not only 
responsible for all cases of  STGD1 but also for the majority of arCRD cases (Appendices 2 
and 5).17 A spectrum of ABCA4-related retinal diseases began to emerge, encompassing 
retinal dystrophies which were previously viewed as distinctly different clinical disorders with 
no common genetic basis (Appendix 6).18 A genotype-phenotype model was proposed in 
which the severity of the retinal dystrophy was inversely related to residual functionality of 
the protein encoded by the ABCA4 gene.16,19-21   
Meanwhile, the transcript of the ABCA4 gene was found to be expressed in both rod and cone 
photoreceptors.14,22 Sun and co-workers located this ABCR protein at the rim of the disc 
membrane in the photoreceptor outer segment,23 and confirmed that this protein was identical 
to the previously identified rim protein (RmP).24 Through different approaches, two groups 
independently reached the conclusion that all-trans-retinal(dehyde) or its conjugate with 
phosphatidylethanolamine (PE), N-retinylidene-PE, is the substrate actively moved by the 
ABCR protein through the disc membrane.14,25,26 Functional impairment of ABCR will lead to 
accumulation of all-trans-retinal in the photoreceptor outer segment and subsequent build up 
of its degradation product A2-E in the cells of the retinal pigment epithelium (RPE).27 
Eventually, the toxic effects of A2-E, which is a major component of lipofuscin,28 result in 
death of the RPE cells and the overlying photoreceptors.29 The mouse model, developed by 
Mata and co-workers, which consisted of transgenic mice carrying homozygous or 
heterozygous ABCA4 null (function) mutations played an essential role in elucidating these 
pathogenic mechanisms in ABCA4-associated disorders.27,30 
 With these newly gained insights, studies in the near future will be directed at 
preventing or slowing down the degenerative process. An important finding, in this respect, 
was the discovery that isotretinoin was capable of blocking the formation of A2-E in Abcr-/- 
knockout mice.31 These results suggested that treatment with isotretinoin might delay the 
onset of visual loss in STGD1 and other ABCA4-related retinal disease.31,32  
The various aspects of ABCA4-related photoreceptor dystrophies will now be addressed in 
greater detail. 
 
 
The ABCR protein  
 
The family of ABC transporters 
Cells must selectively transport a wide variety of substrates across their plasma membranes. 
Adenosine triphosphate (ATP) binding cassette (ABC) transporters constitute the largest and, 
arguably, the most important group of proteins involved in membrane transport.  
 The ABC transporters in the human genome can be divided into seven ABC gene 
subfamilies. This classification is based on analysis of the amino acid sequence alignments of 
the ATP-binding domains and not on the function of the individual ABC transporters.33 
Genome sequence data suggest that ABC transporters comprise the most prevalent protein 
family in many organisms, representing almost 5% of the open reading frames in E. coli.34 
Despite the large numbers of ABC transporters and the overwhelming diversity of substrates, 
these ATP-dependent pumps share a common, modular structure. All functional ABC 
transporter proteins contain two nucleotide-binding domains (NBDs), or ABC domains, and 
two transmembrane domains (TMDs).35 All four domains can be arranged in any possible 
fashion.36 In eukaryotic ABC transporters, these domains may be found on a single long 
polypeptide chain (cystic fibrosis transmembrane regulator (CFTR) and ABCR) or as a 
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functional dimer consisting of two identical “half-transporters”, each containing an NBD and 
a TMD (TAP1/TAP2). 
The NBDs, which are located at the cytoplasmic face of the plasma membrane, couple ATP 
hydrolysis to substrate translocation. In 1998, the first high-resolution structure of the ATP-
binding subunit of an ABC transporter was elucidated.37 All ATP-binding domains of ABC 
transporters share motifs of characteristic conserved residues. The two Walker motifs (A and 
B regions) spaced by 90-110 amino acids and a C region, which lies between these Walker 
motifs, are the hallmark of the ABC transporter superfamily.37-39 The -helical TMD domains 
consist of at least six membrane-spanning helices and contain the substrate binding sites and 
harbour a translocation pathway through which the substrate moves.40 From reports on the 
molecular structure of ABC proteins it is evident that the structure of the TMD will vary from 
ABC transporter to transporter, depending on type and chemical nature (hydrophobic or 
hydrophilic) of the substrate.36,40,41 The exact mechanism through which ABC transporters 
move a substrate through a cellular membrane is unknown, but ATP hydrolysis is thought to 
influence the conformation of the transporter, which alters both the affinity and orientation of 
the substrate binding sites.40,42,43 
 ABC transporters are critically involved in a variety of human diseases. Multidrug 
resistance in tumour cells and microbial pathogens is mediated by an overexpression of ABC 
transporters that function as efflux pumps for a broad range of drugs.38 The best known 
example of these multidrug resistance (MDR) transporter genes is MDR1, encoding the P-
glycoprotein, which is capable of transporting a diverse class of amphipathic drug 
molecules.44 Alternatively, mutations in ABC transporter genes have been associated with a 
number of human inherited diseases, notably cystic fibrosis. This multisystem disorder is 
caused by mutations in ABCC7, which encodes the cystic fibrosis transmembrane regulator 
(CFTR).45 Other examples include Tangier disease (ABCA1),46-48 adrenoleukodystrophy 
(ABCD1),49 and the inherited retinal disorders caused by mutations in the ABCA4 gene.14 
 
Location and structure of the ABCR protein 
The product of the ABCA4 gene is the ABCR protein, a retina-specific ABC transporter 
expressed in both rod and cone photoreceptors.22,23,50 This 250 kD integral glycoprotein is 
located at the rim of the outer segment disc membrane23 (Fig. 1) and corresponds to a protein  
 
 
 
 
 
 
 
Figure 1. Localisation of 
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previously identified as ROS1.2 or the rim protein (RmP).24,51 The mole ration of ABCR to 
rhodopsin is estimated at 1:120.23 Initially, the presence of the ABCR protein was detected in 
rod photoreceptors but not in cones.23 Three years later, however, Molday and co-workers 
were able to demonstrate, using immunofluorescence microscopy and western-blot analysis, 
that ABCA4 is also expressed in foveal and peripheral cone outer segments.22   
As a member of the ABCA subfamily, the ABCR protein is comprised of a single long 
polypeptide chain of 2273 amino acids, arranged in two tandemly organized halves. Each half 
contains an NBD and a TMD.52,53 
The highly conservative spacing between the nucleotide binding sites and the transporter 
motifs is exactly 100 residues. The two NBDs in ABCR are only 35% identical in sequence 
and overall exhibit different properties.54 It was demonstrated that NBD-1 is a general 
nucleotidase (the nucleotide binding preference is as follows: CTP>GTP>ATP>>UTP), 
whereas NBD-2 is a specific ATP-ase.55,56 Recently Ahn et al proposed that the role of the 
two NBDs in ABCR is different in the sense that only NBD-2 binds and hydrolyzes ATP.54 
NBD-1 appears to contain a tightly bound ADP that nevertheless plays a crucial role in 
orchestrating the activity of NBD-2 and therefore in substrate transport. 54 These findings are 
inconsistent with the earlier proposed ABCR reaction cycle by Sun et al; in this model both 
NBD-1 and NBD-2 participate in ATP hydrolysis resulting in substrate transport.57 
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Figure 2. Topological model for ABCR (adapted from Bungert et al.53). ECD, exocytoplasmic 
domain; H1 or H2, first transmembrane segment; TMD, transmembrane domain; NBD, 
nucleotide binding domain; C, C region. 
 
 
 Several studies have speculated on the topological properties of the ABCR 
protein.50,57,58 In 2001, Bungert et al identified the exocytoplasmic N-linked glycosylation 
sites and suggested a refined topological model for ABCR, as depicted in Figure 2.53 In this 
model each half of the ABCR protein contains a transmembrane segment followed by a large 
glycosylated exocytoplasmic domain and a nucleotide binding domain at the cytoplasmic 
side. The authors also proposed that the N and C halves of ABCR are linked by one or more 
disulfide bonds on the exocytoplasmic side. 
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Identification of the transport substrate 
To understand the pathogenesis of ABCA4-related retinal disorders, it is imperative to identify 
the substrate that is transported by the ABCR protein. The localisation of ABCR in the 
photoreceptor outer segment led to the suggestion that ABCR might function as a retinoid 
transporter.14,23,58 Two groups have independently confirmed this putative role of ABCR.25,26 
The first study by Sun and co-workers started from the observation that substrates that are 
actively transported by P-glycoprotein, histidine permease and several other ABC 
transporters, are capable of activating ATPase activity of these proteins. In this study, ABCR 
of bovine rod outer segments was purified and reconstituted in lipid vesicles. Various 
candidate ABCR transport substrates were then tested for their ability to activate the ABCR-
mediated hydrolysis of ATP. From the characteristic way in which all-trans-retinal stimulated 
ABCR ATPase, they concluded that this retinoid was most likely the natural substrate for this 
transport protein.25,59 At the same time, Weng and co-workers studied the ocular phenotype of 
Abcr-/- knockout mice.26 Although it must be noted that mouse retina does not contain a 
macula and therefore resembles the peripheral human retina, many of the features of ABCA4-
associated retinal dystrophies were observed. Mice lacking functional Abcr protein 
demonstrated delayed dark adaptation, increased levels of all-trans-retinal following light 
exposure and increased levels of PE and the Schiff base complex of all-trans-retinal and PE 
(N-retinylidene-PE or APE). In addition, these mice show accumulation of A2-E (N-
retinylidene-N-retinylethanolamine) in photoreceptors and RPE cells. A2-E is a major 
fluorophore of lipofuscin and the final degradation product of N-retinylidene-PE.29 These 
observations led to the conclusion that ABCR acts as an outward directed flippase for N-
retinylidene-PE.26  
Thus, both studies demonstrated that either all-trans-retinal or N-retinylidene-PE is the 
natural substrate for the protein encoded by the ABCA4 gene. Although the finding that the 
increase in ATPase activity by all-trans-retinal was only observed in the presence of PE, 
favours N-retinylidene-PE as ABCR substrate, this matter is still not completely resolved.25,60 
All-trans-retinal and PE are most likely in equilibrium with N-retinylidene-PE and this 
complicates identification of the specific substrate. N-retinyl-PE, the stable reduced form of 
N-retinylidene-PE, failed to stimulate the ATPase activity of ABCR.61 The putative function 
of the ABCR protein as an active retinoid transporter does not mean that in the absence of 
functional ABCR all-trans-retinal can never enter the visual cycle. RP patients with two 
ABCA4 null mutations, as well as Abcr-/- mice, do regenerate rhodopsin and dark adaptation 
does occur, albeit at a slower pace than in the wild type.27 An alternative pathway for the 
recycling of all-trans-retinal must therefore exist, presumably by free diffusion through the 
disc membrane.62 This corresponds with the moderately increased levels (~1.5 fold) of all-
trans-retinal in mice with complete absence of ABCR functionality.26 
 The identification of the substrate for ABCR defines the role of this transport protein 
in the vitamin A pathway. After photobleaching, the photoisomerized all-trans-retinal is 
released from opsin and presumably enters the hydrophobic environment of the disc 
membrane.25,26  It then condensates with PE, which constitutes approximately 40% of the rod 
outer segment lipids, to form the Schiff base N-retinylidene-PE.26 All-trans-retinal, or N-
retinylidene-PE, is then actively moved by ABCR across the disc membrane (Fig. 3). At the 
cytoplasmic side of the membrane, all-trans-retinal becomes available for reduction by all-
trans-retinol dehydrogenase (an enzyme named for the reverse reaction). This reaction seems 
to be the rate-limiting step in the visual pigment pathway.63,64 The resulting all-trans-retinol is 
moved across the subretinal space to the RPE, where it is enzymatically reisomerized to the 
11-cis configuration and transported back to the photoreceptor outer segment. 
It must be emphasized, however, that ABCR functionality may differ in cone photoreceptor 
cells, since the disc membranes in cones are continuous with the plasma membrane, and the 
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intradiscal and extracellular spaces are contiguous. 
 The function of ABCR as all-trans-retinal or N-retinylidene-PE transporter in rod 
photoreceptors is therefore twofold. First, it speeds the clearing of all-trans-retinal from the 
disc interior to the cytoplasm, thereby accelerating dark adaptation and the regeneration of 11-
cis-retinal. Second, in preventing the build up of N-retinylidene-PE, the ABCR protein 
ultimately protects the RPE by limiting the accumulation of lipofuscin.  
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Figure 3. Proposed function of the ABCR transporter. A. All-trans-retinal is released by the 
photoactivated rhodopsin. B. All-trans-retinal enters the hydrophobic disc membrane and reacts 
to form a Schiff base with the amine in PE (which constitutes 40% of the rod outer segment 
lipids). C. All-trans-retinal or the N-retinylidene-PE complex is transported by ABCR to the 
cytoplasmic side. All-trans-retinal is then reduced by all-trans-retinol dehydrogenase and 
transported to the RPE (not shown). PM, plasma membrane; DM, disc membrane, PE, 
phosphatidylethanolamine. 
 
 
The ABCA4 gene and its sequence variations 
 
Characteristics of the ABCA4 gene 
The ABCA4 gene is a member of the ABCA subfamily of genes. In evolutionary terms this 
subfamily of ABC genes appears to have arisen rather recently, since ABCA-related genes are 
represented in multicellular organisms such as Caenorhabditi elegans (flatworm) and 
Drosophila melanogaster (fruitfly), but not in the yeast genome.33 This might indicate that 
this subfamily of ABC transporters evolved to perform specialized functions in multicellular 
organisms.65 The amino acid conservation between human and murine ABCA4 genes is 89%, 
excluding the carboxyl terminal 37 residues that are unique for the murine gene. When human 
ABCA4 is compared to the bovine gene, 88% of the amino acids are conserved.66 
The cytogenetic location of the ABCA4 gene is on the short arm of chromosome 1 at p22.1 
(http://genome.ucsc.edu/; July 2003 freeze).65 The gene is relatively large, it spans 128 kb and 
comprises 50 exons.6 The open reading frame of the ABCA4 gene is 6819 bp, encoding a 2273 
amino acid protein. The exons are relatively small, ranging from 33 to 266 bp.65 Despite the 
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large number of exons, the gene spans a comparatively short genomic region, because the 
introns are also quite small. Several studies reported on the genomic structure of the ABCA4 
gene, providing information on promoter regions and splice site sequences.6,65,67 The 
predicted conserved amino acid domains of ABCA4 include 790 amino acid positions, 
whereas 1483 amino acids occur in regions not conserved, when compared to other ABC 
transporters.68 
 
Mutation detection techniques 
A variety of techniques may be used to survey the ABCA4 coding region for sequence 
alterations (Table 1).  
 
 
Year Author  Patient 
population 
Mutation 
detection 
technique 
Number 
of ABCA4 
alleles  
Number of 
mutations 
Percentage 
identified 
mutations 
1998 Rozet et al.20 France SSCP analysis  
DNA sequencing 
110 35 32% 
1999 Fishman et al.69 North America 
(ancestry not 
mentioned) 
SSCP analysis 
DNA sequencing 
132 41 31% 
1999 Maugeri et al.19 Netherlands, 
Germany and 
Sweden 
SSCP analysis 
Southern blot 
analysis 
DNA sequencing. 
80 50 63% 
1999 Lewis et al.68 North America Heteroduplex 
analysis  
SSCP analysis 
DNA sequencing 
302 173 57% 
2000 Rivera et al.70 Western Europe DGGE 
dHPLC 
SSCP analysis 
DNA sequencing 
288 166 58% 
2000 Simonelli et al.71 Italy SSCP analysis 
Heteroduplex 
analysis 
DNA sequencing 
22 16 73% 
2001 Fumagalli et al.72 Italy DG-DGGE 
DNA sequencing 
88 37 42% 
2001 Webster et al.66 North America 
(ancestry not 
mentioned) 
SSCP analysis 
DNA sequencing 
748 263 35% 
2001 Yatsenko et al.73 North America 
(of Western 
European 
ancestry) 
DNA sequencing 50 33 66% 
Genotyping 
microarray 
(gene chip) 
268 161 56% 2003 Jaakson et al.74 North America 
Western 
Europe and 
Central Europe SSCP 272 149 55% 
 Combined   2360 1124 48% 
 
Table 1. Number of identified ABCA4 mutations in STGD1 patients in literature. SSCP, single strand 
conformation polymorphism analysis; DGGE, denaturing gradient gel electrophoresis; dHPLC, 
denaturing high-performance liquid chromatography; DG-DGGE, double-gradient denaturing 
gradient gel electrophoresis. 
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 Initially, most studies employed single-strand conformation polymorphism (SSCP) to 
screen for ABCA4 mutations.19,20,66,69 In subsequent mutation analysis studies, various 
combinations of other screening techniques besides SSCP have been used, including 
denaturing gradient gel electrophoresis (DGGE), denaturing high-performance liquid 
chromatography (dHPLC) and double-gradient DGGE, which is an optimized version of 
DGGE.68,70-72 In the majority of studies, direct DNA sequencing, which is still considered the 
“gold standard” of mutation detection techniques, was used to identify the sequence 
variations. To detect the large genomic deletions that may be missed with screening 
techniques such as SSCP and DGGE analysis, a few studies used Southern blot analysis.19,75 
Recently, the genotyping microarray (gene chip) was introduced in the screening for disease-
associated alleles in the ABCA4 gene.74 This ABCR400 microarray is cost-effective, and 
although it is not designed to identify new mutations, the gene chip is able to detect  more 
than 98% of the existing ABCA4 mutations (Appendix 5).74,76 
 
Pathogenicity of ABCA4 sequence variations 
A major problem in inferring the pathogenicity of a given sequence variation in the ABCA4 
gene is the high allelic diversity.66,68,70,77 This diversity is not unusual for ABC transporter 
genes.78 Nevertheless, when ABCA4 is compared to other retinal disease genes, the nucleotide 
diversity of the ABCA4 coding region is 1.28, which is 9 to 400 times greater than the gene 
for Best dystrophy (VMD2) and the gene for Malattia Leventinese and Doyne honeycomb 
retinal dystrophy (EFEMP1), respectively.66,70 Each study that surveyed the sequence 
variations in the ABCA4 gene identified a substantial number of variants that were not 
previously reported.19,66,68,70,79 The allelic diversity is perhaps best illustrated by the fact that it 
is unusual for an individual in the general population to be homozygous for the consensus 
ABCA4 sequence.66 Furthermore, although no substantial difference in the incidence of 
disease-associated ABCA4 alleles has been observed between ethnic study populations, a 
substantial diversity in the type and the distribution has been reported.68,74 This diversity 
makes the molecular diagnosis of STGD1 as well as the detection of carriers problematic. It is 
also not helpful that, given the high prevalence and the recessive inheritance pattern of these 
disorders, pathologic ABCA4 mutations will occur relatively frequent in the general 
population.  
 ABCA4 sequence variations cosegregating with the disease and absent in a large 
control population, will most likely represent pathologic mutations, especially when these 
variations are located in conserved domains. Likewise, nonsense mutations leading to 
truncation of the protein, frameshifts and certain splice site mutations can be considered null 
alleles, since they will not generate a functional protein product. The majority of ABCA4 
allelic variations, however, are missense mutations and rare in both patients and control 
population. This makes it difficult to establish, on statistical grounds, whether a particular 
mutation is pathogenic or neutral.14 Ideally, the effect of a specific sequence variation should 
be determined by its phenotypic effect.80 This is difficult to establish in ABCA4 retinal 
disorders, given the high allelic variation and the variability in age of onset and rate of 
progression. An alternative would be a functional assay to determine the effect of ABCA4 
mutations on the functionality of the ABCR protein as outward directed flippase for all-trans-
retinal or N-retinylidene-PE. Sun and co-workers performed such a functional analysis on 
wild type human ABCR and a small number putative pathologic variants.57 Their assay was 
based on ATP binding capacity and all-trans-retinal stimulated ATPase activity. 
 
Allelic variations  
At present, over 400 mutations in the ABCA4 gene have been reported (R. Allikmets, personal 
communication). The majority of the disease-associated ABCA4 alleles consists of missense 
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mutations (~75%). Splice site mutations and small deletions each constitute approximately 
10% (http://archive.uwcm.ac.uk/uwcm/mg/hgmd0.htm). Many single nucleotide changes 
occur at CpG dinucleotides, the spontaneous deamination of 5-methylcytosine results in C to 
T or G to A transitions. The frequency of these hot spot mutations in the ABCA4 gene is 
similar as in other human genes.68 The disease-associated sequence variations are scattered 
throughout the gene, although some authors observed a predilection for the conserved regions, 
notably the NBDs.14,56,81 
 Several “ethnic-group specific” ABCA4 alleles have been discovered. Examples 
include the T1428M mutation, which is rarely found in patients of European descent, but was 
relatively frequently (8%) encountered in Japanese patients.82 The complex L541P/A1038V 
allele is common in patients of German ancestry and has been identified in both STGD1 and 
CRD (Appendix 2).17,70 Finally, the 2588G→C transversion (G863/G863A) is one of the 
most frequently found missense mutation in Northern Europe. The heterozygote frequency is 
high in both STGD1 patients (21/68 (30.9%)) as in the general population.19 An increasing 
carrier frequency was demonstrated from the southwest (carrier frequency in Portugal 0 out of 
199) to the northeast (Sweden 1 out of 19) of Europe.77 The reported heterozygote frequencies 
for this mutation in the United States are considerably lower: 13/150 (8.7%) in patients and 
2/220 (0.9%) in the general population.14,77 2588G→C appears to be in linkage disequilibrium 
with the 2828G→A (R943Q) sequence variant and several polymorphic alleles, which is 
highly suggestive of a founder effect.19 Analysis of lymphoblastoid cell mRNA demonstrated 
that this mutation generates either a glycine to alanine substitution at codon 863 or the 
removal of codon 863 in approximately 50% of the transcripts, on account of a cryptic splice 
site 3 bp downstream.19 It was shown that ABCR protein products with the delG863 and the 
G863A variation resulted in a mild, respectively substantial ABCR ATPase impairment.57 
Hence, it is likely that this variation represents a mild mutation that causes STGD1 only in 
combination with a severe ABCA4 mutation.  
 Two other ABCA4 mutations of particular interest are G1961E and D2177N, both of 
which are implicated in the development of AMD (see below). G1961E is one of the most 
frequently encountered sequence variation in many studies.13,19,66,68 In a recent study 
comparing patients cohorts of diverse ethnicity the G1961E was the most frequently 
encountered alteration, ranging from 7-10% in North America, to 11% in the Netherlands, 
13% in Italy and 21% in Slowenia.74 Functional analysis revealed that both ABCA4 sequence 
variations affect the protein product in vitro. The G1961E protein product demonstrated 
inhibition of ATPase activity by all-trans-retinal, but, surprisingly, the mutant D2177N 
protein exhibited an elevation in ATPase activity relative to the wild type.19,83 In one large 
mutation analysis study the D2177N variation was found at similar frequencies in patients 
with either AMD, STGD1 or controls (2/228, 3/400, and 4/440 alleles, respectively), which 
does also not support a pathogenic role for this mutation.66,70 
 
Efficiency of mutation detection techniques 
With the currently employed techniques a significant number of pathologic ABCA4 sequence 
variations will not be identified (Table 1). The percentage varies greatly among the different 
studies, but it has been argued that with various screening methods  56-62% of the mutant 
alleles in STGD1 families will be identified.75 Even with direct DNA sequencing of all 50 
exons only 66% and 80% of the expected disease alleles could be identified in two separate 
studies.73,84 Although these numbers seem applicable to the majority of studies, some authors 
have reported much lower detection rates.66,69,72 Table 1 summarizes mutation analysis 
studies, which have screened cohorts of STGD1 patients. Differences in mutation detection 
techniques and ethnic study groups aside, the overall mutation detection efficiency in these 
studies not even reaches 50%. 
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There are several possible explanations for the large number of disease-associated alleles that 
remain undetected. First, pathogenic variants might be located outside the regions that are 
screened, such as promoter regions or noncoding – intronic – regions of the gene (inactivating 
an enhancer, activating a suppressor, or activating a cryptic splice site). A second explanation 
would be the misinterpretation of the disease causing status of certain variations because of 
their frequent occurrence in the control populations. Finally, other genes besides ABCA4 
might be responsible, in part or in whole, for the development of the retinal phenotype. A 
phenocopy, such as autosomal dominant Stargardt-like dystrophy caused by a de novo 
mutation in ELOVL4 or PROML1, might be clinically diagnosed as STGD1.85,86 Also, other 
genes might be of influence. A synergistic effect of pathologic ABCA4 sequence variations on 
an autosomal dominant form of Stargardt disease (STGD3) has already been demonstrated.87  
It is unlikely that genetic heterogeneity for STGD1 is the reason for the inability to find all 
predicted disease causing variants, since all families segregating this disorder have been 
linked to the ABCA4 locus on chromosome 1p13-p22.5,8 Moreover, in all studies to date the 
number of heterozygotes outnumber the number of homozygotes, This high number of 
STGD1 patients with only one identified pathogenic sequence variation, argues strongly 
against genetic heterogeneity for STGD1. It is also unlikely that large numbers of genomic 
deletions are undetected by mutation analysis studies. Although such deletions are not 
uncommon in ABC genes,88,89 genomic rearrangements have been observed in only three 
patients with ABCA4-associated retinal disease.19,75,90 
 
Carrier frequency 
The carrier frequency of disease-associated ABCA4 mutations is not precisely known. In a 
study conducted by Maugeri and co-workers, the carrier frequency for mild ABCA4 mutations 
was estimated at 4%.19 However, these figures were based on an incidence of STGD1 of 
1/10.000,91 a figure that is not substantiated and has been disputed by others.92 The presence 
of pseudodominance in 8 of 178 STGD1 families among various studies suggests a carrier 
frequency of 4.5%.19,68,71,73,93 Alternatively, the carrier frequency may also be derived from 
the screening of the ABCA4 gene in control subjects. In a large study addressing ABCA4 
sequence variations in STGD1 and AMD patients, 220 German control subjects were 
analyzed, revealing 12 (5.4%) missense mutations.70 Recently, in a validation study of the 
ABCR genotyping microarray, 9 (9.4%) pathologic ABCA4 mutations could be identified in 
96 control samples originating from North America. Analysis of those mutations, however, 
revealed that not all 9 mutations should be considered pathologic (F. Cremers, personal 
communication). Again, a major difficulty in the determination of the carrier frequency of 
disease-causing alleles lies in the definition of pathologic sequence variations. When 
uncommon polymorphic variants, incorrectly defined as pathologic, have been included, the 
actual carrier frequency may be significantly lower.    
 
 
Clinical and genetic aspects of retinal disorders caused by ABCA4 
mutations 
 
Stargardt disease 
Clinical aspects 
Autosomal recessive Stargardt disease (STGD1; MIM 248200) was first described by Karl 
Stargardt in 1909 and is arguably the most common hereditary macular dystrophy.94 
Surprisingly, the exact prevalence of the disorder is unknown, because the scientific basis of 
the often mentioned number of 1:10.000 is questionable.91,92 Autosomal recessive STGD is 
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considered a monogenic disorder.5,8 Macular dystrophies with similar features have been 
described, but these are all inherited in an autosomal dominant fashion.95-98  
Most patients with STGD1 experience bilateral loss of visual acuity in childhood or early 
adulthood. However, the age at which STGD1 patients develop visual loss may range from 4-
65 years.10,11,68,91,99-102 The mean age of onset in a large study among 150 unrelated and 
genetically proven STGD1 patients was 15.2 years.68  
Some individuals demonstrate minimal fundus abnormalities with a heavily pigmented RPE 
that is easy to overlook (‘vermillion fundus’) and that obscures most details of the choroid.103 
Typically, yellowish flecks can be observed at the level of the RPE. These flecks are variable 
in size, shape and distribution, but are always present in the posterior pole and may extend as 
far as the equator. As the disease spreads centrifugally, new flecks may appear while older 
flecks resorb, during which their colour changes from yellow to grey. On fluorescein 
angiography the flecks are either nonfluorescent or, rarely, demonstrate an irregular pattern of 
fluorescence.102-104 Obstruction of the normal choroidal background fluorescence (dark or 
silent choroid) on the fluorescein angiogram is considered an important feature of STGD1. 
With progression of the disease, loss of RPE cells in the central retina may result in a beaten 
bronze appearance of the macula, a bull’s eye pattern of dystrophy or geographical atrophy in 
the posterior pole. Midperipheral atrophy of the RPE may also develop, which is more evident 
with fluorescein angiography. 
 In 1962 Franceschetti described a phenotype with identical pisciform yellowish flecks, 
but greater in number and extending into the peripheral retina. The majority of these patients 
developed macular degeneration.105 This retinal dystrophy, which he named fundus 
flavimaculatus (FFM), was thought to be characterized by a milder course with better visual 
acuity throughout life than STGD1.105,106 In the following years, several attempts were made 
to distinguish the FFM phenotype from the STGD1 phenotype. Some stated that visual loss in 
STGD1 usually begins in the first two decades, whereas FFM is associated with visual loss at 
or after the end of the second decade.10 Others declared that the distinction between this entity 
and STGD1 with many perifoveal flecks could be made by the central onset of STGD1, 
whereas in FFM the yellow-white flecks are already present when atrophic macular changes 
develop.106 Presently, most authors believe that FFM and STGD1 represent variants of 
essentially the same disorder, in view of the genotypic and phenotypic similarities, even in the 
patients originally described by Karl Stargardt. We will therefore reserve the term FFM to 
describe a subtype of STGD1, characterized by a large number of flecks.10,11 
Interestingly, and in contrast with the earlier reports, more recent studies indicate that the 
morphologic changes and retinal function deterioration, including visual acuity, are more 
severe in patients with the FFM subtype than in patients with STGD1.99,107  
 Occasionally, the clinical findings in STGD1 may be minimal or atypical. The yellow 
flecks may be absent in young children or may be quite small in size and number. The dark 
choroid effect is also not invariably present, especially early in life, and is estimated to occur 
in about 50-85%.101,108,109 The absence of a dark choroid can not simply be attributed to 
misdiagnosis, since this was also observed in genetically proven STGD1 patients.69 A 
significant number of patients with STGD1 may exhibit delayed rod dark adaptation.102,110,111 
Finally, progression of the STGD1 phenotype to a CRD-like disorder with peripheral 
photoreceptor degeneration has been observed by a number of authors.10,99,101 
It must be kept in mind, though, that most studies on the clinical spectrum of STGD1 have 
been performed without molecular genetic conformation of the diagnosis.10,99,102,110,112 
Consequently, these studies may have included patients with the autosomal dominant variant 
of Stargardt disease,99 early-onset AMD, initial stages of cone-rod dystrophy, Bietti 
crystalline dystrophy, familial drusen, as well as several other macular dystrophies. Inclusion 
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of these misdiagnosed cases may have increased the apparent clinical heterogeneity of this 
retinal dystrophy. 
 There is a marked variation in the reports on the electrophysiological abnormalities in 
STGD1. Besides clinical heterogeneity, other factors may have been responsible, including 
misdiagnosis, lack of standardization, and the fact that electrophysiological findings may 
depend on the stage of the progression of the disorder.  
The multifocal ERG allows simultaneous recordings of many local ERGs at the posterior pole 
and is a powerful tool in detecting localized cone dysfunction.113 The multifocal ERG is 
abnormal in almost all STGD1 patients and is capable of detecting foveal dysfunction even in 
STGD1 patients with minimal fundus abnormalities and relative good visual actuity.114  
The pattern ERG (PERG) can also be used to assess functional abnormalities of the macula 
and is abnormal in most STGD1 patients, even in presence of a normal visual acuity.10,115,116 
This finding is unusual in other inherited maculopathies.117  
Several groups have investigated the amplitudes and implicit times in the scotopic and 
photopic standard ERG. Although the results are variable, many STGD1 patients 
demonstrated significant abnormalities, more often in the cone than in the rod driven 
pathway.10,11,99,111,117-124 Since the ERG must be considered a mass response of the retina and 
the macular area contributes only 10-15% to the photopic ERG response, a large photopic loss 
cannot be attributed to macular damage alone.  
Recent ERG studies in genotyped STGD1 patients, employing sensitive methods of detecting 
rod dysfunction, also demonstrated significant abnormalities in the rod photoreceptor system 
that remained undetected by standard ERG techniques.124  
EOG abnormalities, although variable, are present in a significant number of STGD1 
patients.10,11,116  
No consistent relation between specific electrodiagnostic findings and the presence and 
distribution of the fundus lesions has been shown. Thus, patients with widespread retinal 
abnormalities may demonstrate functional loss restricted to the macula. Conversely, patients 
with visible manifestations of the dystrophy restricted to the macula may demonstrate 
generalized rod and cone involvement.10,108,112,115 
 Several subclassifications for STGD1 have been proposed over the 
years.11,69,99,102,112,115 Most of these classifications rely on fundus abnormalities and 
fluorescein angiographic findings. A recent study by Lois et al classified patients with 
STGD1 into 3 groups based on electrophysiological attributes.115 Group 1 demonstrated only 
PERG abnormalities, in group 2 there was additional loss of photopic function and in group 3 
both photopic and scotopic functions were impaired. These electrophysiological findings were 
not related to disease duration or fundus abnormalities. The three groups seemed to represent 
distinct phenotypic subtypes of STGD1 with variable severity of photoreceptor dysfunction. 
However, their conclusion that patients with a normal ERG will always preserve a normal 
ERG, is not in accordance with the abnormalities that we observed in a patient that progressed 
from STGD1 (with a normal ERG) to severe, atrophic CRD (with a nonrecordable ERG) 
(Appendix 6, case 6).18   
To date, no genotypic classification based on large numbers of STGD1 patients with two 
identified mutations in the ABCA4 gene has been presented.69,125  
 
Genetic aspects 
Mutation analysis studies demonstrated that in most STGD1 patients with two identified 
alleles, at least one allele is a missense change or an in-frame deletion.19,68,70 Large studies 
evaluating ABCA4 sequence variations in STGD1 have not revealed patients who were 
homozygous or compound heterozygous for two null mutations or two mild mutations.19,68,70 
This suggests that patients with STGD1 have at least one allele that retains partial function, 
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resulting in diminished but not completely absent ABCR activity.13 This was confirmed in an 
analysis of 59 STGD1 patients with two identified mutations.70 The majority of these patients 
were compound heterozygous (31/59) for two missense mutations or one truncating mutation 
and a missense mutation (25/59). One patient was homozygous for a frameshift mutation 
(5917delG), but an ERG at age 10 revealed widespread dysfunction in both rods and cones 
suggesting an early-stage cone-rod dystrophy.  
The correlation between the severity of the STGD1 phenotype and ABCA4 sequence 
variations has been studied by a number of authors.20,68,69,73,125,126 Earlier clinical studies 
already described similarities in onset, rate and progression of the visual loss, and presence 
and distribution of fundus lesions when related STGD1 patients are compared.10,11,108 This 
intrafamilial homogeneity is more pronounced when electrophysiologic abnormalities are 
considered.117 Recent mutation analysis studies were able to confirm genotype-phenotype 
correlations. Mild forms of STGD1, as defined by clinical presentation and age of onset, 
seemed to be associated with a subset of putatively mild missense mutations. Variants that are 
located outside known functional domains,73 paired missense mutations,20 the G1961E 
mutation,69 missense mutations that affect uncharged amino acids,20 and the absence of 
mutations 5’ to codon 86368 were found to be associated with relative mild phenotypes. By 
contrast, frameshift mutations that occur more 5’ and amino acid substitutions in the amino 
terminal one-third of the ABCR protein were reportedly associated with an earlier onset of 
STGD1.68 Nevertheless, exceptions have been observed. Several studies report marked 
intrafamilial variation of the STGD1 
phenotype, that could not be attributed to 
different stages in the progression of the 
disease.99 Although the genotype 
underlying the STGD1 phenotype was not 
known in these studies, more recent 
analysis in genetically proven STGD1 
patients, confirm the presence of 
intrafamilial phenotypic variation.68,70,73,117 
Furthermore, nonexpression has been 
observed in at least four individuals 
(Appendix 4).73,127 
 
 Histopathology 
A limited number of histological studies 
have been performed on eyes with STGD1. 
An early light microscopic study revealed 
distinctive abnormalities of the RPE, 
notably the intracellular accumulation of a 
pathologic substance, as well as great variation in the size of the RPE cells.102 In 1980, Eagle 
and colleagues reported the scanning electron microscopic findings in a donor Stargardt eye 
and demonstrated that the typical pisciform yellow-white flecks represented aggregates of 
swollen RPE cells engorged to 10 times their normal size with a substance that was identified 
as lipofuscin (Fig. 4).128 The accumulation of lipofuscin in STGD1 was later confirmed by 
non-invasive methods.129 Small but unmistakable accumulation of this material has been 
found as early as the second year of life.130 The increased number of lipofuscin granules and 
subsequent loss of RPE cells occurs in a peripheral/central gradient toward the macula. After 
RPE cell lysis, lipofuscin is absorbed by macrophages. These findings may explain the 
disappearance of the subretinal flecks over time. Individuals with geographic atrophy of 
Figure 4.  Scanning electron microscopy revealing 
grossly enlarged RPE cells in STGD1 (from: Eagle 
et al.125). 
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macula, a typical finding in the later stages of STGD1, demonstrate complete loss of the RPE 
and outer retinal layers in this area.131 
  
Cone-rod dystrophy 
Clinical aspects 
The CRD phenotype represents a group of hereditary diffuse photoreceptor degenerations 
with more severe involvement of cone than rod photoreceptors, as demonstrated by functional 
tests and the pattern of visual loss. In this study, we will use this pattern of photoreceptor loss 
to differentiate this disorder from RP.  
CRD may be seen as an isolated disorder or associated with systemic abnormalities, 
although the latter is uncommon. The inheritance pattern may be any of the classic three 
modes, although isolated or autosomal recessive inheritance is most commonly encountered. 
The prevalence of CRD is unknown but the condition might be relative frequent.132 Moreover, 
a significant portion of patients diagnosed with RP may in fact demonstrate a cone-rod type 
ERG deficit at one stage of their disease.133  
Although the clinical findings in CRD are variable, a combination of certain 
characteristics can be ascribed to the CRD phenotype. Typically, it presents in adolescence or 
early adulthood with loss of visual acuity, mild to marked photophobia, and in some instances 
nystagmus. Other findings include disturbance of colour vision, usually of the red-green type, 
central visual field defects, and impaired rod and cone photoreceptor functions on the ERG. 
Initially, the macular aspect may be normal; in time, fine mottling of the pigment in the 
macula may be observed with slight narrowing of the retinal vessels. In the later stages a 
bull’s eye pattern may develop, as well as atrophy of the RPE and mild bone spicule 
pigmentations.100,132,134-140 A subset of patients may show a prolonged rod dark adaptation.141  
Not only the initial stages of STGD1 and CRD may appear similar, but also the differentiation 
between CRD and RP may be difficult at times. In this context, there is some controversy on 
the ERG findings typically found in CRD. The earlier studies on CRD state that the diagnosis 
of CRD must be based on the reduction or absence of cone responses in the presence of 
quantitatively less reduction in rod responses.134,137 However, more recent studies consider an 
equal impairment of both photoreceptor systems, if accompanied by the characteristic 
features, also to be compatible with CRD.135,139,140  Other characteristics that can be used to 
differentiate patients with CRD from RP are the initial complaints of blurred vision rather 
than night blindness and the fact that pigmentary changes in most CRD patients have a greater 
predilection for the posterior portion of the fundus than the pigmentary changes observed in 
RP. In general, the observed pigmentary disruption of the retina is milder in the CRD group. 
Finally, the pattern of visual field loss is different in these retinal disorders. RP often 
demonstrates a ringscotoma progressing to both the central and peripheral retina, whereas in 
CRD an enlarging central scotoma is typically found.  However, it may be impossible to 
distinguish CRD from RP in the later stages of the disease, since fundoscopic abnormalities 
may be identical and both rod and cone ERGs may be nonrecordable.142 
 Several propositions have been made to classify cone-rod dystrophies. Some 
classification systems focused on fundus aspect; others differentiated according to the various 
patterns of inheritance.134,137,138,143 Recent studies by Yagasaki et al and Szlyk et al made use 
of full-field ERGs, psychophysical threshold profiles and modified perimetric techniques to 
identify functionally distinct subtypes of CRD.139,140 Finally, over the last years, a molecular 
genetic classification of CRD begins to emerge. Besides the ABCA4 gene (CORD3; MIM 
604116), autosomal recessive CRD has been linked to 1 gene (retinol dehydrogenase-5 
[RDH5]) and 2 loci (Table 2). 
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ABCA4-associated retinal 
disease 
Associated disease genes besides 
ABCA4 
Mapped loci 
Ar Stargardt disease 
(STGD1) 
  
Ar Retinitis pigmentosa  CNGA1, CNGB1, CRB1, LRAT, MERTK, 
NR2E3, PDE6A, PDE6B, RGR, RHO, 
RLBP1, RPE65, SAG, TULP1, and USH2A 
RP22, RP25, RP28, and 
RP29 
Ar Cone-rod dystrophy RDH5 CORD8 and CORD9 
Age-related related macular 
degeneration 
CTS3,144 APOE4,145,146 and the manganese 
superoxide dismutase gene147 
Several loci, for example 
1q25-q31148,149and 17q25148 
 
Table 2. Genetic heterogeneity in ABCA4-associated photoreceptor dystrophies (main source: 
RetNet, http://www.sph.uth.tmc.edu/RetNet/). Ar, autosomal recessive. 
 
 
ABCA4-associated CRD 
The first indication that the ABCA4 gene might be involved in autosomal recessive CRD was 
the identification of two distinctly different types of retinal dystrophy in a consanguineous 
Dutch family carrying homozygous or compound heterozygous mutations in the ABCA4 gene 
(Appendix 1).16,150 Four patients in this family shared identical ABCA4 sequence variations 
that led to a retinal phenotype that we classified as an atypical form of CRD, since overlap 
with the RP phenotype was present. In an additional study, however, we could confirm the 
association of typical autosomal recessive CRD cases with mutations in the ABCA4 gene 
(Appendix 2).17 The clinical description of 12 ABCA4-associated CRD patients revealed 
abnormalities typical for CRD, including cone-rod patterns on the ERG when responses could 
still be elicited. Nevertheless, large differences were observed as to age of onset, visual 
acuity, fundus abnormalities, visual field defects and impairment of rod and cone driven ERG 
recordings. Although some of these differences may be ascribed to the stage of the 
progression of the dystrophy, it was felt that the CRD phenotype was highly variable, despite 
the shared causative gene (Appendix 3).151 This impression was confirmed by additional 
studies commenting on the clinical aspects of this particular subtype of CRD.152,153 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Incidence of 
ABCA4 mutations in 
different cohorts of 
arCRD patients. 
#
 Appendix 2;  
§Appendix 5. 
 
 
CRD patients with at 
least one ABCA4 
mutation 
Study Year Number of 
CRD patients 
investigated 
N % 
Papaioannou et al.79 2000 8 4 50% 
Maugeri et al.17 # 2000 20 13 65% 
Paloma et al.154 2001 2 2 100% 
Birch et al.152 2001 30 11 37% 
Briggs et al.155 2001 8 6 75% 
Ducroq et al.156 2002 55 13 24% 
Fishman et al.153 2003 30 16 53% 
Klevering et al.76 § 2004 54 18 33% 
Overall  207 83 40% 
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As summarized in Table 3, mutation analysis studies reported the identification of one or two 
ABCA4 mutations in a significant number of isolated or autosomal recessive CRD cases 
(Appendices 2 and 5).17,76,79,152,153,155-157 When the results of these studies are combined, 
ABCA4 mutations were identified in approximately 40% of the patients with arCRD. The 
variation in incidence of ABCA4 involvement between these studies may be explained by the 
relatively small number of patients, and differences in the efficiency of the mutation detection 
as well as differences in ethnic study populations. In addition, the clinical interpretation of 
these complex retinal dystrophies may have been of influence. In view of the current mutation 
detection efficiency in most studies of approximately 60%, (ref. 73 and references therein), it 
can be estimated that causative mutations in the ABCA4 gene will be present in more than half 
of the autosomal recessive CRD cases.   
Although we are unable to asses the functional consequences of many of these mutations, 
there is no indication that these patients carry homozygous null mutations, suggesting some 
residual ABCR activity in the CRD phenotype. Recently, however, Simonelli and co-workers 
described a CRD patient that carried a homozygous G991X mutation. This nonsense mutation 
is expected to result in a truncated, nonfunctional, ABCR protein.158 
 
Histopathology 
To the best of our knowledge, only one study has reported the histopathologic evaluation of a 
CRD in progress.159 The light and electron microscopic findings in two post-mortem eyes of a 
29-year-old patient CRD patient revealed the presence of abundant lipofuscin-like granules in 
the basal portion of RPE cells and atrophy of the RPE in the macular area. Although the 
underlying genetic defect in this patient was not determined, these observations correspond 
with the expected histopathologic findings in CRD caused by mutations in the ABCA4 gene.   
  
Retinitis pigmentosa 
Clinical aspects 
No absolute definition exists for RP but it may be defined as “a set of progressive hereditary 
disorders that diffusely and primarily affect photoreceptor and pigment epithelial function.”160 
Some, however, prefer an operational definition that includes, among others, the progressive 
loss of night and peripheral vision.160 In this definition RP becomes synonymous with rod-
cone dystrophy, in which the rod photoreceptors are earlier and more severely affected than 
the cone photoreceptors. In this study, where the differentiation between RP and CRD is 
important, we will employ the latter definition.  
The prevalence of RP varies with the study population, but is reported to approximate 1:5000 
worldwide.3 It may be an isolated finding or may be part of a specific syndrome, such as 
Usher and Bardet-Biedl. In addition to all Mendelian patterns of inheritance, digenic and 
mitochondrial forms of RP have been described. The genetic heterogeneity is therefore 
impressive and to date 16 genes and 4 loci have been linked just the autosomal recessive form 
of RP (Table 2). 
There is a wide range in clinical expression, but typical RP patients develop night blindness in 
childhood or early adulthood. In the early stages, progressive constriction of the visual field 
occurs, beginning in the midzonal regions. Central vision is often, but not always, affected in 
the later stage of the dystrophy and frequently leads to severe visual impairment or blindness. 
Loss of vision over time seems to be correlated with the presence of macular lesions early in 
the course of the disease.161 Besides loss of macular photoreceptors, central visual acuity may 
also be affected by cystoid macular edema or the formation of an epiretinal membrane, which 
may occur in some patients in the earlier stages of RP.162 The earliest fundoscopic 
abnormalities include arteriolar narrowing, a grey-green discoloration of the RPE, fine dust-
like intraretinal pigmentations, followed by loss of the pigment from the RPE.163 As 
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photoreceptor loss progresses, intraretinal pigment depositions begin to appear. The 
pigmentary disturbance occurs most prominently in the periphery and commonly in a bone 
spicule pattern due to pigment accumulation within vessel walls.  Although these bone 
spicules are considered characteristic for RP, small irregular clomps and spots of pigment 
may be seen almost as often.164 In addition, marked attenuation of the retinal vessels and a 
waxy pallor of the optic disc become apparent. Other findings frequently encountered in RP 
include myopia, posterior subcapsular cataracts and dust-like particles in the vitreous.163  
Patients with RP, tested with dark adaptometry, may demonstrate elevation of the cone 
segment, the rod segment, or both. Electrodiagnostic responses range from normal to 
nonrecordable in advanced stages of the disease. The scotopic rod-dominated ERG may be 
affected more severely than the photopic cone-dominated ERG, but both tracings may also be 
equally abnormal.165 Both rod- and cone-mediated implicit times can be significantly 
prolonged.166 In general, the EOG is abnormal in diffuse hereditary rod-cone degenerations of 
the retina.166 
  
ABCA4-associated RP 
In 1998, homozygous ABCA4 mutations were detected in patients with an atypical form of RP 
(RP19; MIM 601718) that was characterized by extensive chorioretinal atrophy.15,167 The 
association of autosomal recessive RP with mutations in the ABCA4 gene was confirmed by 
subsequent studies. To the best of our knowledge, 16 unrelated patients with this type of RP 
have been described in literature (Tables 4 and 5). The majority of these patients demonstrate 
a very severe phenotype with an early age of onset (age 8 to 10 years). The fundoscopic 
aspect is characteristic, featuring extreme atrophy and irregular clumps of pigment scattered 
throughout the retina (Chapter 3, patient XI). The course is highly progressive, leading to a 
severely decreased visual acuity of hand movements or light perception. ERG tracings reveal 
nonrecordable rod and cone photoreceptor tracings in the majority of patients (Appendices 1, 
4, 5 and 6).  
 ABCA4 mutations have also been described in a limited number of ‘classic’ RP cases, 
displaying a more characteristic inward progression of the retinal dystrophy (Table 4). In our 
opinion, pathologic involvement of the ABCA4 gene in these 5 patients remains doubtful 
(Appendix 6).18 These patients still retain functional visual acuity and visual field deficits 
range from partial ring scotomas to a severely constricted visual field to 10º diameter. Some 
of these patients were in their sixth decade, this relative mild phenotype can therefore not be 
attributed to an early stage of the disease. In contrast with the typical ABCA4-associated RP 
patients, mostly heterozygous ABCA4 mutations have found in these ‘mild’ RP patients. In 
itself, this is not uncommon in ABCA4-associated retinal disease, but a coincidental finding 
can not be ruled out in view of the high carrier frequency of approximately 5% for ABCA4 
mutations. In addition, the pathologic ABCA4 variants identified in these RP patients are 
commonly associated with STGD1 and not with RP, since they are not null mutations. This 
applies especially to two patients carrying the D2177N (6529G→A) mutation, which is of 
dubious pathogenicity in RP. Finally, longstanding preservation of central vision with 
simultaneous degeneration of the retinal periphery is in contrast with the observed disease 
sequence in other patients with ABCA4-associated retinal dystrophies. However, at this time 
we can not completely exclude the possibility that mutations in the ABCA4 gene may also 
result in a relatively mild RP phenotype.  
Excluding the five RP patients where ABCA4 involvement is dubious in view of the 
identified mutation(s) and/or clinical findings, a total of 12 homozygous or compound 
heterozygous ABCA4 sequence variations have been identified (Table 5). Strikingly, 8 of 
these represent homozygous mutations, suggesting consanguinity or at least a common 
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Table 4. Clinical characteristics of RP patients with ABCA4 mutations. 
 
ERG 
 Study Year 
Number 
of 
families 
Age of 
onset 
(years) 
Age 
(years) Visual acuity Fundus
 Visual field 
Rod Cone 
Martinez-Mir et al.15,167 1997/98 1 8  Low Severe atrophy  ND  
Cremers et al.16 
Klevering et al. # 150  
1998/99 1 6  LP Severe atrophy  ND ND 
Rozet et al.90 1999 1 9  LP Unspecified atrophy  ND ND 
Papaioannou et al.79 2000 1 -  - - - - - 
Birch et al.152 2001 1 - 18 Near normal Atrophy not mentioned Constricted to 10º ND  
Shroyer et al.168 2001 1 10  HM-LP Severe atrophy  - - 
8  0.05 Severe atrophy  ND ND Fukui et al.169 2002 
Year 
2 
8  HM severe atrophy  ND ND 
Rudolph et al.170 2002 1 <8 10 0.1 Atrophic changes    
6  HM-LP Severe atrophy  ND ND Klevering et al.§ 127 2004 
 
2 
10  HM-LP Severe atrophy  ND ND 
7 91 CF Severe atrophy  ND ND 
 61 0.3 Minor atrophic changes Ringscotomas ND ND 
10-20 60 0.1-0.3 Minor atrophic changes Constricted    
10-20 25 0.3 Minor atrophic changes Constricted to 10-15º 
Ringscotoma at 50º 
ND ND 
Klevering et al.† 76 
 
2004 5 
17 48 1.0 Midperipheral atrophy Partial ringscotomas ND ND/ 
 
All patients showed the classic RP features of attenuated vessels, bone spicules and pale or waxy optic discs. A variable degree of retinal atrophy was 
observed as displayed in the ‘fundus’ column. LP, light perception; HM, hand movements; CF, counting fingers; ND, nondetectable,  decreased; , 
severely decreased, #Appendix 1; §Appendix 4; †Appendix 5. 
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Table 5. ABCA4 sequence variants in patients with ABCA4-associated RP.   
 
Study 
Number 
of 
families 
Allele 1 Effect or  
mutation type 
Predicted 
ABCR activity Allele 2 
Effect or 
mutation type 
Predicted  
ABCR activity 
Martinez-Mir et al.15,167 1 E616fs Truncation Absent E616fs Truncation Absent 
Cremers et al.16 
Klevering et al. #  150 
1 IVS30+1G>T Splice site Absent IVS30+1G>T Splice site Absent 
Rozet et al.90 1 IVS13-1G>A Splice site Absent IVS13-1G>A Splice site Absent 
Papaioannou et al.79 1 V424A Missense Unknown    
Birch et al.152 1 T901A Missense Unknown IVS3+2T>C  Unknown Unknown 
Shroyer et al.168 1 W1408R ;  
R1640W 
Missense 
missense 
Absent (combined 
effect) 
V676D Missense Absent 
IVS12+2T>G Splice site Absent IVS12+2T>G Splice site Absent 
IVS12+2T>G Splice site Absent IVS7-45_952 
delinsTCTGACC 
Exon skipping Absent 
Fukui et al.169 2 
IVS7-45_952 
delinsTCTGACC 
Exon skipping Absent IVS7-45_952 
delinsTCTGACC 
Exon skipping Absent 
Rudolph et al.170 1 V1973X Frameshift Absent V1973X Frameshift Absent 
768G>T Splice site Absent 768G>T Splice site Absent Klevering et al.§ 127 2 
IVS33+1G>T Splice site Absent IVS33+1G>T Splice site Absent 
G863/G863A; 
R943Q 
1-Amino acid deletion/ 
missense; 
missense 
Mildly decreased/ 
normal; 
mildly decreased 
R1963fs Truncation Absent 
D2177N Missense Unknown    
D2177N Missense Unknown    
L541P; 
A1038V 
Missense; 
missense 
Severely decreased;   
absent 
   
Klevering et al.† 76 5 
V2050L Missense Unknown    
 
#Appendix 1; §Appendix 4; †Appendix 5. 
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ancestry. The majority of patients with the severe, atrophic form of RP carry two null 
mutations and will therefore not express functional ABCR protein. The complete absence of 
ABCR function explains the much more severe phenotype in these patients compared to the 
STGD1 and CRD phenotype. In addition, a marked similarity in phenotype can be observed 
in these RP patients: unlike most other combinations of ABCA4 mutations the functional 
consequences of two null mutations are always the same. 
 
Histopathology 
Although electron microscopy has revealed lipofuscin deposits in a patient with RP, this study 
was performed on a dominantly inherited form of RP.171 These findings should therefore not 
be used in the discussion on the pathogenesis of ABCA4-associated RP.172 It is to be expected, 
though, that histopathologic and/or autofluorescence imaging studies on genetically proven 
eyes with ABCA4-related RP will demonstrate increased accumulation of lipofuscin in the 
RPE. These studies will have to be conducted at a relative early stage, before the onset of 
widespread RPE atrophy. 
 
 
The ABCA4 gene and age-related macular degeneration  
 
Clinical aspects  
Age-related maculopathy (ARM) has been described for over 100 years and represents a 
group of degenerative disorders of the macula, which are increasingly frequent after 65 years 
of age.173 Early ARM is defined as the presence of (soft) drusen and RPE pigmentary 
abnormalities. The late stage of ARM is similar to age-related macular degeneration (AMD or 
ARMD2; MIM:153800) and includes both ‘dry’ and ‘wet’ AMD. Dry AMD or geographic 
atrophy is characterized by sharply delineated area of hypopigmentation, depigmentation or 
apparent absence of the RPE. Wet AMD, also called neovascular or exudative AMD, is 
characterized by subretinal choroidal neovascular membrane formation.173 Overall, the AMD 
phenotype is highly diverse and ranges from minor atrophic changes to the RPE and 
associated neurosensory detachments to subretinal haemorrhages and disciform lesions 
extending beyond the vascular arcades.174 
 The most important risk factor that has been identified, is advanced age. Most studies 
showed an increased prevalence of all types of AMD in the white populations and there is 
some evidence for increased incidence of neovascular AMD among women.175 Several 
environmental risk factors have been identified, such as light exposure, as well as dietary and 
medication factors. Cigarette smoking, however, is the only risk factor, other than age, that 
has been consistently identified in numerous studies.175 The evidence for genetic factors in 
AMD, derived from twin-concordance, linkage studies and biomolecular investigations, is 
compelling.176 
 In the search for genes involved in the development of AMD, attention was quickly 
focused on heredomacular degenerations bearing phenotypic resemblance with this disorder. 
Examples include Best disease (VMD2), Sorsby fundus dystrophy (TIMP3), Doyne 
honeycomb retinal dystrophy (EFEMP1), and the retinal disorders associated with mutations 
in the RDS/peripherin gene. Various linkage studies, however, could not relate these macular 
dystrophy genes with increased susceptibility for AMD.177-180 This lack of positive linkage 
may not come as a surprise given the fact that these macular disorders are all inherited in an 
autosomal dominant fashion, which makes their association with a multifactorial and 
genetically complex disorder such as AMD less likely. Nevertheless, it may be possible that 
the coincidence of subclinical mutations in a number of these genes could lead to the 
development of AMD.  
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A number of molecular genetic studies have managed to identify a number of genetic 
associations (Table 2). Certain alterations in the manganese superoxide dismutase gene and 
the CST3 gene are significantly associated with an increased risk for AMD.144,147 Conversely, 
a specific polymorphism of the angiotensin converting enzyme gene seems to confer 
protection against the geographic form of AMD.181 In addition, several loci that may 
contribute to the development of age-related maculopathy have been identified in multiplex 
families.148,149 
 
AMD and the ABCA4 gene 
The role of ABCA4, currently the only gene associated with autosomal recessive macular 
dystrophy, in AMD has also been investigated. STGD1 and AMD share obvious phenotypic 
features, such as an increased accumulation of lipofuscin in the RPE and concomitant 
progressive atrophy of the overlying central retina. Also, the observation of late-onset forms 
of STGD1 suggests overlap between the two disorders (Appendix 6).18,66,70,182 To test the 
hypothesis that alterations in the ABCA4 gene contribute to the development of AMD, 
Allikmets and co-workers screened 167 unrelated AMD patients and 220 racially matched 
controls for ABCA4 sequence variations.13 A significant number of 26 (16%) heterozygous 
ABCA4 mutations were noted in the AMD group, compared to 1 (0.45%) in the control 
population. Two variations, G1961E and D2177N, were most frequently found, in 6 (3.6%) 
and 7 (4.2%) of the 167 AMD patients respectively. These findings suggest that some ABCA4 
alterations may enhance susceptibility to AMD in the heterozygous state. A flurry of 
subsequent studies, however, could not confirm the association of the two most frequent 
AMD-associated sequence variations with AMD (Table 6). Only one other study, a large 
international study with 1218 AMD patients and 1258 matched healthy individuals could 
confirm the initial finding.83 This study demonstrated an approximately three-fold elevated 
risk (odds ratio 2.8, 95% confidence interval (CI): 1.2-7.4) of AMD for the D2177N variant 
carriers and a five-fold risk (odds ratio 5.0, 95% CI: 1.6-20) for the G1961E variant carriers. 
 Several issues potentially confound these correlation studies.183 In general, genetic 
analysis in AMD is complicated by the late onset of the disease and the multiple genetic and 
environmental influences that act in concert. In addition, AMD is a morphologically divers 
disorder, which complicates genotype-phenotype correlation. This is illustrated by the large 
number of multiplex AMD families in some studies and the inclusion of both wet and dry 
forms of AMD in most of the studies in Table 1.184,185 The small sample size in many studies 
is perhaps the most important reason for conflicting results.186 This could explain the positive 
correlation found in the ABCR consortium study and in the meta-analysis displayed in Table 
6. Another complicating factor is the ethnic differences between the various study 
populations. In one study, the frequency of the G1961E and D2177N variants ranged from 
0.99% in AMD patients from the United States to 5.1% in patients from Switzerland.187 In 
contrast, similar studies conducted in Asia did not find any of these allelic variants in 245 
AMD patients (Table 6, Kuroiwa et al., Fuse et al. and Baum et al.).82,188,189 Interestingly, the 
G1961E sequence variation was found in 11.5% of healthy controls of Somali ancestry.187 
This raises the question whether G1961E represents a truly pathogenic variation or is in 
linkage disequilibrium with a disease-associated variant. The lack of reports mentioning a 
higher incidence of either STGD1 or AMD in individuals with Somalian ancestry supports the 
latter. Finally, the issue of phenocopies has been raised.183 It is possible to misinterpret a late-
onset or end-stage STGD1 for an atrophic macular degeneration. Given the current efficiency 
in mutation detection (Table 1) one can never completely exclude the possibility of an 
autosomal recessive STGD1 in individuals harbouring the G1961E or D2177N alleles.  
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Table 6. Frequency of heterozygous G1961E and D2177N variants in AMD patients versus control population. 
 
G1961E D2177N 
Authors Year 
AMD Controls 
P (OR) 
[95% CI] 
AMD Controls 
P (OR) 
[95% CI] 
Allikmets et al.13 1997 6/167# 0/220 0.006 7/167# 1/220 0.012 
Stone et al.190 1998 1/182 0/96 0.65 2/182 0/96 0.42 
Kuroiwa et al.82 1999 0/80 0/100 n.a. 0/80 0/100 n.a. 
De la Paz et al.184 1999 0/165§ 0/56 n.a. 2/165§ 0/56 0.56 
ABCR consortium83 2000 19/1218 4/1258 0.001 21/1218 8/1258 0.005 
McNeil et al.191  2000 2/177 0/150 0.29 5/177 0/150 0.45 
Fuse et al.189 2000 0/25 0/40 n.a. 0/25 0/40 n.a. 
Webster et al.66 2001 1/182 0/96 0.65 2/182 0/96 0.43 
Guymer et al.187 2001 5/544 3/689 0.24 7/544 4/689 0.16 
Baum et al.188  2003 0/140 0/95 n.a. 0/140 0/95 n.a. 
Schmidt et al.185 2003 0/70† 0/59 n.a. 0/70† 0/59† n.a. 
Overall  34/2950 7/2859 < 0.0001 (4.7) 
[2.1-10.6] 
46/2950 13/2859 < 0.0001 (3.4) 
[1.9-6.3] 
 
The study of Rivera and co-workers is included in the ABCR consortium study.70,186 Studies in bold have reported statistically 
significant differences in the frequency of G1961E and D2177N alleles between AMD patients versus control population. #All but one 
of the mutations were found in patients with the ‘dry’ form of AMD. §159 familial cases were recruited from 112 multiplex AMD 
families ( 2 affected subjects per family). †70 patients from 165 multiplex AMD families. OR, odds ratio; CI, confidence interval; n.a., 
not applicable. P values were extracted from the one-sided Fischer’s exact test and the odds ratios were calculated from the exact 
conditional hypergeometric distribution. 
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Several studies investigated family members of patients with ABCA4 mutations to 
determine whether siblings, parents or grandparents, who were heterozygous for the affected 
allele, manifest AMD.68,192 Lewis et al. reported a positive family history of AMD in the 
lineage of direct descent to the affected sibship(s) in 31 (21%) of 145 STGD1 families. 
Although this number is higher than expected, no definitive relation can be deduced in view 
of the high prevalence of AMD (>10% of individuals >65 years of age) in the general 
population.193 Another study performed genotype-phenotype analysis in siblings of 26 AMD 
patients carrying putative disease-associated ABCA4 variants.194 A significant correlation 
between the proband’s variant ABCA4 allele and risk of AMD in the siblings was not shown. 
Several studies investigated familial cases of AMD, but could not detect different frequencies 
of ABCA4 sequence variants in patients compared with control subjects.184,185,195 None of 
these mostly small-scale studies was therefore able to demonstrate a statistically significant 
association of AMD with ABCA4 alterations. In contrast, Shroyer and associates, investigated 
22 families and found that AMD-affected relatives of STGD1 patients are more likely to be 
carriers of pathogenic alleles.84 
 Support for the putative role of heterozygous ABCA4 mutations in macular 
degeneration was obtained from the Abcr mouse model. Analysis of the ocular phenotype in 
Abcr+/- mice indicates that A2-E, which is a major fluorophore of lipofuscin,28  accumulates 
in the RPE in a manner resembling the formation of drusen in AMD.30 This suggests that 
individuals heterozygous for ABCA4 mutations may be predisposed to A2-E accumulation 
and late-onset macular degeneration. One has to keep in mind though, that the G1961E or 
D2177N alleles do not represent null mutations.83  
 In summary, the basis for the assumption that certain sequence variations increase 
susceptibility for AMD is founded on the overall observation that these variants are present in 
a greater percentage of AMD patients compared to controls. This finding could not be 
confirmed by smaller-sized studies, as well as by most of the cosegregation studies in AMD 
patients and their relatives. Establishing causality in a highly polymorphic gene such as 
ABCA4 will be difficult in the absence of data on the functional consequences of the G1961E 
or D2177N alleles with regard to ABCR function and lipofuscin accumulation. To investigate 
the role of these variations and perhaps other pathogenic ABCA4 mutations, large series of 
AMD patients will have to be tested with the recently developed ABCR400 gene chip. 
Although circumstantial evidence points to a certain role for this gene in the development of 
AMD, the exact relation between the ABCA4 gene and AMD remains unclear. At present, it 
remains uncertain to which extent and under which circumstances the heterozygous presence 
of mutant ABCA4 alleles would have phenotypic consequences. 
 
 
Pathophysiology of ABCA4 retinal disorders 
 
Biochemical mechanism 
In the last couple of years our understanding of the complex genetic and biochemical 
mechanisms underlying STGD1 and other ABCA4-related disorders has improved 
tremendously. We are now able, at least in the animal model, to describe the process of visual 
loss resulting from dysfunction of the ABCR protein.  
Light exposure leads to elevated levels of all-trans-retinal in the membrane discs of the 
photoreceptor outer segment. Complete or partial inability by ABCR to transport all-trans-
retinal through the disc membrane will prevent reduction of all-trans-retinal by retinol 
dehydrogenase, since this enzyme is located at the cytoplasmic side of the membrane.63 A 
significant portion of all-trans-retinal is therefore excluded from the visual cycle and builds 
up in the lumen of the photoreceptor disc, partially as N-retinylidene-PE. A secondary 
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condensation of N-retinylidene-PE with all-trans-retinal forms A2PE-H2 (dihydro-N-
retinylidene-N-retinyl-phosphatidylethanolamine). Following shedding and phagocytosis of 
the photoreceptor outer segments by the RPE, A2-E (N-retinylidene-N-retinylethanolamine) 
is formed through various intermediates (Fig. 5).27,29 In 11 month old Abcr-/- mice, the A2-E 
levels were approximately 20-fold higher in RPE compared to wild-type mice raised under 
normal lighting.26 A2-E formation ultimately depends on light exposure. Mata et al 
demonstrated that A2-E formation is suppressed when Abcr-/- mice were raised in total 
darkness.27  
 Since RPE cells are unable to clear A2-E, the concentration of this compound will rise 
over time.27 The length of time necessary for A2-E to reach toxic levels will ultimately 
depend on the degree of impairment of the ABCR protein. A2-E has several cytotoxic effects 
on RPE cells. A2-E inhibits the lysosomal degradative functions and impairs the degradation 
of phospholipids from the phagocytosed outer segment.196-198 It acts as a lysosomatropic 
detergent, dissolving cellular membranes.28,199 Secondary to disintegration of the lysosomal 
membrane, subsequent damage to mitochondria releases pro-apoptotic proteins.199 A2-E is 
also capable of sensitizing the RPE cells to blue-light damage.200,201 Eventually, A2-E will 
induce apoptosis in the RPE cells.202 Photoreceptor degeneration will then follow RPE cell 
death, as a result of loss of the RPE support role.203 
 
Correlation with human ABCA4-associated photoreceptor dystrophies  
The above outlined pathogenesis in ABCA4-related ocular disease is consistent with many of 
the findings in patients with STGD1 and related disorders. The typical yellow flecks in 
STGD1 represent RPE cells engorged with lipofuscin.128 Analysis of postmortem retina/RPE 
samples revealed 6- to 12-fold elevated levels of A2-E in samples from FFM/STGD1 patients 
compared with human controls.27 The apparent inverse relation between the number of yellow 
flecks and the severity of the retinal phenotype might be explained by the earlier loss of RPE 
cells in patients with more severe types of dystrophy. This also explains the gradual 
disappearance of flecks in STGD1 patients with progression of the disorder (see also patient 
VII in Chapter 3 and case 5 in Appendix 6).18 
 Defective dark adaptation is the hallmark of RP and is caused by dysfunction or death 
of rod photoreceptors, but delayed dark adaptation has also been found in a limited number of 
patients with STGD1102,110,111 and CRD.141,152 Delayed dark adaptation was more frequently 
encountered in ABCA4-associated CRD compared with CRD as a whole, suggesting that this 
might be a typical finding in ABCA4-associated CRD.141,152 The rate-limiting step in 
rhodopsin turnover at high-light levels was shown to be chromophore regeneration.204,205 
Accordingly, delayed dark adaptation is most likely caused by the insufficient rate of 11-cis-
retinal regeneration, possibly in combination with the accumulation of all-trans-retinal, which 
interacts with opsin to form a ‘noisy’ photoproduct. This suggests that the removal of all-
trans-retinal by ABCR and the subsequent reduction by retinol dehydrogenase, contributes to 
recovery of photosensitivity by lowering the concentration of all-trans-retinal and increasing 
11-cis-retinal regeneration.206 This corresponds to the observation that Abcr+/- and Abcr-/- 
knockout mice, as well as a number of patients with ABCA4-associated retinal disorders, 
exhibit a pronounced delay in dark adaptation.30  
 The absence of the normal background fluorescence is typically associated with 
STGD1, although not all patients demonstrate this peculiar fluororescein angiographic 
finding. Increased levels of lipofuscin, caused by accumulation of A2-E in the RPE cells, are 
thought to absorb the blue excitatory light and thus cause the characteristic ‘dark choroid’ on 
the fluorescein angiogram in these patients.129 A dark choroid has also been observed in 
patients with ABCA4-related CRD,152 but has not been reported in patients with RP caused by 
mutations in ABCA4. These findings suggest that blocking of the choroidal background 
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fluorescence by lipofuscin accumulation does either not occur or may be limited to the early 
stages in patients with severe or complete ABCR transporter dysfunction, perhaps because of 
early atrophy of the RPE.  
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Figure 5. Hypothetical degradation pathway for all-trans-retinal to A2-E in mice and humans. 27,29  
1. After photobleach, all-trans-retinal and PE are in equilibrium with APE. 2. A second condensation 
with an all-trans-retinal molecule may occur and the bis-retinoid A2PE-H2 is formed. This is an 
irreversible step at neutral pH. 3. Oxidation of A2PE-H2 to A2PE occurs within the RPE 
phagolysosomes. 4. Finally A2-E is formed and phosphatidic acid is released through acid hydrolysis 
within the phagolysosomes.  
 
 
 The psychophysical and electroretinographic observations that many STGD1 patients 
exhibit rod and cone deficits throughout the retina, is also in accordance with the proposed 
pathogenesis. In light of these data, STGD1 should not be considered a macular dystrophy but 
rather a disorder affecting the entire retina, although the symptoms and clinically observed 
abnormalities may be limited to the macula. 
 Photoreceptor degeneration in human inherited degeneration in general is commonly 
nonuniform. This is also seen in STGD1 and CRD where photoreceptor death is most severe 
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in the central retina. This may be attributable to regional differences in the human retina, 
demonstrated by the specialized function of the macula and the fact that RPE cells exhibit 
regional characteristics, such as variations in morphology, growth potential and different 
levels of expression of protein.207 Accordingly, these regional differences lead to differences 
in the response of photoreceptors to a mutant gene, but the precise underlying molecular, 
cellular or environmental mechanisms remain speculative. We may, however, safely assume 
that the metabolic strain is highest in the macula when photoreceptor density in this region is 
considered. This applies to cones but also to rods, which are present in a much higher density 
(150.000 per mm2) in the macula when compared to the peripheral retina (30.000 per mm2).208 
It has been shown that the rate of lipofuscin accumulation in the RPE is related to increasing 
age as well as the density of overlying photoreceptors.209 It is therefore likely that ABCR 
dysfunction leading to the accumulation of toxic A2-E in the RPE, will initially manifest at 
the macula. With some residual ABCR transport activity, symptoms might be limited to the 
posterior pole, corresponding with STGD1 and AMD phenotypes. More severe impairment, 
however, could result in peripheral extension of the degenerative process in the later stages of 
disease, resulting in the more widespread CRD-like phenotype. The most severe phenotype is 
RP, characterized by massive atrophy and early loss of visual functions. In our experience, 
photoreceptor degeneration in this phenotype seems to occur almost simultaneously in both 
rod and cone systems. (Appendices 1, 4 and 6).16,127,150 Since loss of visual acuity has a 
greater impact on the visual function than night blindness, initially, the latter may not be 
noticed. This finding corresponds with the majority of ABCA4-associated RP patients that 
carry homozygous null mutations. On the other hand, a limited number of ‘classic’ RP cases 
with ABCA4 gene mutations have been described (Table 4). In our opinion, pathologic 
involvement of the ABCA4 gene in these patients remains doubtful, as discussed in the section 
on ABCA4-associated RP in this chapter.  
 It must be stressed that many of the insights in the underlying biochemical 
mechanisms have been derived from the study of transgenic mice and may not necessarily 
represent the exact pathogenic mechanism in human ABCA4-related disease. Delayed dark 
adaptation, for instance, is a consistent finding in transgenic mice but is not present in many 
patients with STGD1 and other ABCA4-related disease.111,141 Recently, an attempt was made 
to correlate the proposed model of disease sequence with clinical findings in 47 patients with 
STGD1 and CRD.210 This in vivo study observed elevated lipofuscin levels in the early stage, 
as well as photoreceptor/RPE loss, although regional differences were noted. Slowing of the 
retinoid kinetics cycle, when present, was also not homogeneously present in different parts of 
the retina. Furthermore, the extent of slowing correlated with the severity of the disease. 
Although these findings seem to indicate that the disease model in human ABCA4 retinal 
dystrophy is not fully understood, it remains controversial whether these in vivo 
measurements accurately reflect the pathologic processes in the retina. 
 
Genotype-phenotype correlation 
Characterization of the relationship between genotype and phenotype involves (1) 
differentiation between polymorphisms and disease-causing sequence variants, (2) assessment 
of the effect of these pathologic variants and (3) identification of the range of phenotypes 
associated with alterations in the gene. A comprehensive analysis of genotype and phenotype 
in STGD1 is complicated by the high allelic heterogeneity of the ABCA4 gene. Furthermore, 
the absence of a functional evaluation for most of the observed sequence variations, and the 
fact that sequence variations of the ABCA4 gene are often not identified on both alleles makes 
it difficult to estimate the extent of the ABCR transporter activity impairment. Finally, 
comparison of the ABCA4-phenotypes may not be easy, since a limited number of objective 
criteria are available. Moreover, observed differences may be attributable to duration of the 
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disorder and thus merely represent different stages in the progression of the retinal disease. 
Despite these difficulties, a meaningful correlation can be made with regard to ABCA4 gene 
mutations and the resulting type of retinal dystrophy.  
Theoretically, each specific combination of ABCA4 alterations will result in an equally 
specific loss in active transmembrane movement of all-trans-retinal (or N-retinylidene-PE). A 
sliding scale from normal to complete absence of ABCR transport activity thus emerges. 
Herein, ABCR differs from RDS/peripherin, another photoreceptor specific protein implicated 
in multiple retinal dystrophies, which is involved in structural integrity.166 A second 
observation relates to the resulting ABCA4 associated retinal dystrophies. Although quite 
different in clinical presentation, overall, an increase in rate and extend of photoreceptor cell 
death can be observed in patients with STGD1, CRD and RP. In view of these findings, a 
genotype-phenotype model was proposed in which loss of transport function is related with 
the rate and extent of photoreceptor degeneration.15,16,20,211 More specific, in this model the 
activity of ABCR as a transporter of all-trans-retinal through the photoreceptor disc 
membrane is more severely affected in CRD patients compared to STGD1 patients, but not 
completely abolished as in RP patients (Fig. 6). Although certainly not undisputed, AMD is 
also included in this model.  
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Figure 6. The ABCA4 genotype/phenotype correlation model. The plus sign indicates a 
normal allele; ar, autosomal recessive. Decreasing ABCR transport function results in retinal 
phenotypes characterized by increasing photoreceptor cell death. 
 
 
Mutation analysis data, though often unequivocal as explained above, largely seem to concur 
with the proposed genotype-phenotype model. As stated earlier, STGD1 patients typically 
display a severe (null) mutation in combination with a mild missense mutation, or two 
moderately severe missense mutations. These findings suggest that in STGD1 at least partial 
ABCR transport function is retained, resulting in diminished but not complete loss of ABCR 
activity. Conversely, the combination of two ABCA4 null alleles, predicting the absence of 
functional transcript, leads to the severely atrophic RP phenotype. Although mutation analysis 
data largely seem to concur with such a model,125,211 exceptions have been reported.73,158 
Furthermore, it is obvious that the above outlined model does not explain the clinical 
variability encountered in ABCA4 retinal disease. Phenotypic variability of considerable 
degree, even in patients with identical mutations, has been observed.73 The variability in 
phenotypes may be due to allelic differences, genetic modifying factors in the background, 
environmental influences, or a combination of these factors. It is therefore to be expected that 
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both the genotype-phenotype model and the biochemical model for A2-E accumulation 
represent simplified reflections of reality.87  
There is an inherent danger in consequently applying the current genotype-phenotype model 
to prove the pathogenicity of certain allelic variations. This might lead to circular 
argumentation and faulty assumptions. Ideally, the definite pathogenicity of ABCA4 sequence 
variations must be ascertained through analysis of the transcript and/or functional assay of the 
resultant ABC transporter. An exception could be made for obvious null mutations leading to 
complete absence of functional transcript. 
   
Intermediate phenotypes 
The seemingly inverse relation between ABCR function and retinal phenotype will result in a 
continuum of phenotypes ranging from late-onset FFM/STGD1 to a type of RP that is 
characterized by an almost simultaneous degeneration of central and peripheral 
photoreceptors (Appendix 6).18 Besides typical phenotypes such as FFM/STGD1, CRD and 
RP, intermediate phenotypes may be encountered. Such retinal dystrophies have been 
reported throughout the years and classification of these disorders was often difficult. In this 
respect, genetic molecular analysis has stimulated ophthalmologists to classify retinal 
dystrophies less rigidly. 
Examples of intermediate phenotypes include late-onset FFM/STGD1 that overlaps with 
AMD, STGD1 with peripheral involvement, cone-rod dystrophy with extensive peripheral 
degeneration and RP with simultaneous photoreceptor loss in the central and peripheral retina 
(Appendix 6).18 Conversely, distinctly different phenotypes may converge to a similar final 
stage, characterized by extensive chorioretinal atrophy and very low visual functions.  
 Souied and co-workers described a patient similar to the late-onset FFM patient in 
Appendix 6 (case 2).18 Mutation analysis in both patients revealed a heterozygous truncating 
mutation in the ABCA4 gene. According to the genotype-phenotype model a compound 
frameshift and missense mutation would result in STGD1 or CRD. The presence of an 
undetected missense mutation in the other allele was therefore deemed unlikely. It was 
postulated that heterozygous null mutations in the ABCA4 gene could result in mild ABCA4-
related phenotypes, analogous to certain heterozygous sequence variations associated with the 
development of AMD.182  
 It is conceivable that a significant portion of CRD patients initially demonstrate 
abnormalities commonly associated with STGD1. In a recent study we evaluated 19 ABCA4-
related CRD and found that 3 patients (16%) initially had been diagnosed as having STGD1 
(Appendix 5).76 In the early stages of their retinal dystrophy ophthalmoscopy revealed faint 
yellow spots and a variable degree of macular atrophy. As the disease progressed peripheral 
involvement became obvious, including progressive abnormalities of the ERG in a cone-rod 
pattern. Cleary, these phenotypes represent intermediate forms in the spectrum of ABCA4 
retinal dystrophies which may be labelled either as STGD1 with peripheral progression or as 
CRD.   
With the advent of therapeutic approaches, recognition by the general ophthalmologist of the 
various retinal phenotypes associated with ABCA4 mutations becomes increasingly important.  
 
Intrafamilial manifestations of multiple ABCA4 phenotypes 
Since variable combinations of ABCA4 mutations lead to different phenotypes, the genotype-
phenotype model implicitly predicts the occurrence of families harbouring different types of 
ABCA4-associated retinal disorders. At the moment at least 7 of such families have been 
reported.16,27,90,168,170 
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In the 4 families described by our group, 2 families manifested both STGD1 and RP, whereas 
2 other families displayed the combination of RP and CRD (Appendices 1 and 4).16,127,150 In 
three families (Family A, B and K) all causative ABCA4 mutations could be identified.  
In the recently described family A (Fig. 7) two sisters were diagnosed with Stargardt disease 
(STGD1); the eldest sister was compound heterozygous for the mild 2588G→C and the 
severe 768G→T mutation.127 Their uncle had been diagnosed with RP and carried the 
768G→T null mutation homozygously (Appendix 4).127 
 
 
 
 
 
 
 
 
 
 
Figure 7. Pedigree of family A 
harbouring multiple ABCA4-
related retinal dystrophies.  
 
 
 
 
 
 
 In Family B (Fig. 8), all affected individuals carried the IVS33+1G→A mutation.127 
This sequence change inactivates a splice site; in general, such a mutation will result in a 
truncated (nonfunctional) protein. Individuals homozygous for this supposed null allele 
develop RP, with early loss of central and peripheral vision and severe atrophy. The patient 
compound heterozygous for this mutation and the mild 2588G→C mutation,57 demonstrates 
the milder STGD1 phenotype (Appendix 4).19,127  
 
 
 
 
 
 
 
 
 
 
Figure 8. Pedigree of family B 
displaying the combination of 
ABCA4-associated RP and 
STGD1. 
 
 
 
 
 
 Another example, which involves the combination of CRD and RP, is found in the 
consanguineous Family K. Again, homozygosity for a null allele (IVS30+1G→T) results in 
the severe RP phenotype. Compound heterozygosity for this allele and the IVS40+5G→A 
1 2
RP RP
IVS33+1G>A
2588G>C
STGD
3
1 2
I 
II
III
IV
1 2 3
STGD
IVS33+1G>A
2588G>C
IVS33+1G>A
IVS33+1G>A
6421
IVS33+1G>A
IVS33+1G>A
5
B
1 2
AMD
768G>T
1 2 3 4
768G>T
768G>T
RP
768G>T
2588G>C
STGD
1 2 3 4 5 6
I
II
III
IV 1 2 3
STGD
A
Chapter 2 
64 
mutation, with some predicted residual ABCR functionality,70 results in a slightly less severe 
phenotype labelled as CRD-like (Appendix 1).150 
 The frequent homozygous presence of severe ABCA4 mutations in ABCA4-RP patients 
is suggestive of consanguinity (Table 5). However, a second ABCA4 mutation is necessary in 
order for another retinal phenotype to emerge within a family. In this respect, the high carrier 
frequency of pathologic ABCA4 mutations in the general population is important. Therefore, 
the occurrence of variable combinations of STGD1, CRD and/or RP in the same family is not 
as infrequent as once thought (Appendix 4).127 
 
 
The implications for clinical practice 
 
Classification of ABCA4 retinal disorders 
Most present classifications of hereditary retinal diseases are based on the inheritance pattern 
and the clinical phenotype. Inherited retinal disease can be classified as progressive or 
stationary, and whether the abnormalities are located at the macula or affect (nearly) the entire 
retina. Generalized retinal dystrophies are then further divided according to which type of 
photoreceptor is predominantly affected throughout the course of the disease.  
 Because very few retinal disorders are genotypically homogeneous, a genetic 
classification may be preferable to ensure the best genetic, prognostic and therapeutic 
advice.212 However, often the identification of the causative gene does not greatly improve 
classification because a substantial variability in clinical presentation is still observed. 
Different mutations in the same gene may even result in completely different phenotypes. We 
only begin to see the clinical implications of certain mutations, but overall, the correlation 
between genotype and phenotype still holds many mysteries. We do not only need to identify 
the specific genetic defects, we also need to understand the functional consequences before 
accurate predictions regarding the resultant phenotype can be made. Even then, unidentified 
environmental, local and/or genetic factors may exert their influence. At the moment, we can 
not estimate and therefore not predict the effect of those factors. Current clinical 
classifications may eventually be replaced by genetic classifications, but at this moment such 
a classification is unpractical. For the time being, we will have to rely on a classification 
based on a combination of both clinical and genetic findings. 
  
Genetic counselling 
Many studies mention a STGD1 prevalence of 1/10.000, referring to the number brought up 
by Blacharsky in 1988.91 Estimated carrier frequencies for mild, moderate and severe ABCA4 
mutations have been estimated at ~0.04, ~0.018 and 0.008, respectively.19 Based on these 
numbers, the incidences of the various retinal disorders associated with ABCA4 mutations can 
be estimated (Table 7). Furthermore, it can be calculated that a child of a healthy individual 
and a patient with STGD1 will have a risk of 1/83 of developing STGD1, 1/400 of developing 
CRD and 1/500 of developing RP.19  
Screening for mutations, in new patients or family members at risk, in a gene such as ABCA4 
is no longer problematic with the current microarray technology. However, the inability to 
identify all disease causing mutations, the uncertain pathogenicity of several sequence 
variants (in particular missense mutations), and the relatively low risk for retinal disease in the 
offspring of patients and mutation carriers, make routine testing in STGD1 not  
straightforward. Limited screening of already identified allelic variations in a family might be 
of use in selected patient groups.  
 In addition, it is important to gain a better understanding of all the factors, genetic and 
otherwise, that are of influence on the extent and the rate of progression of the retinal 
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dystrophy. In patients with STGD1, for instance, it would be important to predict whether a 
given combination of mutations would result in a dystrophy limited to the central retina, or 
whether the peripheral retina will also be involved in the later stages. At the moment, 
however, the combination of a detailed ophthalmologic examination and an ERG probably 
provides a more accurate prognosis. Also, this method is quicker and more cost-effective than 
routine molecular genetic analysis. 
 
  
  
 
 
 
 
 
 
 
 
Table 7. Estimated incidences of 
combinations of different types of 
ABCA4 mutations and predicted 
associated phenotypes.  
 
 
   
 
Limitation of aggravating factors  
Light damage   
Excessive light exposure may contribute to ABCA4-associated retinal disease in a number of 
ways. The first reason ensues from the primary pathologic defect in these disorders. 
Dysfunction of the ABCR transporter leads to increased levels of all-trans-retinal. 
Accumulation of the toxic A2-E ultimately depends on the formation of all-trans-retinal and 
hence on light exposure.27 The strong light dependence of A2-E formation was shown in 
Abcr-/- mice raised under total darkness versus 12-h cyclic light at 30 lux.27 At 18 weeks 
under cyclic light the levels of A2-E in Abcr-/- mutants were dramatically higher than those of 
wild-type mice (25,7 ± 2,6 vs. 1,98 ± 0,62 pmol/eye). In contrast, A2-E levels were similar 
between 18 week old wild-type and Abcr-/- mice raised in total darkness.27 Interestingly, A2-
E levels were not significantly changed in 5-month-old Abcr-/- mice after prolonged exposure 
to light at 30 versus 120 or 1.700 lux. This suggests that the light-dependent increase in A2-E 
formation plateaus between 30 and 120 lux ambient light.213 This is a fairly low level of light, 
since light in a typical office environment is at least 300-500 lux and light on a grey winter 
day is approximately 5.000-10.000 lux. Therefore, reduction of light exposure to prevent or 
slow down A2-E production seems not very practical in patients with ABCA4-associated 
disease.  
 There is, however, another reason for limitation of light exposure. The level of 
oxidative stress is light dependent and photooxidative damage has been implicated as one of 
the risk factors for AMD.214 Also in ABCA4-associated disorders there is evidence that 
oxidative stress contributes to the retinal pathology. There is a role for retinal or other 
retinoids in photooxidative damage, since (a) photoexcited all-trans-retinal can generate 
singlet oxygen, (b) dietary vitamin A depletion protects the retina from chronic light damage 
and (c) retinas of Rpe65 knockout mice, in which rhodopsin is absent or greatly reduced, are 
highly resistant to oxidative light damage.206 Mutations in the ABCA4 gene might facilitate 
photooxidative damage of the retina and the RPE in several ways. First, it has been 
Combination of 
ABCA4 alleles Incidence Phenotype 
Mild / + 1/25 Normal 
Moderate / + 1/100 Normal 
Severe / + 1/125 Normal 
Mild / mild 1/2.500 Normal 
Mild / moderate 1/10.000 Normal 
Mild / severe 1/12.500 STGD1 
Moderate / moderate 1/40.000 STGD1 
Moderate / severe 1/50.000 CRD 
Severe / severe 1/62.500 RP 
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demonstrated that A2-E is an initiator of blue-light-induced apoptosis in retinal pigment 
epithelial cells (RPE).201 Following irradiation with blue light (430 nm), A2-E has been 
shown to undergo a light-dependent oxidation, by the addition of a singlet oxygen, to yield a 
series of oxirane products.215 These A2-E oxiranes were capable of inducing DNA 
fragmentation in cultured RPE cells.216 In a recent study in Abcr-/- mice, Radu et al 
demonstrated that the conversion of A2-E to oxiranes depends on the level of ambient light.213 
Since A2-E accumulation accelerates when ABCR function is diminished; pathologic ABCA4 
gene mutations are probably associated with increased susceptibility to light toxicity. Second, 
in vitro studies demonstrate that ABCR is highly susceptible to all-trans-retinal mediated 
photooxidative damage. ABCR photodamage occurs selectively at the TMD, which 
presumably harbours the all-trans-retinal translocation site. This suggests that the 
vulnerability of the ABCR protein to photooxidation by all-trans-retinal is related to its 
transporter function.206 Third, the photooxidation derived products from the rod outer segment 
will accumulate in the already by A2-E burdened RPE cells, thereby accelerating RPE 
poisoning.206 
In view of these data, it would seem advisable to encourage patients with STGD1 and other 
ABCA4-associated dystrophies to avoid excessive light exposure. In addition, the benefit of 
antioxidants in these patients should be investigated. The xanthophyll carotenoids – 
zeaxanthin and lutein – are especially of interest, since, besides their antioxidant properties, 
these macular pigments act as a filter of incoming blue light.   
 When available, any form of prevention should be initiated as early as possible and 
preferably before the onset of symptoms, since A2-E, once formed, is not cleared by the 
RPE.27 
 
Vitamin A 
All-trans-retinol, also known as vitamin A, is the precursor of the 11-cis-retinal chromophore. 
Vitamin A is ultimately obtained from dietary sources, generally in the form of carotenoids 
such as -carotene. Though largely unsubstantiated, the supplementation of vitamin A in 
treatment and prevention of ocular disorders is widely practiced, both by clinicians and by the 
general public.  
In a study from 1994, the effects of high dose of oral vitamin A for at least 14 days did not 
result in objective improvement of the dark adaptation in patients with STGD1.118 This may 
not come as a surprise, considering the pathogenesis of ABCA4-associated retinal disorders. 
Slowing the synthesis of 11-cis-retinal has been shown to inhibit lipofuscin accumulation in a 
mouse model of STGD1 disease (see below).31 Since all-trans-retinol is one of the precursors 
of 11-cis-retinal, the supplementation of vitamin A and related compounds such as -carotene 
should be avoided, at least on theoretical grounds, in patients with ABCA4-associated retinal 
disorders.  
A similar dilemma involves the supplementation of vitamin A in patients with AMD or 
individuals at risk for this disorder. A positive effect of this vitamin has not yet been 
conclusively demonstrated. Moreover, in view of its role in A2-E accumulation, the use of 
vitamin A or -carotene supplements in AMD217 should be reconsidered.  
 
Chloroquine derivatives  
The toxic effects of chloroquine, and to a lesser extent hydroxychloroquine, on the 
neurosensory retina and RPE have been well described. Besides a daily dosage exceeding 250 
mg for chloroquine and 400 mg for hydroxychloroquine, no risk factors have been 
identified.218 Shroyer and co-workers evaluated 8 subjects with chloroquine and/or 
hydroxychloroquine retinopathy and found 2 patients with pathogenic ABCA4 mutations. The 
first patient carried the R1129C mutation heterozygously and the second patient was 
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compound heterozygous for the R2107H mutation and the complex allele L1201R;R2107H. 
In view of these data, it can not be excluded that retinotoxic compounds such as chloroquine 
and hydroxychloroquine may contribute to the development of a retinal dystrophy in 
genetically predisposed individuals. However, it is a distinct possibility that the heterozygous 
mutation in the first patient is coincidental, especially in view of the high carrier frequency for 
ABCA4 mutations. Furthermore, the fundus abnormalities in the second patient might also be 
interpreted as a late-onset ABCA4 retinal dystrophy instead of chloroquine retinopathy. This 
interpretation is supported by the ABCA4 mutations that were identified in this patient. These 
predict a severely compromised ABCR protein that, theoretically, could lead to retinal 
dystrophy. 
 
Speculations on treatment strategies 
Therapeutic approaches might be aimed at agents that increase the outflow of all-trans-retinal 
from the photoreceptor outer segments discs. Alternative treatment options include the 
development of agents that are either capable of preventing accumulation of A2-E, or 
degrading the A2-E that already has accumulated in the RPE cells. Since apoptosis is 
considered the final common pathway in inherited photoreceptor, therapy could also be aimed 
at preventing apoptosis.219 For patients in the end stage of the disorder, with already extensive 
loss of photoreceptor cells, the implantation of a retinal prosthesis might become an option.220  
 Ideally, the insertion of a functional copy of the ABCA4 gene in the photoreceptor 
DNA would completely restore the active transport of all-trans-retinal transport through the 
disc membrane.  
Several mechanisms for gene transfer are currently under investigation, each with their own 
advantages and disadvantages. Adenoviruses have been effective in transducing photoreceptor 
cells, but since there is no integration into the host DNA, the gene expression is limited to a 
few weeks.221 An alternative could be found in adeno-associated virus vectors, which have 
also been shown to transduce photoreceptor cells. These parvoviruses insert into the host 
genome at a specific locus, thereby increasing the likelihood of stable transgenic 
expression.221 The packaging limit of such vectors is about 4.8 kb, whereas the cDNA of 
ABCA4 is at least 6.8 kb.222 Interestingly, Ahn and co-workers recently demonstrated that co-
expression of the C and N halves of ABCA4 results in a functional protein.54 Packaging of the 
cDNA of the C and N halves into separate vectors should therefore result in a functional 
protein. RNA viruses may also be used as vectors and were already demonstrated to be 
effective in an animal model of retinal degeneration.223  
Since viral and retroviral vectors may provoke mutagenesis and carcinogenesis, several 
alternative methods of delivering plasmid vectors to the eye are under investigation. These 
include lipid/DNA complexes, microinjection, iontophoretic delivery, bioimplants and 
nanoparticles consisting of DNA encapsulated in biodegradable polymer.221,224,225 
 At this moment, a promising approach involves treatment with isotretinoin (13-cis-
retinoic acid, Roaccutane/Accutane), a drug currently used in the treatment of severe acne. In 
an animal model it was shown that isotretinoin slows rhodopsin regeneration and 
chromophore recycling, resulting in delayed dark adaptation and reduced night vision.32 
Isotretinoin inhibits the 11-cis-retinol dehydrogenase (11cRDH) and probably the retinoid 
isomerohydrolase (IMH) enzymes in the RPE (Fig. 9).32 In the same study it was shown that 
this agent also protects photoreceptors from light-induced damage. In an attempt to slow 
retinal disease by decreasing rhodopsin turnover and consequently A2-E formation, the effect 
of isotretinoin on Abcr-/- knockout mice was tested.31 In untreated Abcr-/- mice, the 
concentration of A2PE-H2 increased almost three fold and A2-E approximately doubled, 
between 3 and 4 months of age. In knockout mice treated with isotretinoin (40 mg/kg for 1 
month) the levels of A2PE-H2 and A2-E were virtually unchanged over the same period. 
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Interestingly, isotretinoin treatment did not only suppress formation of A2-E in Abcr-/- mice 
but also reduced A2-E accumulation in wild type mice by ~40%.31 A recent study showed that 
the formation of A2-E oxiranes in Abcr-/- mice is also strongly suppressed by isotretinoin.213 
 
 
 
 
 
 
 
 
Figure 9. Isomerohydrolase (IMH) 
isomerizes the all-trans-retinylester 
into 11-cis-retinol. This compound 
is subsequently oxidized by 11-cis-
retinol dehydrogenase (11cRDH) to 
form the 11-cis-retinal 
chromophore. Inhibition of 
11cRDH by isotretinoin 
presumably lowers the 
concentration of 11-cis-retinal, 
resulting in delayed dark 
adaptation in some patients and 
decreased accumulation of A2-E in 
Abcr-/- and Abcr+/- mice. 
 
 
 
 
There are still several potential drawbacks to isotretinoin therapy in human ABCA4-associated 
retinal disease. Important matters, such as the efficacy of isotretinoin in human retinopathies 
as well as the therapeutic dose in man, still have to be addressed. Furthermore, when proven 
effective, patients will have to start isotretinoin treatment at the earliest age possible and will 
have to continue using this drug for the rest of their lives. This may be problematic, because 
this drug is associated with a number of serious adverse effects, including symptoms of 
hypervitaminosis A226 and teratogenicity;227 in addition there is evidence that isotretinoin 
therapy might cause depression and suicide.228  
 Once therapeutic options become available for inherited retinal disorders, 
identification of the underlying genetic defect becomes of vital importance. In anticipation of 
such treatments, it may be advisable to collect DNA samples of patients with hereditary 
retinal disease, to allow a more efficient screening for individuals that are eligible for 
treatment.  
 
 
Conclusion 
 
For almost a century we have been looking at STGD1, but the identification of ABCA4 as 
causal gene has enabled us to truly look inside this retinal dystrophy. We have gained many 
new insights in the pathogenesis of STGD1 and its associated retinal disorders from this new 
point of view. A continuum of phenotypes have been linked to mutations in the ABCA4 gene, 
establishing genetic defects in this gene as the most prominent cause of Mendelian inherited 
retinal dystrophies. A genotype-phenotype model has been developed, which offers an 
explanation for the phenotypic diversity ensuing from pathologic ABCA4 sequence variations. 
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In addition, biochemical studies and the development of the Abcr knockout mouse model 
have revealed much of the molecular abnormalities underlying ABCA4 retinal disease.  
Still, there are many issues that need to be resolved. Our present understanding of the 
pathogenicity of the myriad of individual ABCA4 variations and their combinations is 
insufficient to accurately predict the type and extent of the resulting retinal dystrophy. The 
lack of insight in the modifying factors, local, genetic and environmental, does not help in this 
respect. 
Nevertheless, the data gathered over the past seven years, have allowed us to conceive and 
test the first rational treatment modalities. Eventually, these developments will have to result 
in a therapeutic regime capable of slowing or even preventing degeneration of the RPE and 
photoreceptors. Once these options become available, early recognition of the clinical 
phenotypes by the general ophthalmologist, as well as fast and reliable mutation screening 
techniques will become crucial to the treatment. Finally, it is altogether possible that a 
treatment that is capable of preventing A2-E accumulation might also benefit other disorders 
associated with lipofuscin accumulation, notably AMD. In this way, the identification of this 
specific disease gene may be of far greater impact than originally imagined. 
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Patient I – Age-related macular degeneration. This patient is described in appendix 6 (case 1). 
Fundus (age 69): drusen and mild atrophic changes. ABCA4 mutations: allele 1: G1961E; 
allele 2: not identified. 
 
 
 
 
Patient I – (cont.). Fluorescein angiography (one year later): choroidal neovascularization 
located temporal superior as well as inferior to the fovea. Also, the effects of a previous laser 
treatment of the drusen can be seen.  
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Patient II – Late-onset Stargardt disease. This patient is described in Appendix 6 (case 2). 
Fundus (age 69): irregular patches of geographic atrophy in the posterior pole. Faded, 
pisciform flecks in fundus flavimaculatus pattern surround the atrophic lesions. ABCA4 
mutations: allele 1: 768G→T; allele 2: not identified. 
 
 
 
 
Patient II – (cont.). Fluorescein angiography: atrophy in the posterior pole leaving the 
larger choroidal vessels exposed. Blocking of choroidal background fluorescence.  
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Patient III – Stargardt disease. Fundus flavimaculatus subtype (age 33) with multiple 
yellow, pisciform flecks scattered throughout the posterior pole and extending into the 
midperiphery. There is “beaten bronze” atrophy of the macula. ABCA4 mutations: 
allele 1: 2588G→C; allele 2: not identified. 
 
 
 
Patient IV – Stargardt disease. Fundus (age 27): typical yellow flecks and macular 
atrophy (age 27). Currently (age 47), the area of atrophy has spread through the 
entire posterior pole. ABCA4 mutations: allele 1: 768G→T; allele 2: 2588G→C. 
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Patient V – Stargardt disease. This patient is described in Appendix 6 (case 4). Faint, 
irregular flecks that surround the macula. ABCA4 mutations: allele 1: 2588G→C; allele 2: 
IVS40+5G→A. 
 
 
 
 
Patient V – (cont.). Fluorescein angiography: hyperfluorescent dots in the macula and 
typical blocking of the choroidal background fluorescence (dark or silent choroid).  
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Patient VI – Stargardt disease with progression to cone-rod dystroph (late stage). At the 
age of 6, this patient was diagnosed with STGD, as mentioned by Deutman in his thesis in 
1971 (ref. 104 in Chapter 2; patient II-3 on page 158). Over the years, progression to a 
cone-rod phenotype has occurred. At age 35, there is an extensive atrophy of the central 
retina. ABCA4 mutations: allele 1: 768G→T; allele 2: not identified. 
 
 
 
Patient VI – (cont.). Fluorescein angiography: impressive atrophy of the RPE and 
choriocapillaris, with an abrupt zone of transition and relative sparing of the midperiphery. 
There are hyperfluorescent dots in the (mid)periphery. 
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Patient VII – Stargardt disease with progression to cone-rod dystrophy (early 
stage). This patient is discussed in Appendix 5 (patient 16887). Initially, she was 
diagnosed with Stargardt disease. Currently (age 17), visual acuity is only hand 
movements and the ERG is disturbed for both rod- and cone-mediated responses. 
Fundus: large atrophic lesion in the macula surrounded by very faint yellow flecks. 
ABCA4 mutations: allele 1: 768G→T; allele 2: IVS38-10T→C. 
 
 
 
 
Patient VIII – Cone-rod dystrophy. This patient is described in Appendix 5 (patient 
15680) and Appendix 6 (case 7). Fundus (age 52): bull’s eye maculopathy and mild 
attenuation of the retinal arterioles. The ERG is disturbed in a cone-rod pattern. 
ABCA4 mutations: allele 1: G1961E; allele 2: not identified. 
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Patient IX – Cone-rod dystrophy. This patient noticed a decrease in visual acuity 
when he was 10 years old. At age 23, the visual acuity was 0.1 in both eyes. The ERG 
showed photoreceptor dysfunction in a cone-rod pattern. Fundus (age 23): 
“varnished” or “snail slime” appearance of the macula, in combination with an 
irregular bull’s eye pattern. ABCA4 mutations: allele 1: E1087K; allele 2: not 
identified. 
 
 
 
 
Patient IX – (cont.). Fluorescein angiography: moderate blocking of the choroidal 
fluorescence in the midperiphery. Numerous hyperfluorescent dots in the macula and 
peripheral to the temporal vascular arcades.  
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Patient X – Cone-rod-like dystrophy. This patient is a member of the consanguineous 
family in Appendix 1 (patient V-5). Central chorioretinal atrophy with irregular 
hyperpigmentation of the RPE (age 54). ERG deficit in a rod-cone pattern. ABCA4 
mutations: allele 1: IVS30+1G→T; allele 2: IVS40+5G→A. 
 
 
 
Patient XI – Retinitis pigmentosa. This patient is discussed in Appendix 4 (patient III-2, 
family A), as well as in Appendix 6 (case 9). Extensive atrophy, bone spicule 
pigmentation and severe narrowing of retinal vessels (age 53). The hazy spot in the 
centre is caused by anterior polar cataract. ABCA4 mutations: allele 1: 768G→T; allele 
2: 768G→T. 
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Aims: To describe two phenotypic variations of autosomal recessive retinal dystrophy 
occurring in a consanguineous family in a pseudo dominant pattern, resulting from 
mutations in the ATP-binding cassette transporter (ABCA4) gene. 
Methods: Patients of this family underwent an extensive ophthalmic evaluation, 
including fundus photography, fluorescein angiography and electroretinography (ERG). 
Genetic analysis comprised sequence analysis of the retina-specific ABCA4 gene. 
Results: Five patients presented with decreased visual acuity in the second decade, 
central chorioretinal atrophy associated with a central scotoma and severely decreased 
photopic and scotopic ERG responses. This clinical picture, which in our opinion 
resembles a cone-rod dystrophy (CRD), was associated with compound heterozygosity 
for IVS30+1G→T and IVS40+5G→A mutations in the ABCA4 gene. The four remaining 
patients presented with night blindness in the first decade because of a retinitis 
pigmentosa-like dystrophy (RP-like). In addition to a pale ‘waxy’ optic disc, attenuated 
retinal vessels and bone spicule deposits, widespread chorioretinal atrophy was 
observed. The scotopic ERG was extinguished and the photopic ERG was severely 
diminished. Genetic analysis revealed a homozygous 5’ splice mutation IVS30+1G→T in 
the ABCA4 gene. 
Conclusion: Mutations in the ABCA4 gene can cause clinical pictures resembling 
autosomal recessive RP and autosomal recessive CRD. 
 
 
 
Introduction 
 
Autosomal recessive Stargardt disease (STGD1) presents in the first or second decade of life 
with a bilateral gradual diminution of vision due to progressive atrophy of the macular retinal 
pigment epithelium and the choriocapillaris in combination with degeneration of the 
photoreceptors of the posterior pole.1 STGD1 is caused by mutations in the retina-specific 
ATP-binding cassette transporter gene (ABCA4), which also has been shown to be involved in 
age-related macular degeneration (AMD), although the latter finding has been disputed.2-4 We 
describe a single consanguineous family with two different phenotypes: cone-rod-like 
dystrophy (CRD-like) and a retinitis pigmentosa-like dystrophy (RP-like). These phenotypes 
co-segregated with DNA markers flanking the ABCA4 gene and subsequent sequence analysis 
revealed compound heterozygosity (CRD-like) and homozygosity (RP-like) for ABCA4 
mutations. 
 
 
Patients and methods 
 
Patients 
Patients of the consanguineous Family K with hereditary retinal degeneration, originally 
described by Deutman as centroperipheral tapetoretinal degeneration resembling STGD15, 
were re-evaluated. All members of the family were examined by one of the authors (CBH). 
Two different phenotypes could be distinguished based on the clinical findings only. After 
consulting with the department of human genetics we collected blood samples for molecular 
genetic analysis, after informed consent was obtained.  Patient IV-3 had to be examined at 
home because of her poor general condition. Unfortunately she died 3 months later. 
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Clinical and electrophysiological investigations 
After the ophthalmic history was taken, all patients underwent a standard ophthalmologic 
evaluation including detailed fundus examination. In addition, fundus photography, 
fluorescein angiography and electroretinography (ERG) were performed. In ERG tests, the 
patients faced a modified sphere of a Goldmann-Weekers adaptometer, lit by two 40 W 
incandescent lamps in order to furnish a Ganzfeld adaptation. After a scleral contact lens, 
equipped with measuring electrodes, was inserted, a reference electrode was placed on the 
forehead and the patient was earthed by means of two earclip electrodes. A xenon flashlight 
was used for flash responses (flash luminance 6.85 cd.s.m-2 photopic and 0,85 cd.s.m-2 
scotopic). Measurements were taken at photopic and adaptation levels. The scotopic ERG was 
a rod isolated dark adapted scotopic response with white (12 minutes of dark adaptation) and 
blue stimuli (15 minutes of dark adaptation). This ERG technique6 does not precisely meet the 
ISCEV standard, but for reasons of comparison over a long period of time (patient V-9, follow 
up 1969-95) the same method was applied. The lower limit of normality with this technique 
was 100 µV for the photopic b-wave, 150 µV for the scotopic b-wave with a white stimulus 
and 170 µV when a blue stimulus was used. 
 
Genotyping 
DNA was extracted from leukocytes as described previously.7 D1S406 (UT2069) and D1S236 
(AFM205ta11) marker analysis was carried out as described elsewhere.8 Sequence analysis of 
the ABCA4 exons was performed as described by Allikmets et al and Gerber et al.3,9 
 
 
Results 
 
The pedigree of the RP-like/CRD-like family is depicted in Figure 1. Nine members of the 
family were affected, two sibs in generation IV and seven sibs in generation V. No 
abnormalities were found in individuals IV-1, V-1, V-2, V-4, V-6 and V-7.  After the 
ophthalmic history was taken and a full ophthalmic examination was performed (as 
summarized in table 1), two different phenotypes could be distinguished.  
 Five individuals (IV-3, IV-7, V-5, V-10, and V-11) presented with initial complaints of 
decreased central vision or a grey spot in the central field of vision in the second decade. At 
the time of our examination the visual acuity of these five patients was reduced to counting 
fingers. Ophthalmoscopy disclosed a circumscribed area of central chorioretinal atrophy. 
Waxy pallor of the optic disc, attenuated retinal vessels and bone spicule pigment deposition 
in the mid-periphery were not observed in these patients (Fig 2A, B, C). Contrary to the report 
of Deutman in 1971 we did not find the temporal paleness he described in patients IV-3 and 
V-10.5 Goldmann kinetic visual fields of patient IV-3, performed in 1967 when she was 54 
years of age, showed a large central scotoma and contracted isoptres. The visual field of 
patient V-5 at age 27 revealed a central scotoma and restriction of the temporal periphery, at 
that age the photopic ERG was still normal but the scotopic ERG was already moderately 
decreased.5 At the time of our investigation the photopic ERG responses were moderately 
subnormal in patient V-11 and severely subnormal or extinguished in the other four patients. 
The scotopic ERG was extinguished in all patients of this group, except for patients IV-7, V-5 
and V-11 when the blue stimulus with 15 minutes of dark adaptation was used (Table 1).  
The clinical picture of the other affected sibs (V-3, V-8, V-9, and V-12) was altogether 
different. Initially they presented with complaints of decreased night vision at about the age of 
6 years. Gradually the visual acuity of these patients decreased and at the time of our 
examination their visual acuity was light perception, except for the youngest patient (V-12) 
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who could still perceive hand motions. Ophthalmoscopically they all demonstrated classic 
aspects of RP, with a waxy optic nerve head, attenuation of the retinal vessels and pigmentary 
retinopathy with bone spicule deposits in the (mid)periphery. Furthermore, large areas of 
poorly demarcated chorioretinal atrophy were noted in these patients, also in the posterior pole 
(Fig. 2D, E, F). 
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Figure 1. Pedigree of the RP-like/CRD-like family. The black bar represents the D1S406/D1S236 
haplotype carrying IVS30+1G→T mutation, the shaded bar represents the IVS40+5G→A mutation 
in the ABCA4 gene. The diamond symbol denotes healthy children of IV-6 and IV-7. 
  
 
Goldmann perimetry of patient V-3 showed a central scotoma and peripheral restriction at the 
age of 22. Patient V-8 demonstrated restricted visual fields at age 13; the visual field of 
patient V-9 revealed a nasal constriction at age 21 and patient V-12 showed a central scotoma 
and a concentric decrease of sensitivity at the age of 11.5 ERG recordings performed in 
patients V-8, V-9 and V-12 showed severely decreased photopic ERG responses and an 
extinguished scotopic ERG (Table 1).  
 Linkage analysis using highly polymorphic DNA markers from 1p21 showed that all 
affected sibs in generation V inherited the same chromosomal haplotype from their father (IV-
1) indicated by a black bar in Figure 1. Since the mother of these sibs (IV-3), as well as an 
aunt (IV-7), also harbour this chromosomal segment, the corresponding mutation must have 
been present in this family at least since generation I. In addition another genetic defect is 
present in the mother and the aunt (Fig. 1, shaded bar). Four sibs of generation V (V-3, V-8, 
V-9, and V-12) inherited the same haplotype from both parents and consequently are 
homozygous for this chromosomal region. Sequence analysis revealed a severe 5’ splice site 
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Table 1. Clinical findings in patients with ABCA4-associated RP- like or CRD-like dystrophy. 
 
Photopic 
ERG (V) 
Scotopic 
ERG  (V) 
white 
Scotopic 
ERG  (V) 
blue        Patient Genotype Age 
Age of 
onset 
(years) 
Initial  
symptom 
Visual 
acuity Fundoscopy 
OD           OS OD         OS OD OS 
IV-3 HTZ 84 12 VA loss CF Marked central chorioretinal atrophy and mild chorioretinal atrophy 
in the midperiphery. No abnormalities of the vessels and the optic 
disc.  
NR NR NR NR NR NR 
IV-7 HTZ 74 20 VA loss CF Marked central chorioretinal atrophy and irregular 
hyperpigmentation of the pigment epithelium in the posterior pole. 
Patchy chorioretinal atrophy in the midperiphery. Temporal 
paleness of the optic disc. 
20 30 NR NR 75 30 
V-3 HMZ 59 6 Night  
blindness 
LP Central and midperipheral chorioretinal atrophy, midperipheral 
bone spicules, narrow vessels and a ‘waxy’ pale optic disc. 
NP NP NP NP NP NP 
V-5 HTZ 56 15 VA loss CF Central chorioretinal atrophy with irregular hyperpigmentation of the 
retinal pigment epithelium.  
30 20 NR NR 50 
 
30 
 
V-8 HMZ 51 7 Night 
blindness 
LP 
 
Marked central chorioretinal atrophy, midperipheral bone spicules 
and diffuse chorioretinal atrophy. Severe narrowing of the retinal 
vessels and temporal paleness of the optic disc. 
20 40 NR NR NR NR 
V-9 HMZ 50 7 Night 
blindness 
LP Marked central and midperipheral atrophy, with central 
hyperpigmentation and midperipheral bone spicules, narrow 
vessels and paleness of the optic disc. 
NR 
 
80 NR NR NR NR 
V-10 HTZ 48 12 VA loss CF Central chorioretinal atrophy with focal hyperpigmentation.  30 50 NR NR NR NR 
V-11 HTZ 46 12 Central 
scotoma 
CF Central chorioretinal atrophy with focal hyperpigmentation. Small 
round patches of chorioretinal atrophy with mild hyperpigmentation 
in the midperiphery. Mild temporal pallor of the optic disc 
80 80 NR NR 75 30 
V-12 HMZ 43 6 Night 
blindness 
HM Central chorioretinal atrophy with midperipheral patchy atrophy 
Bone spicules, narrow vessels and a pale optic disc. 
20 55 NR NR NR NR 
 
HMZ indicates homozygosity or IVS30+1G→T mutation; HTZ, compound heterozygosity for IVS30+1G→T and IVS40+5G→A mutation. HM, hand movements; VA, 
visual acuity; CF, counting fingers; HM, hand movements; LP, light perception; OD, right eye; OS, left eye; NR, nonrecordable; NP, not performed. Minimal values 
for ERG recordings: 100 µV for the photopic ERG, 150 µV for the scotopic ERG with a white stimulus after 12 minutes of dark adaptation, 170 µV for the scotopic 
ERG with a blue stimulus after 15 minutes of dark adaptation. 
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Figure 2. Patient V-5 (2A) with CRD-like dystrophy in an early stage (28 years of age) and the same 
patient (2B) at a later stage (54 years of age). Patient V-11 with CRD-like dystrophy in a late stage 
(2C). Three patients with RP-like (2D, patient V-9; 2E, patient V-12 and 2F, patient V-3). 
 
 
C D
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mutation IVS30+1G→T at ABCA4 nucleotide position 4539+1. The other three affected sibs 
in this generation (V-5, V-10, V-11) received the haplotype from their mother that was not 
present in their father’s DNA, rendering them compound heterozygous, with a genetic profile 
of the ABCA4 gene resembling their affected mother and aunt. Sequence analysis revealed the 
heterozygous presence of the IVS30+1G→T mutation, as well as another 5’ splice site 
mutation (IVS40+5G→A) at nucleotide position 5714+5. 
 
 
Discussion  
 
In this study we describe a consanguineous family in which the affected members display one 
of two distinctly different phenotypes, either RP-like or CRD-like. These different disease 
phenotypes completely match two different genotypes. Apparently, different combinations of 
gene defects in the ABCA4 gene result in different phenotypic effects. The four patients who 
are homozygous for the IVS30+1G→T mutation present with a clinical picture resembling 
RP, with an age of onset of approximately 6 years. Although this retinal dystrophy harbours 
several aspects of a classical RP (night blindness, peripheral restricted visual fields, typical 
ERG findings, as well as attenuation of the retinal vessels, bone spicule deposits and a waxy 
optic nerve head on ophthalmoscopy), there are some aspects of this phenotype which are not 
typically associated with RP. The extensive chorioretinal atrophy and pigmentary changes in 
the posterior pole, the central scotomas in patients V-3 and V-12, and the substantially more 
reduction in visual acuity than is normally noted in patients with RP lead us to refer to this 
entity as RP-like. 
 The patients displaying compound heterozygosity for the IVS30+1G→T and 
IVS40+5G→A mutations develop a retinal dystrophy which occurs later in life, with an age of 
onset varying from 12 to 20 years. In these patients decrease of visual acuity and/or a central 
scotoma is the presenting symptom. At the time of examination the visual acuity did not 
exceed counting fingers in all five patients. Ophthalmoscopically, all patients show a 
circumscribed area of chorioretinal atrophy, mostly restricted to the posterior pole. No 
ophthalmoscopic abnormalities were observed that could be attributed to RP. Strikingly, the 
central localisation of the retinal dystrophy in patients with compound heterozygosity is not 
reflected in their ERG recordings, which in general demonstrates an affected cone system but 
an even more severely affected rod system. This cannot simply be attributed to the fact that 
most patients have reached an end stage, since early ERG recordings of V-5, at 27 years of 
age, show the same phenomenon – that is, the scotopic ERG is more affected than the 
photopic ERG. These ERG responses are very similar to the ERG findings in sibs with 
homozygous mutations and the resulting RP-like phenotype. It must be mentioned, however, 
that the measurement of the scotopic responses was unconventional, for reasons stated earlier, 
and the 12 minute period of dark-adaptation when a white stimulus was used, may not have 
disclosed the entire potential for the development of a rod response. Although the 
chorioretinal atrophy is far more widespread in this group compared with the central atrophy 
observed in the compound heterozygous patients, the results of functional tests such as the 
ERG are virtually identical. Thus, the retinal disorder in the compound heterozygous patients 
is more difficult to classify. Since perifoveal yellow spots were never observed and the 
choroidal fluorescence was never obscured in fluorescein angiography,10 it is our belief that 
the original diagnosis of STGD1 disease is not appropriate. Nevertheless, all these patients 
initially presented with blurred central vision rather than nyctalopia and the fundus of patient 
V-5 at 28 years of age shows a well demarcated oval shaped depigmentation of the retinal 
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pigment epithelium in the posterior pole. The visual fields of patients IV-3 and V-5 show a 
central scotoma or decreased central sensitivity in combination with a mild peripheral 
restriction. The ERG findings are atypical and suggest severely affected cone and rod systems 
with a slight emphasis on damage to the latter. In view of these findings the most likely 
diagnosis in our opinion is CRD,  although the ERG recordings make it difficult to fit this 
phenotype into previous subtypes of CRD.11,12 We therefore have referred to this type of 
dystrophy as CRD-like. When classified as CRD this phenotype would fit best in the group 
described by Szlyk et al as type 2a CRD.11 It is also possible that these patients have a form of 
RP which is mainly located centrally, so called central RP or inverse RP,13,14 although this 
entity is not very well defined in literature. The fact that this retinal dystrophy cannot be 
accurately classified, underscores that these diseases need to be defined in genetic terms rather 
than the current subjective and variable phenotypic terminology. 
 Allikmets et al recently identified mutations in a photoreceptor cell-specific ATP- 
binding cassette transporter gene (ABCA4) in STGD1.3 Another report from the same group 
describes alterations in one allele of the ABCA4 gene in some AMD patients, although these 
findings were not confirmed in a correspondence by Stone et al.2,4 Our findings suggest that 
mutations in ABCA4 not only result in STGD1 but can also cause autosomal recessive CRD-
like phenotypes and autosomal recessive RP-like phenotypes. Compound heterozygosity for 
IVS30+1G→T and IVS40+5G→A mutations results in a clinical picture resembling CRD, 
whereas homozygosity for the IVS30+1G→T mutation causes an RP-like phenotype. Based 
on the greater severity of the RP-like phenotype compared with the CRD-like phenotype and 
STGD1, the IVS30+1G→T mutation can be regarded as a true null allele. A mutation at the 
+1 position of a 5’ splice site invariantly inactivates the corresponding splice site. The 
possible effects of this mutation are discussed in more detail elsewhere.15 In accordance with 
our hypothesis we and others thus far have not found 2 ABCA4 null mutations in STGD1 
patients3 (J. Kaplan, personal communication; own observation). In addition, Martínez-Mir et 
al recently identified a homozygous 1-bp deletion in the ABCA4 gene of 6 siblings from a 
consanguineous RP family.16 This deletion results in a frameshift early in the coding region 
and thus represents a true null allele. The IVS40+5G→A mutation lowers, but probably does 
not abolish, the splice potential of the corresponding splice site, which may explain the less 
severe phenotype observed in the compound heterozygous CRD-like patients. The fact that 
both CRD-like and RP-like phenotypes can be caused by mutations in the same gene is not 
without precedent. Previously, mutations in the RDS/peripherin gene were associated with a 
myriad of different phenotypes, including autosomal dominant forms of RP,17 CRD,18 macular 
dystrophy,19 pattern dystrophies of the retinal pigment epithelium,19-22 and central areolar 
choroidal dystrophy.23 
 
 
Aknowledgments 
This study was supported by the British Retinitis Pigmentosa Society, the National Foundation Fighting 
Blindness, the Rotterdamse Vereniging Blindenbelangen, the Algemene Nederlandse Vereniging ter Voorkoming 
van Blindheid, the Stichting Blindenhulp, the Stichting de Drie Lichten, the Gelderse Blindenvereniging, the 
Landelijke Stichting voor Blinden en Slechtzienden and the Royal Netherlands Academy of Arts and Sciences. 
 
 
References 
 
 1.  Deutman AF, Hoyng CB. Macular diseases. Retina. Edited by Ryan S.J. St Louis, Mosby, 2001, pp. 1216-
1219. 
Appendix 1 
100 
 2.  Allikmets R, Shroyer NF, Singh N et al. Mutation of the Stargardt disease gene (ABCR) in age-related 
macular degeneration. Science 1997, 277:1805-1807. 
 3.  Allikmets R, Singh N, Sun H et al. A photoreceptor cell-specific ATP-binding transporter gene (ABCR) is 
mutated in recessive Stargardt macular dystrophy. Nat Genet 1997, 15:236-246. 
 4.  Stone EM, Webster AR, Vandenburgh K et al. Allelic variation in ABCR associated with Stargardt 
disease but not age-related macular degeneration. Nat Genet 1998, 20:328-329. 
 5.  Deutman AF: The hereditary dystrophies of the posterior pole of the eye. Assen, van Gorcum & Comp. 
n.v., 1971, pp. -150. 
 6.  Thijssen JM, Pinckers A, Otto AJ. A multipurpose optical system for ophthalmic electrodiagnosis. 
Ophthalmologica 1974, 168:308-314. 
 7.  Bach I, Brunner HG, Beighton P et al. Microdeletions in patients with gusher-associated, X-linked mixed 
deafness (DFN3). Am J Hum Genet 1992, 51:38-44. 
 8.  Hoyng CB, Poppelaars F, van de Pol TJ et al. Genetic fine mapping of the gene for recessive Stargardt 
disease. Hum Genet 1996, 98:500-504. 
 9.  Gerber S, Rozet JM, van de Pol TJ et al. Complete exon-intron structure of the retina-specific ATP 
binding transporter gene (ABCR) allows the identification of novel mutations underlying Stargardt 
disease. Genomics 1998, 48:139-142. 
 10.  Gass J.M.D.: Stereoscopic atlas of macular diseases. St Louis, CV Mosby, 1997. 
 11.  Szlyk JP, Fishman GA, Alexander KR, Peachey NS, Derlacki DJ. Clinical subtypes of cone-rod 
dystrophy. Arch Ophthalmol 1993, 111:781-788. 
 12.  Yagasaki K, Jacobson SG. Cone-rod dystrophy. Phenotypic diversity by retinal function testing. Arch 
Ophthalmol 1989, 107:701-708. 
 13.  Godel V, Regenbogen L. Functional evaluation in central retinitis pigmentosa. Ophthalmologica 1977, 
174:121-128. 
 14.  Niemeyer G, Demant E. Cone and rod ERGs in degenerations of central retina. Graefes Arch Clin Exp 
Ophthalmol 1983, 220:201-208. 
 15.  Cremers FPM, van de Pol DJ, van Driel M et al. Autosomal recessive retinitis pigmentosa and cone-rod 
dystrophy caused by splice site mutations in the Stargardt's disease gene ABCR. Hum Mol Genet 1998, 
7:355-362. 
 16.  Martinez-Mir A, Paloma E, Allikmets R et al. Retinitis pigmentosa caused by a homozygous mutation in 
the Stargardt disease gene ABCR. Nat Genet 1998, 18:11-12. 
 17.  Farrar GJ, Kenna P, Jordan SA et al. A three-base-pair deletion in the peripherin-RDS gene in one form of 
retinitis pigmentosa. Nature 1991, 354:478-480. 
 18.  Nakazawa M, Kikawa E, Chida Y et al. Autosomal dominant cone-rod dystrophy associated with 
mutations in codon 244 (Asn244His) and codon 184 (Tyr184Ser) of the peripherin/RDS gene. Arch 
Ophthalmol 1996, 114:72-78. 
 19.  Wells J, Wroblewski J, Keen J et al. Mutations in the human retinal degeneration slow (RDS) gene can 
cause either retinitis pigmentosa or macular dystrophy. Nat Genet 1993, 3:213-218. 
 20.  Kim RY, Dollfus H, Keen TJ et al. Autosomal dominant pattern dystrophy of the retina associated with a 
4-base pair insertion at codon 140 in the peripherin/RDS gene. Arch Ophthalmol 1995, 113:451-455. 
 21.  Nichols BE, Sheffield VC, Vandenburgh K et al. Butterfly-shaped pigment dystrophy of the fovea caused 
by a point mutation in codon 167 of the RDS gene. Nat Genet 1993, 3:202-207. 
 22.  Weleber RG, Carr RE, Murphey WH, Sheffield VC, Stone EM. Phenotypic variation including retinitis 
pigmentosa, pattern dystrophy, and fundus flavimaculatus in a single family with a deletion of codon 153 
or 154 of the peripherin/RDS gene. Arch Ophthalmol 1993, 111:1531-1542. 
 23.  Hoyng CB, Heutink P, Testers L et al. Autosomal dominant central areolar choroidal dystrophy caused by 
a mutation in codon 142 in the peripherin/RDS gene. Am J Ophthalmol 1996, 121:623-629. 
 
  
Appendix 2 
 
 
 
 
 
 
Mutations in the ABCA4 (ABCR) gene are the major cause 
of autosomal recessive cone-rod dystrophy 
 
 
 
 
 
 
Alessandra Maugeri1, B. Jeroen Klevering2, Klaus Rohrschneider3, Anita Blankenagel3,  
Han G. Brunner1, August F. Deutman2, Carel B. Hoyng2, Frans P.M. Cremers1 
 
 
 
 
 
The departments of 1Human Genetics and 2Ophthalmology, University Medical  
Centre Nijmegen, Nijmegen, The Netherlands; and the 3University Eye Clinic,  
Ruprecht-Karls-Universität, Heidelberg, Germany 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
From: the American Journal of Human Genetics 2000;67:960-966.
ABCA4 gene mutations are the major cause of recessive cone-rod dystrophy 
103 
The photoreceptor cell-specific ATP-binding cassette transporter gene (ABCA4; 
previously denoted “ABCR”) is mutated in most patients with autosomal recessive (AR) 
Stargardt disease (STGD1) or fundus flavimaculatus (FFM). In addition, a few cases 
with AR retinitis pigmentosa (RP) and AR cone-rod dystrophy (CRD) have been found 
to have ABCA4 mutations. To evaluate the importance of the ABCA4 gene as a cause for 
arCRD, we selected 5 patients with arCRD and 15 patients with isolated CRD, all from 
Germany and the Netherlands. Single strand conformation polymorphism analysis and 
sequencing revealed 19 ABCA4 mutations in 13 (65%) out of 20 patients. In six patients, 
mutations were identified in both ABCA4 alleles; in seven patients, mutations were 
detected in one allele. One complex ABCA4 allele (L541P;A1038V) was found exclusively 
in German patients with CRD; one patient carried this complex allele homozygously, 
and five others were compound heterozygous. These findings suggest that mutations in 
the ABCA4 gene are the major cause of arCRD. A primary role of the ABCA4 gene in 
STGD1/FFM and arCRD, together with the gene’s involvement in an as-yet-unknown 
proportion of cases with arRP, strengthens the idea that mutations in the ABCA4 gene 
could be the most frequent cause of inherited retinal dystrophy in humans. 
 
 
 
Inherited chorioretinal dystrophies show a high degree of clinical and genetic heterogeneity 
(RetNet Web site). Clinical classification is relatively straightforward for those diseases that 
display typical fundoscopic and electrophysiological abnormalities – for example, gyrate atrophy 
(MIM 258870), choroideremia (MIM 303100), Stargardt disease (STGD1[MIM 248200]), and 
Best vitelliform macular dystrophy (MIM 153700). Linkage studies in each of these diseases 
have suggested the involvement of a single locus, thereby facilitating the positional cloning of 
the underlying genes.1-4 In other inherited chorioretinal diseases, however, the clinical and 
genetic classification is much more difficult, because the phenotypes are less distinctive. 
Consequently, the identification of the genes involved in this group of retinal disorders often 
relies on a ‘brute force’ approach, in which promising candidate genes are screened for 
mutations in a large cohort of patients with chorioretinal dystrophies (Dryja 19975 and 
references therein). Traditionally, retinitis pigmentosa (RP [MIM 268000]) is considered a rod-
cone dystrophy, with earlier and more serious involvement of the rod photoreceptors as 
compared with cone photoreceptors. Conversely, there is a group of patients in whom the cone 
degeneration is more prominent than the degeneration of rods. In this cone-rod pattern of retinal 
dystrophy, or cone-rod dystrophy (CRD [MIM 120970, MIM 601777, MIM 600624, MIM 
603649, MIM 604116, MIM 600977]), the photopic cone b-wave amplitude is reduced more 
than the scotopic rod b-wave amplitude in the electroretinogram (ERG).6 At the end stages of 
both rod-cone and cone-rod dystrophy the ophthalmologic characteristics tend to coalesce.7 
Recent studies have suggested that the photoreceptor-specific ATP-binding cassette 
transporter ABCR, recently renamed “ABCA4” (MIM 601691), works as an N-retinylidene-
phosphatidylethanolamine flippase on the disc membrane of both cone and rod photoreceptor 
cells. 8-10 We and others have shown the involvement of the ABCA4 gene in STGD1/FFM and in 
a few families and patients with autosomal recessive (ar)RP (RP19 [MIM 601718]) and arCRD  
(CORD3 [MIM 604116]).1,11-15 Moreover, heterozygous ABCA4 mutations were found in 16% 
of patients with age-related macular degeneration (AMD [MIM 153800]).16 Although the 
significance of this finding is under debate,17 at least two ABCA4 mutations (G1961E and 
D2177N) have been shown, in a large multicentre study, to be statistically more frequent in 
patients with AMD compared with controls.18  
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Figure 1. Fundus appearance in four patients with ABCA4-associated CRD. A. Patient 11872 with 
perifoveal atrophy in bull’s eye pattern of the retinal pigment epithelium (RPE) and atrophy of the RPE 
outside the macula. B. Patient 9633, with pericentral atrophy of the RPE. The arteries are attenuated. C. 
Patient 9378, with central hypo- and hyperpigmentation, patchy atrophy of the RPE.  D. Patient 9369, 
with atrophy of the RPE around the optic disc. Bone spicules along arteries and venules in the 
midperiphery; the retinal arterioles are attenuated. Patients 9378 (C) and 9369 (D) were classified as 
atypical. 
 
 
These studies suggest a model in which the most severe retinal disorder associated with 
ABCA4 mutations, RP, is caused by two ABCA4 null alleles, whereas CRD and STGD1 are due 
to combinations of ABCA4 mutations yielding residual ABCR function.11-14,19-22 On the basis of 
this model and the grouping of ABCA4 mutations in different classes of severity, we estimated 
that ABCA4 mutations could be responsible for CRD in 1 in 50,000 individuals.14 Since arCRD 
represents a relatively rare disorder, we hypothesized that ABCA4 could be an important cause of 
arCRD. In this study, we tested this hypothesis by evaluating the ABCA4 gene in patients with 
arCRD.  
The ABCA4 genotype-phenotype correlation model11,14,22 suggests that retinal 
dystrophies form a phenotypic continuum. In this study, we selected a group of patients that 
clearly is clinically distinct from STGD1 and classic RP. Clinical investigations were 
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performed in two different centres, the Department of Ophthalmology at the University 
Medical Centre in Nijmegen and the Eye Clinic in Heidelberg. At the time of diagnosis, the 
ophthalmologists were not aware of the results of the mutation analysis. 
 
 
 
ABCA4 allele 1 
 
ABCA4 allele 2 
 
Patient 
 
 
Inheritance 
 Nucleotide change           Effects Nucleotide change             Effects 
9250a Isolated 1622T>C;3113C>T L541P;A1038Vb 194G>A G65Eb 
9303 AR 1622T>C;3113C>T L541P;A1038Vb   
9336 Isolated 6658C>T Q2220X   
9369a AR 6601-6602delAG frameshift   
9370 Isolated 1622T>C;3113C>T L541P;A1038Vb   
9371 Isolated 1622T>C;3113C>T L541P;A1038Vb 1622T>C;3113C>T L541P;A1038Vb 
9378a Isolated 768G>T 5’ splice mutationb   
9553 AR 2588G>C ∆G863/G863Ab IVS35del-2>+2del4 3’ splice mutation 
9633 Isolated 1622T>C;3113C>T L541P;A1038Vb 4469G>A C1490Yb 
9650 Isolated 3364G>A E1122Kb   
9887 Isolated 4793C>A A1598D 6329G>A W2110X 
11872 Isolated 634C>T R212Cb   
13163a AR 1622T>C;3113C>T L541P;A1038Vb IVS36+1G>A 5’ Splice mutationb 
 
Table 1. ABCA4 mutations in patients with CRD.  
 
a
 Patients with atypical CRD. 
 
b Previously described in patients with STGD1.12,14,23,24 
 
 
Rod-cone and cone-rod patterns of retinal degenerations were diagnosed predominantly 
on the basis of ERG patterns. Patients were diagnosed as CRD when the b-wave of the 
photopic ERG (cone response) was more severely reduced than the b-wave of the scotopic 
ERG. In addition, these patients demonstrated the following features: decreased visual acuity, 
impaired colour vision, central or paracentral scotomas and fundoscopic evidence of 
maculopathy. Patients with STGD1/fundus flavimaculatus were excluded from this study. 
Yellow-white, irregular shaped flecks in the posterior pole and macular atrophy in the later 
stages of the disease were considered characteristic features of this type of inherited macular 
degeneration. Furthermore, these patients often demonstrate blocking of the normal 
background fluorescence on fluorescein angiography and normal or nearly normal full-field 
ERGs. Patients with RP show scotopic rod amplitudes more severely reduced than their 
photopic cone amplitudes, and typically develop night blindness and progressive impairment 
of the midperipheral visual field in adolescence. Fundoscopic abnormalities include narrowed 
retinal vessels, bone spicule pigmentation and waxy pallor of the optic disc. Patients with 
these RP characteristics were also excluded from this study.  
Twenty unrelated patients were included in this study. In five families, two or more 
siblings were affected, suggesting AR inheritance. In each of the remaining 15 families only 
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one patient with CRD was identified. Thirteen of these patients were considered typical CRD 
cases. Representative fundus photographs are shown in Figure 1-A and B. In seven patients, 
either the ophthalmologic examination was not complete or some clinical findings commonly 
not associated with CRD were observed, although the ERG recordings showed a cone-rod 
type of retinal degeneration. Three patients (9250, 9369, and 9661) demonstrated severe 
narrowing of retinal vessels and bone spicules in the midperiphery in the later stages of their 
disease (Fig. 1-D). One patient (9378) showed typical patchy areas of chorioretinal atrophy in 
the midperiphery (Fig. 1-C). In another patient (8547), there was only minimal progression of 
the retinal dystrophy. Visual fields were not available in patient 11630. His ERG showed 
virtually extinguished cone responses in the presence of slightly subnormal rod responses. 
Finally, in patient 13163 the retinal dystrophy was in a final stage with nonrecordable ERG 
patterns. These seven patients were therefore classified as having “atypical” CRD.  
 
1622TC 3113CT
control
a b
c d
e f
#9370
CRD
#9371
CRD
 
 
Figure 2. DNA sequences in patients 9370 and 9371 carrying the complex ABCA4 allele 
L541P;A1038V. a-b,  Normal nucleotide sequences of exon 12 (a) and exon 21 (b) in a 
control individual. c-d, Heterozygous 1622T→C (c) and 3113C→T (d) nucleotide changes 
in patient 9370. e-f, Homozygous 1622T→C (e) and 3113C→T (f) nucleotide changes in 
patient 9371.  
 
 
Using the single strand polymorphism (SSCP) and direct sequencing techniques,1,14,25 
we searched for mutations in the 50 exons and flanking intron sequences of the ABCA4 gene.  
Nineteen ABCA4 mutations were identified in 13 of 20 patients (Table 1). In six 
patients, mutations were found in both ABCA4 alleles; in seven patients one ABCA4 mutation 
was found. ABCA4 mutations were identified in 4 (80%) of 5 patients with arCRD, and in 9 
(60%) of 15 patients with isolated CRD. Thirteen mutant ABCA4 alleles were found in 9 of 13 
patients who showed the “classic” signs of CRD. Six mutant ABCA4 alleles were identified in 
4 out of 7 patients classified as having atypical CRD.  
Among 13 different mutations, 8 had been identified previously in patients with STGD1 
and, with the exception of the frequent 2588G→C founder mutation,14 were not present in  
100 healthy control individuals.12,14,23 Five mutations were novel. One is a missense mutation 
(A1598D) which was not found in 100 control individuals. Four are thought to represent null 
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mutations, either because they introduce a stop codon (W2110X, Q2220X), result in a 
frameshift (6601-6602delAG), or disrupt a splice site (IVS35-2→+2del4). A complex 
L541P/A1038V allele was found in 7 of 19 mutant alleles. Surprisingly, this complex ABCA4 
allele was exclusively found in 6 of 14 German patients with CRD. One patient carried this 
complex allele homozygously, three patients were compound heterozygous and two patients 
were heterozygous (Table 1 and Figure 2).  
In this study, we identified ABCA4 mutations in 65% of the patients investigated, with 
no significant difference between patients that we classified as having typical versus atypical 
CRD (69% vs. 57%). In total, ABCA4 mutations have been identified in 80% of the patients 
with arCRD and in 60% of those with isolated CRD. Assuming AR inheritance for all patients 
included in this study, we identified ABCA4 mutations in 19 (47.5%) of the 40 alleles. In 
patients with STGD1, a disease that is thought to be genetically homogeneous, ABCA4 
mutation analysis yielded mutations in ~60% of the alleles.12,14 Apparently, a proportion 
(~30%) of the ABCA4 mutations currently are missed because the limitations of the SSCP 
analysis technique and because many splice mutations could be located in the noncoding 
sequence. Hence, it is possible that some of the 7 CRD patients in whom we did not find an 
ABCA4 mutation do in fact carry ABCA4 mutations. Moreover, some of the 6 cases of isolated 
CRD without ABCA4 mutations might be caused by non-ABCA4-associated de novo 
autosomal dominant gene defects. These data suggest that, in > 70% of patients with arCRD, 
the disease is due to pathologic ABCA4 mutations. We conclude that mutations in the ABCA4 
gene are the major cause for arCRD.  
 
 
ABCR function
Phenotype
ABCA4 mutation
allele 1
ABCA4 mutation
allele 2 moderate
arCRD arRP
moderate
STGD1
moderate mild
severe/
moderate
AMD/
normal
+
+
normal
+
severe severe
severe
severe
 
 
Figure 3. Genotype-phenotype correlation model and estimated incidence of ABCA4 mutations in 
patients with retinal dystrophies (adapted from the work by van Driel et al22). The model shows the 
inverse correlation between the ABCR residual activity and the severity of the retinal dystrophy. 
The most severe phenotype, RP, is caused by two null/severe ABCA4 mutations. If the ABCR 
activity is partially retained, patients will develop either CRD, as the result of a severe mutation 
inherited together with a moderate mutation, or Stargardt disease (STGD1), in case of a 
combination of severe and mild ABCA4 mutations or two moderately severe ABCA4 mutations. 
 
 
A prominent pathologic role of ABCA4 in arCRD underscores the “ABCR-genotype-
phenotype model” (Fig. 3), in which we predicted arCRD to occur whenever the ABCR 
activity is severely but not completely compromised – for example, by a combination of a 
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“moderate” and a “severe” ABCA4 mutations.11,14,22 This model was based in part on the 
observation that two ABCA4 null mutations were invariably found in families with atypical 
arRP,11,26 and in part on genotype-phenotype comparison in a family with RP and CRD11 and 
in patients with STGD1.1,12,14 A frequent mild ABCA4 founder mutation (2588G→C) was 
found in 37% of European STGD1 patients14 and was never found homozygously in this or 
other groups of patients.1,12,14 In most of the compound heterozygous patients with STGD1, 
the 2588G→C mutation was accompanied by severe ABCA4 mutations. 14 
Although we consider the genotype-phenotype model an oversimplification of the 
diverse functional effects that mutations can have on the presumed N-retinylidene-
phosphatidylethanolamine flippase activity of ABCR9,10 and ABCA4-associated pathology, it 
allows us to evaluate the severity of novel mutations and of combinations thereof, and to test 
the model’s validity in patients with ABCA4-associated pathology other than STGD1. On the 
basis of the model, CRD patients should not carry two null ABCA4 alleles. Although the 
number of CRD patients in which both ABCA4 mutations are found is still low and the 
consequences of individual mutations have not been functionally tested, this indeed seems to 
be the case.  
 According to the model (Fig. 3), the mild 2588G→C mutation, in combination with 
an ABCA4 mutation on the other allele, should cause STGD1 and not CRD or RP. 
Nevertheless, one patient with CRD (9553) was a compound heterozygote for the 2588G→C 
mutation and a severe splice-site mutation. As reported elsewhere in patients with 
STGD1,12,21,27 it is possible that patient 9553 carries an allele with the 2588G→C mutation 
and another as-yet-undetected mutation. Moreover, the paucity of the 2588G→C mutation in 
patients with CRD is in contrast to its frequent occurrence in Western European patients with 
STGD1 (1/20 cases with CRD vs. 15/40 cases with STGD1;14 p<.01, one-sided Fisher's exact 
test), strengthening our hypothesis that it only contributes to STGD1 pathology. Seven alleles 
in six German patients with CRD were found to carry two missense mutations 
(L541P;A1038V). The frequency of this allele is surprisingly high in our group of patients 
with CRD, comparable to the frequency of the 2588G→C ABCA4 founder mutation in 
European patients with STGD1 (7/40 alleles in patients with CRD vs. 15/80 alleles in patients 
with STGD1).14 The ABCA4 allele carrying only the A1038V mutation is one of the most 
frequent alleles in patients with STGD1 in the U.S. (15/150).12 However, among a total of 357 
non-German STGD1 patients, only 4 (1.1%) were shown to carry the L541P;A1038V 
allele.12,14,15,23,24,28 In contrast, the complex allele was found in 22/155 (14.2%) German 
patients with STGD114 (B.H. Weber, personal communication), indicating that this complex 
allele most  likely is not specifically involved in CRD. 
In conclusion, we have found that, despite the high clinical variability observed among 
patients with CRD, mutations in the ABCA4 gene are responsible for the majority of the cases. 
These findings confirm our previous hypothesis on the importance of ABCA4 involvement in 
CRD,14 which is surprising in view of the high degree of genetic heterogeneity seen in other 
retinal dystrophies.  
Future studies will concentrate on the ABCA4 analysis of patients with arRP, which, on 
the basis of our genotype-phenotype model and previous estimates,14 should carry ABCA4 
mutations in ~8% of the cases. Since other known arRP genes are mutated in 5% of the 
patients,5,29,30 mutations in ABCA4 may well be the most frequent cause of nonsyndromic 
retinal dystrophy in humans. 
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Purpose: to describe the phenotype of 12 patients with autosomal recessive or isolated 
cone-rod types of progressive retinal degeneration (CRD) caused by mutations in the 
ABCA4 gene. 
Methods: The charts of patients who had originally received a diagnosis of isolated or 
autosomal recessive CRD were reviewed after molecular analysis revealed mutations in 
the ABCA4 gene 
Results: In two of the patients both the photopic and scotopic electroretinogram were 
nonrecordable, in the remainder the photopic cone b-wave amplitudes appeared to be 
more seriously affected than the scotopic rod b-wave amplitudes. Although the clinical 
presentation was heterogeneous, all patients experienced visual loss early in life, 
impaired colour vision and a central scotoma. Ophthalmoscopy revealed evidence of 
early-onset maculopathy, sometimes accompanied by involvement of the retinal 
periphery in the later stages of the disease. 
Conclusions: Mutations in the ABCA4 gene are the pathologic cause of the CRD-like 
dystrophy in these patients, and the resultant clinical pictures are complex and 
heterogeneous. Given this wide clinical spectrum of CRD-like phenotypes associated 
with ABCA4 mutations, detailed clinical subclassifications are difficult and may not be 
very useful.   
 
 
 
Introduction 
 
Most present classifications of retinal dystrophies are based on whether the disease is 
progressive or stationary and whether the retinal disease is generalized or located 
predominantly in the macula. Generalized retinal dystrophies are further divided according to 
which type of photoreceptor is mainly affected in the early stages and most severely 
throughout the course of the disease. Additional findings such as yellow-white fundus flecks 
and a dark choroid on fluorescein angiography, as in Stargardt disease (STGD), are attributed 
to specific retinal disorders.  
Although there are several definitions of retinitis pigmentosa (RP), “typical” RP is  
considered to demonstrate rod-cone patterns of retinal degeneration on the electroretinogram 
(ERG).1,2 Patients with typical RP demonstrate progressive loss of night and peripheral vision 
and show ophthalmoscopic features such as attenuated retinal vessels, bone spicules in the 
retinal (mid)periphery and a waxy paleness of the optic disc. Conversely, a group of patients 
with a progressive retinal disorder shows cone-rod patterns on ERG testing. These retinal 
dystrophies, commonly described as cone-rod dystrophies (CRDs), form a clinically 
heterogeneous group of disorders characterized by most of the following features: early loss 
of visual acuity, deficits in colour vision, progressive impairment of the visual field and, 
sometimes, nystagmus. In time, pigmentary changes become apparent in the macular area, 
often followed by variable degrees of midperipheral pigmentation. The ERG is abnormal with 
either cone (photopic) responses more reduced than rod (scotopic) responses, or equally 
reduced cone and rod systems.1-8  
Mutations in the adenosine triphosphate (ATP)-binding cassette transporter (ABCA4) 
gene are responsible for a spectrum of retinal dystrophies including STGD1, autosomal 
recessive CRD and autosomal recessive RP.9-15 ABCA4 is located in the disc membrane of the 
rod outer segments and recently it was demonstrated by Molday et al. that the ABCA4 gene is 
also expressed in retinal cones.16,17 In the present study we describe a group of patients with 
autosomal recessive or isolated cone-rod retinal dystrophy caused by mutations in the ABCA4 
gene. 
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Patients and methods 
 
The protocol of this study adhered to the provisions of the Declaration of Helsinki. After 
informed consent was obtained, blood samples were taken and molecular analysis on the 
ABCA4 gene was performed as described by Maugeri et al.14 The charts of patients with 
ABCA4 mutations who originally had received diagnoses of isolated or autosomal recessive 
CRD were reviewed. All patients originated from the University Medical Centre Nijmegen 
(Nijmegen, The Netherlands) and the University of Heidelberg (Heidelberg, Germany). In this 
study the diagnosis of CRD was based on the following criteria: initial complaints of blurred 
central vision without a history of night blindness, impairment of colour vision and 
fundoscopic evidence of maculopathy without or with mild peripheral retinopathy.3-5,7,8 In 
patients with recordable ERGs a cone-rod pattern of degeneration had to be present (i.e., the 
photopic b-wave impairment was greater or equal to the scotopic b-wave amplitude 
impairment). Patients 9250 and 13163, who had nonrecordable ERGs, were included because 
their histories and clinical features were similar to those of other patients with cone-rod 
degeneration and they were believed to represent advanced cases of CRD. In addition to an 
ophthalmologic examination, Goldmann kinetic perimetry routinely was performed using III-
4-e and I-4-e isoptres. Colour vision was tested with the Ishihara and Panel D15 tests, except 
in patients 9369, 9378 and 10125, who were tested under conditions described earlier18. 
Because these patients were examined in two different clinics and ERGs were recorded over a 
long period of time, the methods, instrumentation and analysis techniques of the 
electroretinography varied. The ERGs in patients 9369, 9378, 10125 and 11872 were 
performed as described by Thijssen et al.19 The employed ERG method in patients 9370, 
9553, 9633 and 13163 was described by Alexandridis et al.20 The ERGs of the remaining 
patients (9250,  9371 and 9650) are of a more recent date and were performed according to 
the International Society for Clinical Electrophysiology (ISCEV) standard.21  Fundus 
photographs were taken in most patients and some of the patients (9650, 9369, 9378, and 
10125) also underwent fluorescein angiography.  
  
 
Results 
 
The results of the molecular genetic analysis have been summarized in Table 1. The clinical 
characteristics of the 12 patients with ABCA4 associated retinal dystrophy resembling CRD 
have been summarized in Table 2. Most did not have affected family members and therefore 
could not be classified as autosomal dominant, autosomal recessive or X-linked. Four patients 
reported a brother or sister with subnormal vision. In view of the reputedly normal visual 
acuity of the parents and the molecular defects, the inheritance pattern of the gene defects in 
these patients (individuals 9303, 9369, 9553, and 13163) was classified as autosomal 
recessive. 
The visual acuity of the patients did not exceed 20/200 and, on average, was much 
lower. With the exception of patient 9553, the age of onset was at or before the age of 12, and 
in each of the patients blurred vision was the initial symptom. Night blindness did not occur 
except in patients 9378 and 10125, in the final stages retinal degeneration. Evidence of 
maculopathy in the form of a bull’s eye maculopathy or pigmentary changes was present in 
all the patients reported in this study (Figure 1-A). The functional equivalent of the mainly 
centrally located retinal pathology was a central scotoma, varying from 8º to more than 40º. In 
all but one patient, the scotoma was absolute. Only in patient 9378 was the central scotoma 
relative and surrounded by absolute scotomas. Fundoscopic evidence of early peripheral 
involvement of the retina was mild, and only in the later stages of the disease did peripheral 
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changes characteristic of RP, such as narrowing of retinal vessels and bone spicules, occur in 
patients 9369 (Fig. 1-B) and 10125. Similarly, mild constriction of the visual fields occurred 
only in two patients (9650 and 10125) and only in the advanced state. Colour vision was 
tested in 10 patients. Six demonstrated a red-green defect, and in two of these (patients 11872 
and 10125) it was accompanied by a blue-yellow defect. In the remaining four patients, colour 
vision was severely disturbed to a degree that the exact type of impairment could not be 
assessed.  
The ERG recordings demonstrated degeneration of both rods and cones. When ERG 
responses could be elicited, the cones appeared to be affected as much as the rod 
photoreceptors and, in most of the patients, even more severely. The ERG responses in five 
patients progressively deteriorated until no photopic and scotopic responses could be 
recorded. In these patients, with exception of individuals 9250 and 13163, ERG recordings of 
an earlier date were used in Table 1. This applies to patient 9369, in whom an ERG was 
recorded at age 12 (all ERG responses had been nonrecordable since the age of 21), patient 
9378 at age 33 (all ERG responses at age 46 were nonrecordable) and patient 10125 at age 8 
(in 1998, at age 28, the ERG responses were no longer recordable). Recent ERG findings 
were not available for patients 9650 and 9371. Their ERGs were recorded in 1989 and 1985, 
respectively. The remaining ERG values were derived from ERG recordings performed in the 
last four years. Of patient 9371 only the ERG values of the left eye were available.  
 
 
  
 
 
 
 
 
 
 
 
 
 
Table 1. Results of 
mutation analysis in 
patients with ABCA4-
associated cone-rod 
dystrophy 
 
 
 
Two patients warrant a more detailed description, due to the unusual course of their 
retinal dystrophies. Patient 9378, at the age of 12, had blurred vision with fundoscopic 
evidence of irregular chorioretinal atrophy in the posterior pole. At that time, there were no 
peripheral abnormalities on ophthalmoscopy, and there was no history of night blindness. The 
ERG demonstrated an equal reduction of both cone- and rod-mediated responses. Later in life, 
however, fundoscopic changes developed that were characteristic of RP, and the patient 
reported a decrease in night vision. With fluorescein angiography partly confluent patches of 
chorioretinal atrophy were visible (Fig. 1-C).  
The clinical picture of patient 10125 differed from that of the other patients. Initially, disease 
in this patient was diagnosed as STGD1 because of the Bull’s eye maculopathy, the granular 
pigment alterations in the macular area, and the pisciform flecks surrounding the posterior 
ABCA4 mutations Patient 
Allele 1 Allele 2 
9250 1622T>C; 3113C>T 194G>A 
9303 1622T>C; 3113C>T  
9369 6601-6602delAG  
9370 1622T>C;3113C>T  
9371 1622T>C;3113C>T 1622T>C;3113C>T 
9378 768G>T  
9553 2588G>C IVS35del-2+2del4 
9633 1622T>C;3113C>T 4469G>A 
9650 3364G>A  
10125 IVS30+1G>T 3085C>T 
11872 634C>T  
13163 1622T>C;3113C>T IVS36+1G>A 
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pole. At age 8 his visual acuity had decreased to 20/200 in both eyes. When he was referred to 
our clinic in 1998 at the age of 28, peripheral degeneration in the form of narrow retinal 
vessels and deposition of peripheral bone spicules had developed, in addition to the earlier 
described disease of the central retina. A fluorescein angiogram showed typical findings: a 
central small hypofluorescent spot enclosed by an ellipsoid – a markedly hyperfluorescent 
area that in turn was surrounded by hyperfluorescent dots against a dark background most 
likely caused by obscuration of choroidal background fluorescence (Fig 1-D). Early ERG 
recordings were not available, the ERG recordings at age 28 represent the final stage of the 
degenerative process, with absence of both cone and rod responses. This retinal dystrophy 
seemed to have evolved from STGD1 into a more widespread retinal degeneration, resulting 
in loss of function of both rods and cones. 
 
C D
A B
 
 
Figure 1A-D. Fundus pictures and fluorescein angiograms of patients with (atypical) CRD. Patient 11872 (1-A) 
with a bull's eye maculopathy. Patient 9369 (1-B) demonstrating CRD in the later stages with attenuation of the 
retinal arterioles and irregular pigmentations temporal of the macula. Fluorescein angiograms of patient 9378 
(1-C) showing confluent patches of chorioretinal atrophy. Patient 10125 (1-D) with central hypofluorescence 
enclosed by an ellipsoid hyperfluorescent area. In the surrounding area hyperfluorescent flecks are visible; the 
choroidal background fluorescence seems blocked as seen in STGD1. 
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Table 2. Patients with cone-rod degeneration and ABCA4 mutations.   
Visual acuity Photopic ERG (V)* Scotopic ERG (V)* 
ID Sex Age (years) 
OD        OS 
Age of 
onset 
(years) 
Fundoscopy Colour 
vision Perimetry 
OD OS OD OS 
9250 M 30 
 
CF           CF 6 Pigment clumping in the 
macula. 
 NP Large central scotoma 
over 40º. 
ND† 
 
ND† 
9303 M 21 20/400   20/400 7 Granular pigmentary 
changes in the macula. 
Diffusely 
disturbed 
Central scotoma of 20º 
degrees. 
Severely decreased|| Severely decreased|| 
9369 F 40 LP           LP 8 RPE hypopigmentation in 
the posterior pole. In later 
stages: RP-like changes 
R-G defect Central scotoma 
varying from 10º-30º. 
65 (65%)   80 (80%)§ 140 (90%)      160 (nl)§ 
9370 M 15 
 
20/200   20/200 7 Granular aspect of the 
RPE in the macula. 
NP Concentric central 
scotoma of 8º. 
10 (13%)   9 (13%)‡ 29 (29%)     29 (23%)‡ 
9371 M 38 20/400   20/400 10 Bull’s eye maculopathy. R-G defect Concentric central 
scotoma of 20º. 
NP             29(16%)† NP  54 (30%)† 
9378 F 50 CF           CF 12 Bull's eye maculopathy, 
narrow vessels and 
peripheral patchy atrophy 
Severely 
disturbed 
Large absolute 
paracentral 
scotomas.  
30 (30%) 30 (30%)§ 70 (47%)     90 (60%)§ 
9553 F 45 20/400   20/400 25 Bull’s eye maculopathy. 
Peripheral RPE mottling. 
Severely 
disturbed 
Large central scotoma 
over 40º. 
14 (14%)   19 (19%)‡ 41 (41%)     24 (24%)‡ 
9633 M 22 20/400   20/200 12 Atrophy of RPE in the 
posterior pole. Bull’s eye 
maculopathy. 
R-G efect Central scotoma of 
20º. 
12 (16%)   12 (16%)‡ 61 (62%)     39 (39%)‡ 
9650 F 20 20/400   20/400 5 Central granular aspect of 
RPE. 
R-G defect Large central scotoma 
of 30º and relative 
constriction of III-4. 
70 (39%)   106 (59%)† 272 (nl)      115 (76%)† 
10125 M 30 20/200   20/200 8 Bull’s eye maculopathy. 
Later: peripheral changes 
characteristic for RP. 
Severe R-
G defect, 
mild B-Y 
defect 
Central scotoma of  
  10º-15º with mild 
peripheral restriction. 
75 (75%)   80 (80%)§ 130 (87%)   140 (93%)§ 
11872 M 30 20/200   20/200 10 Bull's eye pattern. B-Y and  
R-G defect  
Central scotoma of 
25º. 
23 (23%)         35 (35%)§ 110 (73%)     95 (63%)§ 
13163 M 15 20/400   20/200 6 Granular aspect of RPE in 
the macula.  
Severely 
disturbed 
Central scotoma of 
10º-15º. 
NR‡ NR‡ 
 
F, female; M, male; CF, counting fingers; LP, light perception; NP, not performed; R-G, red-green; B-Y, blue-yellow, NR, nonrecordable. * Between parentheses: percentage 
of the ERG value compared to the lower limit of the normality, normal ERG values are indicated as 'nl'.  
† Minimal values for ERG recordings: 150 µV for the photopic ERG, 180 µV for the scotopic ERG. ‡ Minimal values for ERG recordings: 99 µV for the photopic ERG, 75 µV 
for the scotopic ERG. § Minimal values for ERG recordings: 100 µV for the photopic ERG, 150 µV for the scotopic ERG. || ERG performed with skin electrodes. 
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Discussion 
 
Progressive CRD is a clinically heterogeneous retinal disorder, but typical findings include: 
reduced visual acuity, impairment of the central visual field, colour vision deficits and 
fundoscopic evidence of maculopathy with no or few midperipheral retinal pigment 
deposits.3,4,7,8 There is some dispute about typical ERG findings in CRD. Some state that the 
diagnosis of CRD must be based on the reduction or absence of cone responses in the 
presence of quantitatively less reduction in rod responses, whereas others state that an equal 
impairment of both photoreceptor systems, if accompanied by the characteristic features, 
suffices to justify the diagnosis of CRD.3,7,8,22 Several propositions have been made in the past 
to classify cone-rod disorders. Some classification systems have focused on individual case 
reports and were based on nosologic aspects; others have made a distinction according to the 
various patterns of inheritance.3,6,23,24 In recent studies by Yagasaki et al. and Szlyk et al. 
made use of full-field ERGs, dark adaptometry and modified perimetric techniques to identify 
functionally distinct subtypes of CRD.7,8 Finally, over the past few years, a molecular genetic 
classification of CRD has emerged.  
At the moment four genes and three loci have been implicated in autosomal dominant 
CRD, whereas one X-linked locus has been described.25-32 Thus far, two loci and one gene 
(ABCA4) have been associated with autosomal recessive CRD.12,33,34 The genetic 
heterogeneity seen in CRD is matched by the range of the clinical findings attributed by 
various investigators to this type of retinal dystrophy.  
Whatever the classification system used, some patients display retinal disorders that cannot be 
classified satisfactorily. Often these retinal degenerations involve overlapping features. Krill 
et al. reported that 9 out of 45 patients with cone degenerations showed typical features 
associated with fundus flavimaculatus.5 Heckenlively described 76 patients with cone-rod 
patterns on the ERG in whom retinal disease otherwise met the standard definition of RP 
(progressive peripheral visual field loss with ring scotoma).2 Alternatively, as seen in patient 
10125 in this study, patients with STGD1 have been described who had progressive 
peripheral retinal degeneration with severe abnormalities in the ERG and electro-oculogram 
(EOG) later in life – a condition that has been described by Fishman as secondary progressive 
cone-rod dysfunction.4  
The association of CRD and a dark choroid has also been described previously.35,36 
The atypical pattern of retinal degeneration with confluent patches of chorioretinal atrophy in 
patient 9378 resembles that in another previously described unrelated patient with CRD-like 
disease caused by mutations in ABCA4.37  
In the molecular genetic study by Maugeri et al., in which 11 of the 12 patients with 
autosomal recessive CRD described in this study were analyzed, ABCA4 mutations were 
found in 13 of 20 unrelated patients, strongly suggesting that ABCA4 mutations are the major 
cause of this disorder. If this is true, the genetic heterogeneity in autosomal recessive CRD, 
compared with, for example, classic RP, is surprisingly low. Because autosomal recessive 
inheritance is believed to be the most frequent mode of inheritance of monogenic 
chorioretinal disorders, it is very possible that a large fraction of the patients with CRD, who 
have been clinically studied previously, carry ABCA4 mutations. In that case, the explanation 
for the high variability of the clinical findings in autosomal recessive CRD would not be 
genetic heterogeneity but rather the genotype-phenotype model for ABCA4. According to this 
model, there is an inverse relationship between the presumed residual ABCA4 function as an 
N-retinylidene-PE flippase and the severity of the disorder.12,37,38 As a consequence, a 
continuum of phenotypes is to be expected ranging from STGD1 to CRD to RP. Although this 
is probably a simplified representation of reality and needs corroboration by detailed 
biochemical studies of individual mutations, as described previously, this model explains why 
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mutations in the ABCA4 gene could give rise to phenotypes that do not satisfy the standard 
classification of retinal dystrophies.39  
Two patients in this study might reflect borderline CRD phenotypes. Patient 9553 
carries a combination of a mild (2588G→C) and a severe ABCA4 mutation, which, according 
to the genotype-phenotype model described earlier, should be associated with STGD1. We 
have previously discussed that most likely, one of the pathologic mutations has not yet been 
identified in this patient.14 However, the age of onset in this patient (25 years) is relatively 
high, and although other features like visual acuity, perimetry and ERG findings are typical of 
CRD, this may indicate a relatively mild subtype. Another, more convincing example of 
blending of ABCA4 associated phenotypes is patient 10125. The molecular findings of this 
patient have not yet been described elsewhere. He carries a severe splice site mutation 
(IVS30+1G→T) in combination with a nucleotide change leading to a stop codon at Gln1029. 
A patient with RP who was homozygous for the IVS30+1G→T mutation has been 
described,12 whereas the Q1029X mutation has not been described.12 Both mutations can be 
considered to be null alleles. According to the proposed ABCA4 model, the clinical phenotype 
in patient 10125 should be RP. Instead, this patient exhibits a typical retinal dystrophy, which 
gradually progresses from STGD1 to a more widespread degeneration of photoreceptors in a 
cone-rod pattern later in life. At present both rod and cone ERG responses are not detectable, 
indicative of a final stage similar to that in many patients with RP. Functional studies are 
necessary to clarify whether these specific ABCA4 mutations are responsible for the particular 
progression of the retinal degeneration in this patient, or whether other as yet unknown 
modifying factors play a role.  
In this study we have described 12 unrelated patients with a retinal dystrophy 
resembling CRD caused by mutations in the ABCA4 gene. In a previous study we described 
the ophthalmologic features in five siblings with a CRD-like retinal dystrophy who were 
carrying ABCA4 mutations.37 From the clinical data of these patients and previous molecular 
studies in patients with autosomal recessive CRD, two important conclusions can be 
drawn.12,14 First, the genetic basis of autosomal recessive CRD is less heterogeneous than was 
thought based on the variability in clinical pictures, because mutations in the ABCA4 gene 
seems to be the major pathologic cause. Second, given the wide clinical spectrum of CRD-
like phenotypes associated with ABCA4 mutations, detailed clinical subclassifications are 
difficult and may not be very useful.   
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Objective: To investigate the clinical spectrum and molecular causes of retinal 
dystrophies in 3 families. 
Design: Family molecular genetics study. 
Participants: Sixteen patients and 15 relatives in 3 families. 
Methods: Members of 3 families with multiple ABCA4-associated retinal disorders were 
clinically evaluated. DNA samples of all affected individuals and their family members 
were analyzed for variants in all 50 exons of the ABCA4 gene. 
Main outcome measures: ABCA4-associated retinal phenotypes and mutations in the 
ABCA4 gene. 
Results: In family A, 2 sisters were diagnosed with autosomal recessive Stargardt disease 
(STGD1); the eldest sister was compound heterozygous for the mild 2588G→C and the 
severe 768G→T mutation. Another patient in this family with a severe type of retinitis 
pigmentosa (RP) carried the 768G→T mutation homozygously. In family B, 2 siblings 
presented with an RP of severity similar to that encountered in family A. Both were 
homozygous for the severe IVS33+1G→A mutation. Two other family members with 
STGD1 were compound heterozygous for the 2588G→C and IVS33+1G→A mutations. 
In family C all 5 siblings of generation II demonstrated age-related macular 
degeneration (AMD). In generation III and IV, 2 STGD1 patients and 1 patient with 
cone-rod dystrophy (CRD) patient were found. In 1 STGD1 patient we identified a 
heterozygous 768G→T mutation. Sequence analysis of the entire ABCA4 gene did not 
reveal the remaining two mutations. Nevertheless, the two patients with STGD1, the 
patient with CRD and two of the AMD patients shared a common haplotype spanning 
the ABCA4 gene. 
Conclusions: Different mutations in the ABCA4 gene are the cause of STGD1 and RP or 
CRD in at least two and, possibly, three families. Patients with RP caused by ABCA4 
mutations are characterized by an early onset and rapid progression of their retinal 
dystrophy, with extensive chorioretinal atrophy resulting in a very low visual acuity.  
Various combinations of relatively rare retinal disorders as STGD1, CRD and RP in one 
family may not be as uncommon as once believed, in view of the relative high carrier 
frequency of ABCA4 mutations (about 5%) in the general population. 
 
 
 
Introduction 
 
The retina-specific adenosine triphosphate (ATP)-binding cassette transporter (ABCA4, 
previously called ABCR) gene was originally found to be mutated in patients with autosomal 
recessive Stargardt disease (STGD1).1 In addition, ABCA4 mutations were found to be 
responsible for autosomal recessive cone-rod dystrophy (CRD) and autosomal recessive 
retinitis pigmentosa (RP).2-7 The ABCA4 gene encodes the ABCR protein that is located in the 
membranes of the rod and cone outer segment discs.8,9 ABCR probably functions as an 
outwardly directed flippase for N-retinylidene-phosphatidylethanolamine (N-retinylidene-PE) 
transporting all-trans-retinal from the outer segments lumen to the photoreceptor 
cytoplasm.10,11 ABCA4-associated retinal dystrophies may be caused by the accumulation of 
A2E, a major lipofuscin fluorophore, in the retinal pigment epithelium (RPE) cells resulting in 
RPE cell death and secondary loss of photoreceptors.12  
 In 1997 Allikmets et al. reported a total of 13 different ABCA4 sequence alterations in 
26 (16%) of 167 unrelated age-related macular degeneration (AMD) patients.13 Two of the 
most frequent AMD-associated variants found in this study (D2177N and G1961E) were 
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evaluated in a larger investigation including 1,218 unrelated AMD patients and 1,258 
comparison individuals. The two sequence changes were found in 3.4% of the AMD patients 
and in approximately 0.95% of the control subjects and it was concluded that the risk of AMD 
is elevated approximately 3-fold in D2177N carriers and approximately 5-fold in G1961E 
carriers.14 Other groups, however, could not find a significant difference in the prevalence of 
heterozygous ABCA4 mutations in exudative and dry AMD patients and control groups, 
although the number of individuals analyzed in these studies were smaller.15-20  
 In the proposed genotype-phenotype model for ABCA4 there is an inverse relationship 
between the presumed residual ABCA4 function and the severity of the retinal dystrophy.2,6,21 
Because different combinations of ABCA4 mutations lead to different phenotypes, this model 
implicitly predicts the occurrence of families harbouring different types of ABCA4-associated 
retinal disorders.2,3,6,7 In this study we present the clinical and genetic findings in 3 families 
with multiple ABCA4-associated retinal disorders. 
 
 
Materials and methods 
 
Clinical investigations 
All affected individuals and their family members from 3 families with ABCA4-related retinal 
dystrophies were studied (Fig. 1-3). Informed consent was obtained from all patients after the 
nature of the investigation was explained. All were examined by at least one of the authors, 
except for patient IV-3 in family A, whose medical records were studied. At the time of 
clinical examination, data of the molecular genetic analysis were not available. All examined 
individuals underwent visual acuity testing and slit-lamp biomicroscopy before indirect 
ophthalmoscopy after dilation. Five patients underwent fluorescein angiography within the 
last 3 years. Two patients underwent Goldmann kinetic perimetry. Electroretinography and 
electro-oculography were performed for all 4 patients diagnosed with RP or CRD and for 2 
patients with STGD1. The electrophysiological tests were performed according to the 
International Standard for Clinical Electrophysiology of Vision (ISCEV) standard, except for 
the electroretinograms (ERGs) of patient IV-1 in family C in 1984 en 1986, for which the 
employed method is described elsewhere.22,23 Colour vision was tested in 5 patients under 
standard conditions, as described earlier.24 
 Early AMD was characterized by any of the following findings in the macular area: 
soft drusen, choroidal or outer retinal hyperpigmentation associated with drusen, and 
depigmentation of the RPE. Late AMD may be atrophic (dry) or neovascular (wet or 
exudative); in the latter, any of the following features may be found: RPE detachment, 
choroidal neovascularisation, scar/glial tissue, and macular hard exudates unrelated to any 
other retinal vascular disease.25 The diagnosis of STGD1 disease was based on the presence of 
a progressive retinal dystrophy with beaten-metal atrophy of the macula and/or yellow-white 
pisciform flecks in the posterior pole with onset of bilateral central vision loss in childhood or 
early adulthood.26 Fundoscopic characteristics typical for RP (i.e. attenuated retinal vessels 
and bone spicules) should not be present, and the full-field ERG, when performed, had to be 
normal. The diagnosis of CRD was based on the following criteria: initial complaints of 
blurred central vision without a history of night blindness, impairment of colour vision and 
fundoscopic evidence of maculopathy with or without mild peripheral retinopathy. In patients 
with recordable ERGs, a cone-rod pattern of voltage losses had to be present (i.e. the photopic 
b-wave impairment was equal to or greater than the scotopic b-wave amplitude 
impairment).27-29 RP was diagnosed in patients who developed night blindness early in life 
with progressive constriction of their visual field. Signs on fundoscopic examination include 
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attenuated retinal vessels, depigmentation of the RPE, intraretinal bone spicule pigmentation 
and a waxy pallor of the optic disc. The ERG responses had to be decreased in a rod-cone 
pattern or nonrecordable when the disease had reached an end stage.30,31  
 
ABCA4 haplotype and mutation analysis 
Haplotype analysis (family C) was performed with microsatellite markers spanning the 
ABCA4 locus. Microsatellite markers were (from pter to cen): D1S424 (AFM203vd4), 
D1S2804 (AFMb363xf9), D1S406 (UT2069), D1S236 (AFM205ta11) and D1S497 
(AFM331vb1). A single ABCA4 nucleotide polymorphism (635G→A) present in exon 6 
assessed by restriction analysis was used as an intragenic marker. Single strand conformation 
polymorphism (family B) and/or direct sequence analysis of the 50 exons of the ABCA4 gene 
(families A, B and C) were performed with the primers and under the conditions as described 
elsewhere.1,32,33 
 
 
Results 
 
Ophthalmologic findings 
A total of 16 affected individuals could be identified in 3 families; the clinical data are 
summarized in table 1.  
 Family A. Three different ABCA4-associated retinal phenotypes could be identified. 
The most serious phenotype encountered in this family was undoubtedly present in patient III-
2, who was diagnosed with an end-stage RP (Fig. 4-A). In addition to the clinical findings 
already mentioned in Table 1, Goldmann perimetry demonstrated eccentric fixation and small 
residual visual fields temporal in both eyes and nasally in the right eye. The fundoscopic 
findings, which included bone spicule pigmentation and irregular hyperpigmentation, severe 
attenuation of the retinal vessels, and extensive chorioretinal atrophy, are highly suggestive for 
the diagnosis of RP. His initial complaint at age 6, however, was a decrease in visual acuity, 
and given the fact that both scotopic and photopic ERGs were nonrecordable, and that this 
patient could not remember whether night blindness was one of the initial symptoms, the 
diagnosis of CRD could not be excluded completely. His father (II-1) experienced a recent 
decrease in visual acuity, and ophthalmologic examination in our clinic revealed an exudative 
macular degeneration. A fluorescein angiogram clearly demonstrated an active subretinal 
choroidal neovascularisation in the right eye, which was unfortunately not amendable to 
treatment. The ophthalmic findings in the sisters (IV-2 and IV-3) were in accordance with the 
diagnosis of STGD1 (Fig. 4-B).  
 Family B. In generation II of this family, 3 of 5 siblings experienced severe visual loss 
early in life. Individuals II-3 and II-4 were clinically examined; only patient II-4 could be 
electrographically tested (Table 1). Due to the severe visual loss, Goldmann perimetry and 
colour vision tests could not be performed. In both patients, visual loss in their early teens was 
the initial symptom, but neither could remember whether night blindness was also present at 
that time (almost 70 years ago). In view of the fundoscopic appearance a diagnosis of RP was 
made (Fig. 4-C). Patients IV-1 and IV-3 both experienced visual loss in the second decade. 
Presently, the visual acuity in both patients varies from 20/200 to 20/80. The ophthalmologic 
findings in these patients are typical for STGD1, including yellow pisciform flecks 
surrounding the posterior pole and atrophic changes of the macula.  
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Figure 1. Pedigree of family A The type of retinal dystrophy and the  identified 
ABCA4 mutation(s) are denoted for each individual. Unaffected individuals are 
represented by open symbols. 
 
1 2
RP RP
IVS33+1GA
2588GC
STGD
3
1 2
I 
II
III
IV
1 2 3
STGD
IVS33+1GA
2588GC
IVS33+1GA
IVS33+1GA
6421
IVS33+1GA
IVS33+1GA
5
B
 
 
Figure 2. Pedigree of family B. The type of retinal dystrophy and the  identified 
ABCA4 mutation(s) are denoted for each individual. Unaffected individuals are 
represented by open symbols. 
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Figure 3. Pedigree of family C. The ABCA4 haplotypes and known mutations are depicted. 
The most relevant haplotypes are represented by uniform grey colours. The haplotypes with 
identical shades of grey share the same DNA segment spanning the ABCA4 locus and are 
therefore thought to share the presence or absence of an ABCA4 mutation. 
 
 
  Family C. In generation II, all siblings are affected by AMD. Phenotypes 
ranged from early AMD with soft drusen (patients II-2 and II-3) to late exudative AMD, 
with a large number of soft drusen (patients II-1 and II-6; Fig. 4-D) and late AMD with 
mainly geographic atrophy (patient II-5). Patients with STGD1 were encountered in the 
third and fourth generation of family C (patients III-3 and IV-2). The initial symptom of 
visual loss occurred relatively late in patient III-3, at 30 years of age. In addition, the 
development of his macular dystrophy was somewhat asymmetrical. At age 34, visual 
acuities were 20/32 in the right eye and counting fingers in the left eye; 4 years later 
visual acuity had dropped to 20/125 in the right eye, whereas the poor vision in the left 
eye remained stable. Ophthalmoscopy demonstrated typical yellow flecks near the 
posterior pole and beaten bronze atrophy of the macula (Fig. 4-E). Fluorescein 
angiography showed areas of diminished choroidal background fluorescence near the 
posterior pole and midperiphery. The ERG demonstrated no abnormalities and the 
electro-oculogram (EOG) was mildly decreased (Arden ratio: right eye, 1.56 and left 
eye, 1.44). Goldmann perimetry demonstrated a relative central scotoma of 7º in the 
right eye; perimetry in the left eye was not possible. The second STGD1 patient (IV-2) 
presented with minute yellow flecks around the posterior pole. Strikingly, the EOG in 
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this patient was nonrecordable; an ERG with a corneal contact lens unfortunately was 
not possible. Goldmann kinetic perimetry showed a congruent paracentral scotoma  
 
C D
A B
E F
 
Figure 4. Selection of fundus pictures of patients from families A, B and C. 
A. Patient III-2 in family A with retinitis pigmentosa (RP) characterized by extensive chorioretinal 
atrophy, irregular hyperpigmentation, paleness of the optic disc and narrowing of retinal vessels. B. The 
yellow flecks in patient IV-2 of family A are typical of STGD1. C. ABCA4-associated RP in patient II-4 of 
family B, there is extensive chorioretinal atrophy, attenuation of retinal vessels and irregular 
hyperpigmentation. D. Exudative AMD with disciform reaction following choroidal neovascularisation in 
patient II-6 of family C. E. STGD1 in patient III-3 of family C with pisciform yellow flecks scattered 
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around the posterior pole and ‘beaten bronze atrophy’ of the macula. F. Bull’s eye aspect of the macula 
in patient IV-1 of family C, The electroretinogram is indicative of CRD. 
  
inferior to the fovea, and colour vision testing demonstrated a red-green defect. Fluorescein 
angiography was performed and demonstrated a silent choroid with small hyperfluorescent 
dots surrounding the posterior pole. The patient was diagnosed with STGD1, although 
secondary progression to a more widespread retinal dystrophy may occur in view of the EOG 
findings. The last patient in this family (IV-1) was diagnosed with CRD (Fig. 4-F). At age 6 
his visual acuity had already decreased to counting fingers. The ERG performed at age 8 
showed degeneration of the photoreceptors in a cone-rod pattern (Table 1). Two years later the 
photopic responses were no longer recordable, and the scotopic responses had decreased 
further. Colour vision tests demonstrated a red-green defect and a minor blue-yellow defect. In 
both eyes a central scotoma of 10º was present, but the visual field was not constricted. 
 
Molecular genetic analysis 
 Family A. Sequence analysis of all 50 exons of the ABCA4 gene in RP patient III-2 
revealed homozygosity for a 768G→T change in exon 6 (Table 2) The same mutation was 
carried heterozygously by his father (patient II-1), who was affected by AMD. Patient II-2, 
affected by STGD1, was compound heterozygous for the 768G→T mutation and a 2588G→C 
mutation in exon 17 (Table 2). DNA of her sister, also diagnosed with STGD1 (patient IV-3), 
was not available for genetic analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Segregation  
of mutations in the 
patients of the families A, B 
and C.  
  
 
 
 Family B. Both patients diagnosed with RP in generation II (patient II-3 and II-4) were 
homozygous for a novel splice site mutation in intron 33 (IVS33+1G→A). Grandchildren of 
patient II-4, affected by STGD1 (patients IV-1 and IV-3), were compound heterozygous for 
the IVS33+1G→A and the 2588G→C mutations (Table 2.)  
 Family C. Haplotype analysis, with markers spanning the ABCA4 locus, revealed the 
sharing of a common ABCA4 allele in all patients with STGD1 or CRD (patients III-3, IV-1 
ABCA4 mutations Family Patient Diagnosis 
Allele 1 Allele 2 
A II-1 AMD 768G>T  
A III-2 RP 768G>T 768G>T 
A IV-2 STGD1 768G>T 2588G>C 
A IV-3 STGD1 768G>T 2588G>C 
B II-3 RP  IVS33+1G>A  IVS33+1G>A 
B II-4 RP  IVS33+1G>A  IVS33+1G>A 
B IV-1 STGD1  IVS33+1G>A 2588G>C 
B IV-3 STGD1  IVS33+1G>A 2588G>C 
C II-1 AMD   
C II-2 AMD   
C II-3 AMD   
C II-5 AMD   
C II-6 AMD   
C II-3 STGD1   
C IV-1 CRD IVS38-10T>C  
C IV-2 STGD1 768G>T  
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and IV-2), and in two out of five patients with AMD (patients II-3 and II-6). Sequence 
analysis did not detect an ABCA4 mutation in the shared allele. Patient III-3, affected by 
STGD1, shared the same haplotypes with his brother (individual III-1). Ophthalmologic 
examination, however, showed no sign of retinopathy in individual III-1 at age 53. Upon 
sequence analysis, no ABCA4 mutations were found in patient III-3. Patient IV-1, diagnosed 
with CRD, carried an IVS38-10T→C variant on the maternal allele. Patient IV-2, diagnosed 
with STGD1, inherited from her mother the 768G→T mutation.  
 
 
Discussion 
 
The genotype-phenotype correlation model for ABCA4 mutations proposes that there is an 
inverse relationship between the presumed residual ABCA4  function and the severity of the 
disorder.2,3,21 As a consequence, a continuum of phenotypes arises. The combination of a mild 
and a severe ABCA4 mutation will result in STGD1, whereas a moderate and a severe 
mutation will cause CRD. Finally, two severe ABCA4 mutations will result in a retinal 
dystrophy resembling RP.  
 In this study we describe 3 families in which we encountered different combinations of 
retinal disorders – that is, AMD, RP and STGD1 (family A); RP and STGD1 (family B); and 
AMD, CRD and STGD1 (family C). Three different pathologic mutations in the ABCA4 gene 
could be identified in these families: 2588G→C, 768G→T and IVS33+1G→A.  
The 2588G→C mutation is one of the most frequent ABCA4 mutations identified in patients 
with STGD1. We assume that this is a relative mild mutation, based on the observed 
combinations of mutations in STGD1 patients and the relatively high frequency of this 
mutation in the general population. Therefore the 2588G→C mutation would only cause 
STGD1 in combination with a severe mutation.33 The second mutation (768G→T) is a splice 
site mutation that has previously been described in patients with STGD1 and CRD.5,33 RNA 
analysis in a patient who was compound heterozygous for the 768G→T and the 2588G→C 
mutations failed to show a detectable transcript for the 768G→T allele, strongly suggesting 
that 768G→T is a severe ABCA4 mutation.33 The third mutation (IVS33+1G→A) has not 
been described before. This sequence change also inactivates a splice site.  In general, the 
effect of such a mutation will be a truncated (nonfunctional) protein. It is therefore likely that 
the IVS33+1G→A allele represents a severe ABCA4 mutation. 
Genotype-phenotype correlation in these families is relatively straightforward for 
families A and B, but is more difficult in family C. In families A and B we were able to 
identify ABCA4 mutations in all patients with STGD1 and RP (Figs. 1 and 2). In both 
families, patients with STGD1 were compound heterozygous for a mild mutation (2588G→C) 
and a severe mutation (768G→T or IVS33+1G→A). The 3 patients in families A and B who 
were diagnosed with RP were all homozygous for a severe ABCA4 mutation (768G→T or 
IVS33+1G→A). These findings agree with the above-mentioned genotype-phenotype 
correlation model. 
 In the complex family C, all 3 individuals presenting with an early onset retinal 
dystrophy were found to share an identical DNA segment spanning the ABCA4 locus (the 
black haplotype 3,1,6,A,3,7 in figure 3). Unfortunately, we were unable to associate any 
ABCA4 mutation with this haplotype. This is not uncommon, because previous ABCA4 
mutation analyses in patients with STGD1 could identify mutations in approximately 60% of 
the ABCA4 alleles.18,33-35 Because STGD1 is thought to be a genetically homogeneous 
disorder, it seems apparent that a large number of ABCA4 mutations escape commonly used 
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mutation analysis techniques. Unidentified mutations might be located in the ABCA4 
promoter region, or deep in introns. Alternatively, the whole gene or part of the gene might be 
heterozygously deleted. Therefore, we believe that the shared haplotype (3,1,6,A,3,7) in the 
patients of family C carries an as yet unknown ABCA4 mutation. The same line of reasoning 
applies for the maternal haplotype (3,3,6,G,8,4) of patient IV-1 (Fig. 3). This allele carries the 
IVS38-10T→C variant, which in itself is probably not pathologic.18,36  However, the 
occurrence of this variant in 10% of patients with STGD1 and CRD and in none of 384 
control individuals strongly suggests that the IVS38-10C variant is in linkage disequilibrium 
with an as yet undetected pathologic ABCA4 mutation (Maugeri and Cremers, unpublished 
results). Also, the presence of a severe ABCA4 mutation (768G→T) in the maternal haplotype 
(8,4,5,G,8,2) of patient IV-2 makes it likely that ABCA4 mutations are responsible for the 
retinal dystrophies in the patients IV-1 and IV-2. The brothers III-1 and III-2 in family C share 
the same haplotypes, although III-3 has STGD1 whereas his brother is unaffected. Whether 
this discrepancy is a result of nonexpression of STGD1, as observed in 3 patients from 3 
unrelated families,37 or of a de novo mutation in the maternal allele of patient II-2 remains as 
yet unclear.   
Although not undisputed, it has been demonstrated that at least two ABCA4 mutations 
are associated with AMD at a statistically significant level.14 In family A, the AMD patient 
(II-1) is heterozygous for the 768G→T ABCA4 mutation, which may be one of the 
predisposing factors in this patient for AMD. In family C all siblings in generation II were 
diagnosed with AMD. Linkage analysis failed to identify an ABCA4 allele that was present in 
all AMD patients. Based on these molecular findings and in view of the variability in clinical 
features of the AMD, we can make no prediction regarding the putative role of ABCA4 as a 
cause of AMD in this family.3 
Including the present study, 12 families (24 patients) with ABCA4-related RP have 
been described.2-4,6,7,38-42 In 21 patients two severe mutations in the ABCA4 gene, probably 
resulting in the absence of functional ABCR protein, are associated with the RP phenotype. 
Clinical data from these patients suggests that extensive chorioretinal atrophy and very low 
final visual acuity (hand motions or light perception) are common features in this type of 
RP.3,6,7 ERG recordings demonstrate nonrecordable rod- and cone-mediated responses in most 
of these patients.6 Although the presenting symptom in most of these patients was night 
blindness, the 3 patients in this study could only remember a decrease in visual acuity as 
initial symptom. It is possible that night blindness developed simultaneously and our patients 
did not notice it at that time, or could not remember when interviewed so many years later. 
The extensive chorioretinal atrophy, the severe attenuation of the retinal vessels and bone 
spicule formation are all characteristic of RP. However, because no ERG recordings are 
available at the early stages in these patients, we cannot rule out that the phenotype partly 
overlaps with CRD. It is conceivable that in some patients with ABCA4-associated RP, 
deterioration of both rod and cone systems evolve simultaneously and that relative mild 
complaints as night blindness and constriction of the peripheral visual field, are not noticed 
initially when the visual acuity drops. In these situations the clinical boundaries between RP 
and CRD are not clearly defined. In the end stage of this type of retinal dystrophy most of the 
cone and rod photoreceptors are lost, and both the scotopic and the photopic ERG becomes 
nonrecordable. When there is not enough information to determine with certainty which 
photoreceptor system was predominantly affected in the early stage, the distinction between 
CRD and RP becomes difficult. In these patients the diagnosis will depend on the remaining 
features of the retinal dystrophy rather than the nonspecific ERG findings. When we also take 
into account that these features will change over time, it becomes clear that various 
investigators will not always agree on the correct diagnosis. Detailed clinical investigations of 
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patients in the early phases of a retinal dystrophy associated with two severe (null) ABCA4 
mutations might shed light on this matter.  
The presence of multiple ABCA4-related disorders within one family supports the 
proposed genotype-phenotype model for this gene, which proposes an inverse relationship 
between the presumed residual function of ABCA4 as a N-retinylidene-
phosphatidylethanolamine flippase and the severity of the disorder.21 In view of the relatively 
high heterozygote frequency of ABCA4 mutations in the general population (about 5%), the 
recurrence of ABCA4-associated phenotypes is not a rare finding.18,33 The child of a patient 
with two ABCA4 mutations, causing STGD1, CRD or RP, on average has a 2.5% chance of 
developing an early-onset retinal disease. When one of these retinal disorders is diagnosed, 
specific inquiries should be made to exclude the presence of other ABCA4-associated retinal 
disorders in the family. Mutation analysis in an RP patient is facilitated in the presence of a 
relative with STGD1, since this strongly suggests involvement of the ABCA4 gene. Early 
diagnosis of these disorders is important not only to help establish an accurate prognosis for 
the patient, but also for selected individuals duals who might be eligible for future treatments 
aimed at slowing down the progression of these retinal disorders.12  
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Mutations in the ABCA4 gene have been associated with autosomal recessive Stargardt 
disease (STGD1), cone-rod dystrophy (CRD), and retinitis pigmentosa (RP). We 
employed a recently developed genotyping microarray, the ABCR400 chip, to search for 
known ABCA4 mutations in patients with isolated or autosomal recessive CRD (54 
cases) or RP (90 cases). We performed detailed ophthalmologic examinations and 
identified at least one ABCA4 mutation in 18 (33%) patients with CRD and in 5 (5.6%) 
patients with RP. Single strand conformation polymorphism (SSCP) analysis and 
subsequent DNA sequencing revealed 4 novel missense mutations (R24C, E161K, P597S, 
G618E) and a novel 1-bp deletion (5888delG). Ophthalmoscopic abnormalities in CRD 
patients ranged from minor granular pigmentary changes in the posterior pole to 
widespread atrophy. In 12 patients with recordable ERG tracings, a cone-rod pattern 
was detected. Three patients demonstrated progression from a retinal dystrophy 
resembling STGD1 to a more widespread degeneration, and subsequently received the 
diagnosis of CRD. In addition to a variable degree of atrophy, all RP patients displayed 
ophthalmologic characteristics of classic RP. When detectable, ERG recordings in these 
patients demonstrated rod-cone patterns of photoreceptor degeneration. In conclusion, 
in this study we show that the ABCA4 mutation chip is an efficient first screening tool 
for autosomal recessive CRD.  
 
 
 
Introduction 
 
The ABCA4 (ABCR) gene was identified as the gene underlying autosomal recessive 
Stargardt disease (STGD1).1 Since the cloning of the ABCA4 gene, other studies have 
implicated this gene also in autosomal recessive CRD (arCRD) and in autosomal recessive RP 
(arRP).2-17 In addition, heterozygous ABCA4 mutations were found in 16% of cases with age-
related macular degeneration (AMD).18 The high prevalence of heterozygous ABCA4 
mutations in the general population and the inability of relatively small-sized studies to 
replicate this result, shed doubt on the significance of the molecular findings in patients with 
AMD.19-24 In a larger independent study, two ABCA4 mutations were significantly associated 
with AMD.25 
The ABCA4 gene encodes the ABCR protein, previously identified as the rim protein 
(RmP), a retina-specific (adenosine triphosphate) ATP-binding cassette transporter. This 
protein is thought to act as a flippase for N-retinylidene phosphatidylethanolamine (N-
retinylidene-PE), thereby facilitating the transport of all-trans-retinal from the disk lumen to 
the photoreceptor cytoplasm.26,27 In Abcr-/- mice, N-retinylidene-PE is converted, through 
various intermediates, into A2-E, a major component of lipofuscin. A2-E accumulates in toxic 
levels in the retinal pigment epithelium (RPE), eventually resulting in the degeneration of the 
RPE and the overlying neuroretina. Interestingly, Abcr-/- mice raised in complete darkness do 
not accumulate A2-E, suggesting that avoiding excessive light might be beneficial for humans 
with ABCA4-associated retinal dystrophy.28 Recently, Radu and colleagues were able to 
rescue retinal dystrophy in Abcr-/- mice by treating them with isotretinoin (Accutane or 13-
cis-retinoic acid), a drug commonly used in dermatology for the treatment of cystic acne.29 
Both studies show that therapeutic approaches for humans with ABCA4-associated retinal 
dystrophies are feasible, which underlines the importance to identify patients with CRD and 
RP caused by mutations in ABCA4. 
Numerous mutation analysis studies in patients with STGD1 have yielded more than 
400 different ABCA4 mutations.1,6,9,22,32-35 Unlike STGD1, arCRD and arRP are not 
genetically homogeneous disorders (RetNet at http://www.sph.uth.tmc.edu/RetNet).2,36-38 
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Studies investigating the role of ABCA4 mutations in arCRD estimate involvement of this 
gene in 24-75% of all cases.5-9,11,16 ABCA4 mutation analysis in arRP patients thus far was 
restricted to families in which STGD1 and RP segregated.4,10,14,15,17  Therefore, it has not been 
possible to accurately predict the contribution of ABCA4 mutations to arRP pathology. 
Recently, a genotyping microarray (ABCR400 chip) was developed that contains all currently 
known ABCA4 mutations and reliably identifies all known ABCA4 mutations in patients with 
STGD1.39  
In this study, we utilized the ABCR400 microarray to systematically screen for 
mutations in patients with isolated or autosomal recessive RP (90 patients) and CRD (54 
patients). We re-evaluated the clinical features in patients with ABCA4 mutations and provide, 
for the first time, an assessment of the contribution of ABCA4 gene mutations as a cause for 
arRP in the Caucasian population. 
 
 
Materials and methods 
 
Patients and controls 
The charts of 90 patients with isolated (56) or autosomal recessive (34) RP and 54 patients 
with isolated (35) or autosomal recessive (19) CRD were collected from the centres 
collaborating in this study. RP patients were ascertained in Nijmegen (74), Rotterdam (10), 
and Heidelberg (6). CRD patients were ascertained in Heidelberg (36), Nijmegen (16), and 
Rotterdam (4). Some of these cases might be due to X-linked or autosomal dominant 
mutations. In the remainder of this manuscript the patient groups will be designated as CRD 
and RP.  
This study was approved by the institutional review board (CCMO). After informed consent 
was obtained, blood samples were taken. Samples from 93 healthy Dutch blood donors were 
used as controls. The clinical data of all patients were examined and, when clinical data were 
incomplete or obtained with obsolete methods, patients were clinically re-evaluated. Kinetic 
perimetry was performed with the Goldmann perimeter. A recent electroretinogram (ERG), 
recorded in accordance with the International Society for Clinical Electrophysiology for 
Vision (ISCEV) protocol,40 was available for all patients, except for patient 9444. The 
employed ERG methods for this patient, as well as the earlier ERGs of 3 other patients, were 
performed as described by Thijssen et al41 (patients 12608 and 15680) and Alexandridis et 
al42 (patient 15730).  When possible, colour vision was tested with the Ishihara and Panel D15 
tests. The diagnosis of CRD was based on initial complaints of decreased or blurred central 
vision, without a history of night blindness. Maculopathy, characterized by a bull’s eye 
pattern or granular alterations of the macular RPE, with or without relatively mild peripheral 
retinopathy were considered typical. Visual field testing usually shows a central scotoma, 
whereas the peripheral fields are either normal or show a mild to moderate constriction. In 
addition, ERG recordings in CRD either show reduction or absence of cone responses in the 
presence of quantitatively less reduction in rod responses, or an equal impairment of both 
photoreceptor systems.43-46 The initial symptom in most RP patients is night blindness. Visual 
field defects typically originate in the midperiphery, with gradual enlargement to both the 
periphery and the centre of the retina. Typically, the ERG recordings demonstrate 
photoreceptor degeneration in a rod-cone pattern.47 In selected cases, especially in the later 
stages of both CRD and RP, rod- and cone-mediated ERG recordings may be equally 
impaired or may even become nonrecordable, which makes it difficult to provide an accurate 
diagnosis. In such cases, the nature of the initial complaints, the aspect of the fundus and – if 
available – ERG recordings of an earlier stage of the retinal dystrophy are used to 
discriminate between RP and CRD. 
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Mutation screening 
The microarray mutation analysis of the ABCA4 gene with the ABCR400 chip was performed 
as described earlier.39  In patients with one ABCA4 mutation, we searched for additional 
mutations using single strand conformation polymorphism (SSCP) analysis and DNA 
sequence analysis of aberrantly migrating fragments as described elsewhere (ref. 5 and 
references therein). The ABI PRISM Big Dye Terminator Cycle Sequencing V2.0 Kit was 
used for sequencing and the reactions were analyzed with the ABI PRISM 3700 DNA 
analyzer (Applied Biosystems). Four novel missense mutations were tested in 93 control 
DNA samples. The presence of R24C (70C→T) was analyzed using HinfI restriction 
fragment analysis of PCR-amplified exon 2. The normal PCR product (191 nts) was cut into 
fragments of 167 and 24 nts; the PCR product with the 70C→T alteration was not digested. 
E161K (481G→A) was tested using MboII, which cuts the normal PCR product of exon 5 
(240 nts) in 3 fragments (170, 40, 30 nts) and the mutant PCR product in two fragments (200 
and 40 nts). The P597S (1789C→T) mutation was analyzed using AlwI, which cuts the 
normal PCR product of exon 13 (280 nts) into fragments of 100, 90, 60 and 30 nts and the 
mutant PCR product into fragments of 160, 90 and 30 nts. An amplification-refractory 
mutation specific (ARMS) assay48 was performed to test G618E (1853G→A). For specific 
amplification of the mutant sequence, the SSCP reverse primer was used and a mutation-
specific forward primer (5’ GCAGGACATGGTTGAACAGCA 3’). ARMS cycling 
parameters consisted of 94oC for 5 min, followed by 35 cycles of 94oC for 30 sec, 58oC for 30 
sec, 72oC for 1 min, and a final extension of 5 min at 72oC using 2.0 mM MgCl2.  
 
 
Results 
 
Mutation analysis 
Genotyping was performed on DNA isolated from blood samples of 54 CRD patients and 90 
RP patients with the ABCR400 chip. We identified ABCA4 mutations in 18 (33%) patients 
with CRD (Table 1) and in 5 (5.6%) patients with RP (Table 2). Eleven of 54 CRD patients 
were compound heterozygous (9) or homozygous (2) for ABCA4 variants; 7 were 
heterozygous. Four out of 90 RP patients were heterozygous; one patient was compound 
heterozygous for ABCA4 variants. Although the segregation of the L541P and A1038V 
mutations could not be tested in the respective families, we have grouped them as complex 
alleles, based on  previous observations that these alterations invariably occur in cis 
configuration in German patients with CRD (Table 1).5,34 Indeed, all 4 patients carrying these 
variants (14488, 14752, 16242 and 16582) were from Germany. Likewise, the 2588C and 
2828A variants are presumed to be located in the same allele since the 2588C allele in 
previous studies was always found together with 2828A (see discussion).33,51  
Next, we employed SSCP analysis and DNA sequencing in patients with one ABCA4 
mutation and identified 5 novel ABCA4 mutations that were not present on the microarray – 
that is, R24C, E161K, P597S, G618E, and 5888delG. None of the 4 new missense mutations 
could be identified in a panel of 93 healthy control individuals. An overview of the identified 
ABCA4 mutations is given in Tables 1 and 2. The 5888delG mutation is predicted to result in 
the truncation of the second nucleotide binding domain of the ABCR protein and can thus be 
considered a null mutation. The 4 novel missense mutations significantly alter the charge or 
hydrophobicity of the respective amino acid residues, which invariably are conserved in 
mouse Abcr and, with the exception of R24, also in ABCA1 (data not shown). R24 is located 
in the N-terminal cytoplasmic domain, one residue next to the first transmembrane domain of 
ABCR. E161 is located in the first luminal loop; P597 and G618 are both located in first 
cytoplasmic loop. 
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ABCA4 Allele 1 ABCA4 Allele 2 CRD 
Patient 
number 
Inheri-
tance 
Nucleotide            
change Effect 
Nucleotide 
change Effect 
Mutations 
segregate 
12608 Isolated IVS38-10T>C Unknown* IVS38-10T>C Unknown* yes 
14488 Isolated 1622T>C 
3113C>T 
L541P  
A1038V 
Not identified NA 
14750 Isolated 4918C>T R1640W Not identified NA 
14752 Isolated 1622T>C 
3113C>T 
L541P  
A1038V 
IVS38-10T>C Unknown* ? 
15105 Isolated IVS36+2T>C Splicing IVS40+5G>A Splicing ? 
15428 Isolated 1622T>C 
3113C>T 
L541P  
A1038V 
2300T>A V767D ? 
15429 Isolated 52C>T R18W 70C>T R24C ? 
15680 Isolated 5882G>A G1961E Not identified NA 
15730 Isolated 2588G>C 
2828G>A 
G863/G863A 
R943Q 
2588G>C 
2828G>A 
G863/G863A 
R943Q 
? 
16242 Isolated 1622T>C 
3113C>T 
L541P   
A1038V 
Not identified NA 
16243 Isolated 5381C>A 
481G>A 
A1794D 
E161K 
1789C>T P597S ? 
16569 Aut. rec. 3259G>A E1087K Not identified NA 
16582 Isolated 1622T>C 
3113C>T 
L541P  
A1038V 
IVS38-10T>C Unknown* ? 
16583 Isolated 194G>A G65E 768G>T Splice site ? 
16697 Isolated 2588G>C 
2828G>A$ 
G863/G863A 
R943Q 
1853G>A 
4297G>A 
G618E 
V1433I 
yes 
16755 Isolated 2588G>C 
2828G>A 
G863/G863A 
R943Q 
Not identified NA 
16887 Isolated 768G>T Splicing IVS38-10T>C Unknown* yes 
17906 Aut. rec. 768G>T Splicing Not identified NA 
 
Table 1. ABCA4 sequence variants in CRD patients. Novel variants in bold lettering. 
*Mutation which is presumed to be in linkage disequilibrium with unknown pathologic ABCA4 
mutation. $Polymorphic variants 4203A, 5603T, and 5682C also present. ?, Segregation analysis not 
possible or not determined; NA, not applicable. 
 
 
In 3 cases with isolated CRD (12608, 16697, and 16887), we were able to perform 
segregation analysis of the mutations. The mutations in patients 12608 and 16887 were shown 
to be located on different chromosomes. In family members of patient 16697, the 2588C; 
2828A variants segregated from the G618E; V1433I mutations. For the other patients with 
two or more ABCA4 variants, no parents or unaffected siblings were available for genetic 
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analyses. The 3 variants identified in patient 16243 were arbitrarily indicated in the table 
since we were unable to test their segregation. 
 
 
ABCA4 Allele 1 ABCA4 Allele 2 RP 
Patient 
number 
Inheritance 
Nucleotide 
change Effect 
Nucleotide 
change Effect 
9304 Aut. rec. 2588G>C; 
2828G>A$ 
G863/G863A; 
R943Q 
5888delG R1963fs 
9444 Aut. rec. 6529G>A D2177N Not identified 
9545 Isolated 6529G>A D2177N Not identified 
14753 Isolated 1622T>C; 
3113C>T 
L541P;  
A1038V 
Not identified 
17597 Isolated 6148G>C V2050L Not identified 
 
Table 2. ABCA4 sequence variants in RP patients. Novel variant in bold lettering. 
$Polymorphic variants 4203A, 5603T, and 5682C also present.  
 
 
Clinical analysis of CRD patients with ABCA4 mutations 
An overview of the clinical findings in the patients with ABCA4-associated CRD is given in 
Table 3. The fundus photographs of 3 CRD patients (15680, 16687 and 16569) are depicted in 
Figure 1A-C. All CRD patients experienced a loss of central visual acuity as the initial 
symptom. In most patients a central scotoma was present, varying from 10 to 40º in size. The 
visual acuity in most of these patients is 20/125 or lower. An exception is patient 15429 with 
a visual acuity of 20/32; since this patient is 53 years of age, this finding can not be attributed 
to an early stage of the disease progression. Colour vision tests could be performed in 11 
patients, all of whom demonstrated a red-green defect. In 10 of the 18 patients, the photopic 
(cone) responses on the ERG are more severely decreased compared to the scotopic (rod) 
responses. In patients with nonrecordable or equally reduced cone and rod responses, the 
diagnosis CRD was based on earlier ERG recordings, the initial symptoms and the overall 
aspect of the fundus.  
Three patients (14752, 16697, and 16887) presented with yellow flecks, located at the 
posterior pole and midperiphery (Fig. 1-B, patient 16887). Two of these individuals were 
initially diagnosed with STGD1 and demonstrated characteristic blocking of choroidal 
background fluorescence. However, in the later stage of their disease, these patients 
developed full-field ERG abnormalities in a cone-rod pattern. These patients should therefore 
be classified either as STGD1 with peripheral involvement or as CRD. 
 
Clinical analysis of RP patients with ABCA4 mutations 
The clinical data of the 5 RP patients with ABCA4 mutations are summarized in Table 4. The 
fundus of patient 17597 is depicted in Figure 1-D. Typical RP features like peripheral bone 
spicules and progressive attenuation of the retinal vasculature were invariably present. Only 
patient 9304 demonstrated extensive chorioretinal atrophy. Colour vision tests could be 
performed in 3 patients: all had blue-yellow type defects. In patients 9304 and 14753, no 
scotopic and photopic ERG responses could be elicited; the other 3 patients demonstrated a 
rod-cone pattern of photoreceptor degeneration. 
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Table 3. Clinical data of CRD patients with ABCA4 mutations.  
  
Visual acuity ERG 
No Sex Age (yrs) 
OD OS 
Fundoscopy Perimetry 
Photopic Scotopic 
12608 M 40 HM HM Peripheral bone spicules and extensive chorioretinal 
atrophy. Very pale optic disc. 
Central scotoma of 40º. NR NR 
14488 F 48 CF 20/400 Diffuse, granular RPE changes in macula, peripheral 
pigmentations.  
Central scotomas of 25º in right eye 
and 10 deg in left eye. 
  
14750 M 17 CF CF Central hyper- and hypopigmentation of the RPE   Large paracentral scotomas  NR NR 
14752 F 17 20/400 20/400 Yellow spots in the posterior pole. Central RPE 
mottling. 
Central scotoma of 15-20º. 
 
/ NR  
15105 M 25 20/200 20/125 Granular aspect of macular RPE Central scotoma of 10-15º.   
15428 F 53 CF CF Chorioretinal atrophy at the macula with extensive 
hypo- and hyperpigmentation. 
Central scotoma of 10-15º. 
Peripheral constriction (50º-60º). 
  
15429 F 53 20/32 20/32 Large central chorioretinal atrophy with small island.  Central scotoma of 15-20º.   
15680 F 51 HM HM Chorioretinal atrophy, Bull’s eye maculopathy. Central scotoma and bad fixation  (1985) 
  
 (1985) 
  
15730 M 30 CF CF Granular RPE changes at the macula Right eye: only island 20-40º in 
superior field. Left eye: central 
scotoma of 20º. 
 (1985) 
NR 
 (1985) 
NR 
16242 F 23 20/200 20/200 Bull’s eye with central chorioretinal atrophy Central scotoma and ringscotoma   NR  
16243 M 40 20/125 20/100 Initially granular RPE atrophy at the macula, later 
geographical atrophy. 
Central scotoma of 10º.   
16569 M 11 20/400 20/400 Granular RPE changes at the macula. No bone 
spicules and no attenuated retinal vessels.  
Large central scotomas. /NR  
16582 F 19 20/400 20/400 Mild granular changes at the macula Central scotoma of 20º.   
16583 M 17 20/200 20/400 Granular changes at the macula Central scotoma of 10-20º.   
16697 F 24 20/125 20/125 Bull’s eye maculopathy. Mild flecks at posterior pole. (Para)central scotomas.   
16755 F 62 CF 20/400 Granular RPE changes at the macula Central scotoma of 30-40º. /NR /NR 
16887 F 17 20/400 20/400 Central chorioretinal atrophy. Granular changes at 
midperiphery 
Central scotoma   
17906 F 14 20/63 20/63 Dark pigmentations at the macula, surrounded by 
hypopigmented halo 
(Para)central scotomas NR  
 
 CF, counting fingers; HM, hand movements; NR, nonrecordable;  = decreased;  = severely decreased. 
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Table 4.  Clinical data of RP patients with ABCA4 mutations. 
 
Visual acuity 
 
ERG 
No Sex Age (yrs) 
OD    OS 
Fundoscopy Perimetry 
Photopic Scotopic 
9304 F 87 CF CF Severe chorioretinal atrophy. Presently, impossible to perform. 
Ringscotomas in the past. 
NR NR 
9444 M 61 20/63 20/63 Bone spicules and attenuated vessels. Minor 
excavation of disc. 
Ringscotomas.  (1982) 
NR 
 (1982) 
NR  
9545 F 60 20/63 20/200 Bone spicules and attenuated vessels. Glaucomatous 
aspect of left optic disc. 
Initially ringscotomas, later 
progressive constriction of visual 
field. Also Bjerrum scotomas, more 
pronounced in the left eye than in 
the right eye.  
  
14753 F 25 20/63 20/63 Gliosis at the macula, attenuated retinal vessels. Central island of 10-15º. 
Ringscotoma of 50º. 
NR NR 
17597 F 48 20/20 20/20 Peripheral bone spicule pigmentations, mild 
attenuation of vessels, midperipheral atrophy 
Partial ringscotoma /NR NR 
 
CF, counting fingers; HM, hand movements; NR, nonrecordable;  = decreased;  = severely  decreased. 
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Figure 1. Fundus pictures of patients with CRD and RP. A. CRD patient 15680 with bull’s eye 
maculopathy and temporal pallor of the optic disc (with myelinated nerve fibres).  In the periphery (not 
visible) there are minor hyperpigmentation, the retinal vessels are of normal size. B. Chorioretinal 
atrophy in the posterior pole of CRD patient 16887. Mild granular changes located at midperipheral 
retina (not visible). This patient was initially diagnosed as STGD1 in view of the yellow flecks, which 
are still faintly visible.  C. CRD patient 16569 (age 12) demonstrating an obvious pallor of the temporal 
optic nerve head and atrophic changes in the macula. At that time, the photopic ERG is already 
nonrecordable and the scotopic ERG is severely decreased. D. RP patient 17597 shows typical RP 
features such as bone spicules in the periphery and attenuated retinal vessels. Large choroidal vessels 
can be seen in the midperiphery indicative of atrophic changes. 
 
 
Discussion 
 
In previous ABCA4 mutation analysis studies, RP patients were ascertained because of their 
familial relationship with STGD1 patients. In this study, we describe the first systematic search 
for ABCA4 mutations in patients with isolated or autosomal recessive RP. In addition, this is 
the first CRD mutation analysis study that is primarily based on a genotyping microarray. The 
ABCA4 gene has shown an extraordinary allelic heterogeneity and most of the sequence 
variants have been observed in only a few cases. Therefore, the interpretation of the pathologic 
nature of sequence variants, in particular missense mutations and apparently benign variants is 
problematic.  
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Pathogenicity of ABCA4 variants 
In Table 5, the functional consequences of ABCA4 missense mutations – that is, ABCR protein 
expression, ATP binding and ATPase activity – are summarized. Likewise, the known or 
predicted effects of the splice site mutations are indicated. The pathologic nature of two 
conservative missense mutations (V1433I and V2050L) is questionable. The IVS38-10T→C 
variant is a splice acceptor variant that has no detrimental effect on splicing, but has been found 
in 27 of 518 STGD1 patients compared with 1 of 316 ethnically matched control 
individuals.34,35 Therefore, it is likely that the IVS38-10T→C variants observed in 5 CRD 
alleles in the patient cohort, are in linkage disequilibrium with an unidentified pathologic 
ABCA4 mutation. In 2 RP patients we identified the D2177N mutation heterozygously. The 
D2177N mutation has never been found in patients with STGD1 but was found to be associated 
with age-related macular degeneration at a statistically significant level.25 As shown by Sun 
and co-workers, this mutation, contrary to other mutations, results in increased ATP hydrolysis 
when compared to the wild type protein.52 These data do not allow us to draw a definitive 
conclusion with regard to the pathologic nature of D2177N.  
 
 
Missense 
mutation 
Nature of amino acid 
change Effect on ABCR function (ref.) 
R18W Non-conservative Unknown 
R24C Non-conservative Unknown; adjacent to 1st transmembrane domain 
G65E Non-conservative Unknown 
E161K Non-conservative Unknown 
L541P Conservative Decreased ATP-binding and ATPase activity (52) 
P597S Non-conservative Unknown 
G618E Non-conservative Unknown 
V767D Non-conservative Decreased ABCR expression (10) 
G863A Non-conservative Decreased ATPase activity (52, 53) 
R943Q Non-conservative Decreased ATPase activity (53) 
A1038V Conservative Decreased ATP-binding and ATPase activity (52) 
E1087K Non-conservative Decreased ATP-binding (52) 
V1433I Conservative Unknown 
R1640W Non-conservative Unknown 
A1794D Non-conservative Introduction charged aa in 10th transmembrane domain 
G1961E Non-conservative Decreased ATP-binding & ATPase activity (52) 
V2050L Conservative Unknown 
D2177N Non-conservative Increased ATPase activity (52) 
 
Splice site 
mutation Effect on mRNA (ref) Predicted effect on ABCR protein 
768G>T NMD (33) No protein 
IVS36+2T>C Unknown Truncation of exon 36 resulting in V1673fs? 
IVS38-10T>C No effect (34) Variant in linkage disequilibrium with unknown mutation 
IVS40+5G>A 350-bp insertion in 
~50% of mRNA (34) 
Insertion of aberrant amino acid stretch? 
 
Table 5. Functional implications of missense and splice site mutations. NMD = nonsense-mediated decay. 
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The detection of the 2588C mutation in 4 patients is an unexpected finding. This variant is 
homozygously present in 1 CRD patient and heterozygously in 3 CRD/RP patients. Based on a 
genotype-phenotype correlation model proposed by us and others, individuals carrying two 
2588C alleles would not be expected to show retinal pathology because this variant was 
deemed a mild allele.33,51 In 3 of the 2588C carrying haplotypes (in patients 15730 and 16755; 
Table 1), the 2588C and 2828A variants are not accompanied by the polymorphic variants 
4203A, 5603T and 5682C (data not shown), but might have been linked to a more severe 
mutation in the 3’ part of the gene. Also, the 2588C variant has been found in cis with an 
intragenic deletion spanning exon 14 of the ABCA4 gene in a French RP patient.4 Secondly, 
other genetic factors might have a significant effect on the phenotypic outcome of ABCA4 
mutations. This was recently demonstrated in one of two siblings with autosomal dominant 
STGD3-associated macular dystrophy; in this patient a heterozygous ABCA4 mutation 
aggravated the retinal dystrophy.54 Finally, in view of the high carrier frequency of the 2588C 
allele in the Dutch and German populations, patients 15730 and 16755, who only carry the 
2588C variant(s), might do so by chance. 
 
Phenotypic spectrum of CRD and RP patients with ABCA4 mutations 
CRD patients present with a substantial clinical heterogeneity as observed in other 
studies.7,13,16,17 This variability is expressed in the rate of visual loss, the extend of the visual 
field defects and the ophthalmoscopic appearance. Three of the 18 ABCA4-associated CRD 
patients in this study represent a subtype that initially resembles STGD1 but, contrary to the 
classic juvenile macular degeneration of Stargardt, progresses to a more widespread loss of 
cone and rod photoreceptors. Ideally, improved genotype-phenotypes correlations in the future 
would enable the early detection of STGD1 patients that are at risk for progression to this CRD 
phenotype.  
Thus far, patients with RP and ABCA4 mutations have demonstrated a remarkably 
homogeneous phenotype, characterized by severe loss of visual functions, extensive atrophy 
and early loss of ERG responses.2-4,10,12,15,17 In this study, only 1 of 5 RP patients with ABCA4 
variants (9304) demonstrates this characteristic atrophy. The RP phenotype in the remaining 
patients is moderately severe, with variable atrophy. In addition, ERG responses can often still 
be elicited. Given this clinical presentation and the fact that homozygous null mutations were 
not found in these patients, it is possible that the ABCA4 mutations did not contribute to the RP 
phenotype in some or all of these 4 patients. If, on the other hand, alterations in the ABCA4 
gene are responsible for these RP phenotypes, the phenotypic variability of ABCA4-associated 
RP is higher than assumed.  
 
ABCA4 involvement in CRD and RP patients 
Genotyping of 90 RP patients revealed heterozygous pathologic sequence variations in the 
ABCA4 gene in 5 individuals. As discussed above, only one of these 5 RP patients shows the 
ophthalmologic features seen in other RP patients with ABCA4 mutations. Taken into 
consideration the high heterozygosity frequency of ABCA4 mutations in the general population, 
these data strongly suggest that ABCA4 mutations are only a minor cause (2-5%) of arRP not 
exceeding the contribution of most other arRP genes (http://www.sph.uth.tmc.edu/Retnet).  
We also identified 27 putative pathologic ABCA4 alleles in 18 (33%) of 54 patients with 
CRD. Four additional missense mutations in 3 of these patients were identified using SSCP and 
sequence analysis. Besides the ABCA4 gene only one other gene (retinol dehydrogenase 5 - 
RDH5) and two loci (CORD8 on 1q12-q24 and CORD9 on 8p11) have been implicated in 
arCRD.36-38  If earlier data are combined with the results of this study, ABCA4 mutations are 
found in 40% of the arCRD cases (Table 6). It can be estimated that, on average, the mutation 
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detection efficiency for ABCA4 mutations is 60% (ref. 39 and references therein), suggesting 
that ABCA4 mutations will be present in approximately 67% of the patients with arCRD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6. Incidence of ABCA4 
mutations in different cohorts of 
CRD patients. 
 
 
 
 
Microarray analysis as a tool for DNA diagnostics in CRD and RP 
The analysis of the ABCA4 gene is of importance to establish the mode of disease inheritance 
in CRD families, which is associated with very different recurrence risks in the offspring of 
mutation carriers. In the future, genotyping may also be helpful to accurately predict the 
development of ABCA4-associated retinal dystrophies, especially for the subgroup of patients, 
initially diagnosed as STGD1 with subsequent progression to CRD. In addition, identification 
of patients with causal ABCA4 mutations might become very important if novel insights 
regarding ABCA4-associated pathology and treatment of Abcr-/- mice develop into therapeutic 
options for human patients. It is likely that mutation chip technology, which enables fast, 
reliable and cost-efficient mutation analysis, will play an important role in these future 
developments. 
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Background. The majority of studies on the retina-specific ATP-binding cassette 
transporter (ABCA4) gene have focussed on the molecular genetic analysis and 
comparatively few studies have described the clinical aspects of ABCA4-associated 
retinal disorders. In this study we will demonstrate the spectrum of retinal dystrophies 
associated with ABCA4 gene mutations. 
Patients and methods. Nine well-documented patients representing distinct phenotypes in 
the continuum of ABCA4-related disorders were selected. All patients received an 
extensive ophthalmologic evaluation, including kinetic perimetry, fluorescein 
angiography, and electroretinography (ERG). Mutation analysis had been performed 
previously with the genotyping microarray (ABCR400 chip) and/or single strand 
conformation polymorphism analysis in combination with direct DNA sequencing. 
Results. In all patients, at least one pathologic ABCA4 mutation was identified. Patient 
10034 represented the mild end of the phenotypic spectrum, demonstrating exudative 
age-related macular degeneration (AMD). Patient 24481 received the diagnosis of late-
onset fundus flavimaculatus (FFM), patient 15168 demonstrated the typical FFM 
phenotype, and patient 19504 had autosomal recessive Stargardt disease (STGD1). 
Patients 11302 and 7608 exhibited progression from FFM/STGD1 to cone-rod dystrophy 
(CRD). A more typical CRD phenotype was found in patients 15680 and 12608. Finally, 
the most severe ABCA4-associated phenotype was retinitis pigmentosa (RP) in patient 
11366. This phenotype was characterized by extensive atrophy with almost complete loss 
of peripheral and central retinal functions.   
Discussion. We describe 9 patients during different stages of disease progression; 
together, these patients form a continuum of ABCA4-associated phenotypes. Besides 
characteristic disorders such as FFM/STGD1, CRD and RP, intermediate phenotypes 
may be encountered. Moreover, as the disease progresses, marked differences may be 
observed between initially comparable phenotypes. In contrast, distinctly different 
phenotypes may converge to a similar final stage, characterized by extensive 
chorioretinal atrophy and very low visual functions. The identified ABCA4 mutations in 
most, but not all patients, were compatible with the resulting phenotypes, as predicted 
by the genotype-phenotype model for ABCA4-associated disorders. With the advent of 
therapeutic options, recognition by the general ophthalmologist of the various retinal 
phenotypes associated with ABCA4 mutations becomes increasingly important.  
 
 
 
Introduction 
 
Mutations in the photoreceptor-specific ATP-binding cassette transporter (ABCA4) gene are 
responsible for autosomal recessive Stargardt disease (STGD1), but have also been implicated 
in autosomal recessive forms of cone-rod dystrophy (arCRD) and retinitis pigmentosa 
(arRP).1-4 A spectrum of ABCA4-related retinal diseases has thus emerged, encompassing 
retinal dystrophies, which were previously viewed as clinically distinct disorders with no 
common genetic basis. Whereas STGD1 is considered a monogenic disorder, arRP and 
arCRD are genetically heterogeneous, which means that these retinal phenotypes may 
originate from mutations in a number of different genes. Although the contribution of ABCA4 
to the development of arRP seems modest ( 5%),5 it has been estimated that this gene is 
involved in approximately 60% of the arCRD patients.4-8 Finally, specific heterozygous 
ABCA4 mutations have been found in a statistically significant higher number of patients with 
age-related macular degeneration (AMD) when compared with control subjects.9,10 However, 
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this putative role of ABCA4 in the development of AMD has been disputed by others and 
therefore remains a topic of ongoing debate.11-14 
 The ABCA4 gene encodes an ATP-binding cassette (ABC) transport protein located at 
the rim of the photoreceptor discs. This ABCR protein is involved in the transport of all-
trans-retinal through the disc membrane.15,16 The proposed pathogenetic mechanism in 
ABCA4-associated disorders has mostly been derived from the studies of transgenic mice and 
involves the accumulation of all-trans-retinal in the photoreceptor discs due to dysfunction of 
the ABCR protein.16-18 Following shedding and phagocytosis of the photoreceptor outer 
segments by the retinal pigment epithelium (RPE), all-trans-retinal is converted to a 
substance named A2-E (N-retinylidene-N-retinylethanolamine).17,19 This bisretinoid is a 
major component of lipofuscin and will ultimately lead to destruction of the RPE cells and 
overlying photoreceptors.17,20-22 Alongside this biochemical model, comparison of the retinal 
phenotype with the underlying ABCA4 mutations has resulted in the development of a 
genotype-phenotype model that correlates the severity of the retinal disorder with the degree 
of ABCR protein dysfunction.2,3,23,24 
 Clinical observations confirm the presence of a spectrum of phenotypes, implicitly 
predicted by the inverse relation between ABCR protein function and retinal phenotype. Thus, 
different combinations of ABCA4 mutations will not only give rise to classic retinal 
dystrophies such as STGD, CRD and RP, but also to intermediate and overlapping forms. In 
this case report study we demonstrate a continuum of retinal phenotypes by discussing both 
typical and atypical ABCA4-associated retinal disorders.  
 
 
Patients and methods 
 
The charts of 9 patients from the University Medical Centre Nijmegen, representing specific 
retinal phenotypes associated with mutations in the ABCA4 gene, were collected. Following 
explanation of the nature of this genotype-phenotype correlation study, informed consent was 
obtained from all participants. In addition to the data accumulated over the years, a detailed 
ophthalmologic examination was performed, including slit lamp biomicroscopy and fundus 
examination. In addition, the size and the extent of visual field defects were assessed with 
Goldmann kinetic perimetry in all patients. Recent fluorescein angiograms were available for 
all patients to assist in the evaluation of the extension of the retinal pathology and to 
determine the level of blocking of the choroidal background fluorescence. Finally, a recent 
electroretinogram (ERG) according to International Society for Clinical Electrophysiology of 
Vision (ISCEV) protocol was obtained from all patients.25 In many cases ERGs and electro-
oculograms (EOGs) of an earlier date were available; the employed recording techniques have 
been described previously.26  
 Two mutation screening techniques were employed to detect mutations in the ABCA4 
gene. Single strand conformation polymorphism (SSCP) analysis was used in all but two 
patients. The aberrantly migrating fragments were subsequently analyzed with direct DNA 
sequencing.1,4,27,28 In patients 12608 and 24481 mutation screening was performed with a 
genotyping microarray, the ABCR400 chip.29 In patient 24481, in which we identified one 
ABCA4 mutation, we searched for additional mutations with denaturing gradient gel 
electrophoresis (L.H. Hoefsloot, unpublished data). 
Two of the patients (12608 and 15680) in this study have participated in a recent mutation 
analysis study that analyzed a large cohort of RP and CRD patients for the presence of 
ABCA4 mutations.5  
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Results 
 
Most participants in this study have been patients in our clinic for a considerable period of 
time and this is reflected by a mean follow up of more than 20 years (range 3-51 years). The 
clinical findings in the 9 patients during different stages of their retinal dystrophy are 
presented as case reports. A summary of the clinical data can be found in Table 2; the results 
of the ABCA4 mutation analysis and the functional implications of these mutations can be 
found in Tables 1 and 3, respectively.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.  Results of the 
ABCA4 mutation analysis. 
 
 
 
 
 
Case 1 – Age-related macular degeneration 
At 69 years of age, patient 10034 was referred to our hospital with an early AMD; the visual 
acuity was 0.5 in both eyes. Ophthalmic examination revealed mild lens opacities and a soft 
drusen maculopathy in both eyes (Fig. 1-A). One year later he developed a parafoveal 
choroidal neovascularisation in the right eye that was successfully treated with laser 
photocoagulation.  
 
Case 2 – Late-onset fundus flavimaculatus 
In 1995, at 60 years of age, patient 24481 noticed a mild loss of visual acuity in the left eye. 
Visual acuity was 1.0 in the right eye and 0.6 in the left eye. In 2003, the visual acuity in the 
right eye had decreased to 0.1; vision in the left eye was stable at 0.6. Ophthalmoscopy 
revealed geographic atrophic changes in the posterior pole, as well as faint pisciform yellow 
flecks that extended just beyond the vascular arcades (Fig. 1-B). The fluorescein angiogram 
demonstrated blocking of choroidal background fluorescence. Hyperfluorescent areas of 
atrophy surrounded the central macula; small hyperfluorescent dots were also present. The 
ERG was normal. 
 
Case 3 – Fundus flavimaculatus 
Patient 15168 experienced a decrease in visual acuity at the age of 15. Visual acuity was 0.6 
in both eyes but steadily decreased to 0.1 over a six-year period. Ophthalmoscopy revealed 
widespread pisciform yellow flecks characteristic for fundus flavimaculatus. Both maculae 
demonstrated a localized “beaten bronze” atrophy (Fig. 1-C). Fluorescein angiography 
demonstrated mild blocking of background fluorescence and minute hyperfluorescent dots. 
ABCA4 mutations  Case Patient 
number 
Allele 1                    Allele 2 
1 10034 G1961E  
2 24481 768G>T  
3 15168 G683A/G863;R943Q 768G>T 
4 19504 G683A/G863;R943Q IVS40+5G>A 
5 11302 768G>T  
6 7608 G683A/G863;R943Q 768G>T 
7 15680  G1961E  
8 12608 IVS38-10T>C IVS38-10T>C 
9 11366 768G>T 768G>T 
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Over the past 25 years, most of the flecks have disappeared and the macular atrophy has 
increased slightly. Recent ERG and EOG tests were not disturbed. The younger sister of 
patient 15168 also developed a retinal dystrophy. Although an identical set of ABCA4 
mutations was found in the younger sister of patient 15168, her phenotype resembled the 
more classic STGD1 phenotype with fewer and more centrally located flecks in combination 
with atrophy of the macula. The ERG of his sister also remained normal, but the light 
peak/dark trough (Lp/Dt) ratio on the EOG was 1.4 and thus abnormal.     
 
Case 4 – Stargardt disease 
At age 14, patient 19504 noticed a decrease in visual acuity. Over the years, her visual acuity 
gradually declined until vision was 0.3 in OD and 0.4 in OS at age 23. Ophthalmoscopy 
revealed mild pigmentary abnormalities in the macula, encircled by a discrete number of 
irregular yellow-white dots (Figure 1-D). A typical blocking of choroidal fluorescence was 
seen on the fluorescein angiogram, as well as confluent hyperfluorescent dots in the posterior 
pole. The ERG recordings have always remained normal, but the EOG was subnormal (Lp/Dt 
ratios of 1.6 at age 23, and 1.7 at age 32). Visual field testing showed a decreased sensitivity 
of the central retina in 1987 that did not progress significantly over the years. The visual 
acuity in 2003 (age 39) was 0.1 in OD and 0.05 in OS. Except for a minor increase in 
pigmentary abnormalities in the macula, no progression of the fundoscopic abnormalities was 
observed.    
 
Case 5 – Stargardt disease with progression to CRD (early stage) 
Patient 11302 experienced a decrease in visual acuity when she was 9 years old. An 
ophthalmologic examination demonstrated mild metamorphopsia and a moderately decreased 
visual acuity of 0.5 in both eyes. Small, yellowish flecks and minor alterations of the RPE in 
the macula were observed in both eyes (Figure 1-E). A fluorescein angiogram was made and 
showed an almost complete blocking of background fluorescence, as well as tiny 
hyperfluorescent dots, surrounding the posterior pole and extending into the midperiphery. 
These dots did not correspond with the yellowish flecks. An ERG proved impossible to 
perform because of her young age, but the EOG was severely disturbed (Lp/Dt ~1)  
At the most recent visit in 2003 (age 14), the visual acuity was 0.05 in both eyes. The 
yellowish flecks had almost disappeared and the macula showed a “beaten bronze” aspect. In 
addition, a mild attenuation of the retinal vessels was seen. Fluorescein angiography 
demonstrated numerous hyperfluorescent spots throughout the fundus, much larger in number 
when compared to the angiogram at age 9. The spots confluated in the macula and made the 
obscuration of the choroidal background fluorescence less obvious. Visual field testing 
showed decreased central sensitivity with relative central-inferior scotomas. The photopic 
ERG was nonrecordable and the scotopic ERG was decreased, demonstrating photoreceptor 
degeneration in a cone-rod pattern.  
 
Case 6 – Stargardt disease with progression to CRD (late stage) 
Patient 7608 was 20 years of age when she experienced a decrease in visual acuity. In 1960, 
at age 31, patient 7608 was referred to our clinic. The visual acuity was 0.05 in both eyes; the 
ophthalmoscopy findings were typical for STGD: numerous yellowish flecks in the central 
retina and mild atrophy in the posterior pole. Goldmann perimetry revealed relative central 
scotomas of approximately 15º. An ERG at age 38 was undisturbed, but the EOG was clearly 
abnormal (Lp/Dt ratio: 1.3). Fluorescein angiography demonstrated central hyperfluorescence 
surrounded by hyperfluorescent spots and blocking of choroidal background fluorescence.  
Over the years, progression of the retinal dystrophy was observed. The atrophic changes in 
the macula increased, whereas the yellowish flecks gradually disappeared. An ERG at age 41 
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demonstrated abnormalities in a cone-rod pattern. Gradually, a progressive, outward directed 
atrophy of the choriocapillaris, RPE and overlying neural retina developed (Figure 1-F). The 
ERG became nonrecordable for both rod and cone responses. Presently (age 75), visual acuity 
is hand movements only and visual field testing is no longer possible. 
 
Case 7 – Cone-rod dystrophy 
Patient 15680 noticed a decrease in visual acuity early in her third decade. Gradually, her 
visual acuity deteriorated to counting fingers in both eyes. The first visual field in the charts 
dates from 1994 at the age of 42. It shows a very small central island of 3º, surrounded by an 
absolute ring scotoma of approximately 60º. An ERG revealed impaired rod and cone 
photoreceptor functions in a cone-rod pattern. The EOG was severely disturbed. At the most 
recent ophthalmologic examination in 2003 (age 51), the visual acuity was hand movements 
in both eyes. Ophthalmoscopy showed a bull’s eye maculopathy. There was temporal pallor 
of the optic nerve head (Figure 1-G). Visual field testing showed central scotomas in both 
eyes; the small central islands, however, were no longer present. The ERG showed severely 
disturbed cone- and rod-mediated responses. 
 
Case 8 – Cone-rod dystrophy with extensive atrophy 
Patient 12608 first experienced a decrease in visual acuity at the age of 12 years. When he 
first visited our institute at the age of 17, his visual acuity was 0.1 in both eyes. 
Ophthalmoscopy revealed few abnormalities: a mild hyperpigmentation in the macula and 
small, atrophic lesions in the midperiphery. Strikingly, on the fluorescein angiogram 
numerous hyperfluorescent lesions were seen throughout the retina that could not be seen 
ophthalmoscopically. (Figure 1-H). In the midperiphery, where the hyperfluorescent spots 
were less dense, the angiogram also revealed blocking of the choroidal background 
fluorescence. Visual field testing revealed an absolute central scotoma of 30º and 10º in the 
right and left eye, respectively. The photopic ERG was severely disturbed and the scotopic 
ERG was subnormal. The EOG was abnormal.  
In time, the retinal dystrophy progressed and visual acuity decreased to hand movements. A 
severe atrophy developed, extending from the macula in an outward direction (Figure 1-I). 
Bone spicules pigmentations emerged in the retinal midperiphery. Besides a slow enlargement 
of the central scotomas, nasal constriction of the visual fields was observed. The ERG 
recordings deteriorated in a cone-rod pattern until responses could no longer be elicited. 
 
Case 9 – Retinitis pigmentosa 
The initial symptoms in patient 11366 were a decrease in visual acuity in combination with 
night blindness, at the age of 7. Within a year, his visual acuity dropped to 0.1. During that 
period, ophthalmoscopy showed pigmentary abnormalities in both the central and peripheral 
retina. Visual field testing in 1968 (at age 22) revealed severely constricted visual fields. In a 
recent examination, the visual acuity was reduced to hand movements in the right eye, and 
light perception in the left eye. Biomicroscopy showed circumscribed anterior polar cataracts 
in both eyes. Fundoscopic examination revealed a very pale optic disc, attenuated retinal 
vessels, widespread atrophy of posterior pole and midperiphery, and extensive bone-spicule 
pigmentations (Figure 1-J). Nummular shaped patches of atrophy, approximately 1 to 3 disc 
diameters in size, are present in the retinal periphery. The cone and rod derived ERG 
responses proved nonrecordable.  
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Table 2. Clinical characteristics of patients displaying ABCA4-associated retinal disorders. 
 
Visual 
acuity 
ERG                 Case ID Age 
(yrs) 
Sex Age of 
onset 
(yrs) 
OD OS 
Ophthalmoscopy Perimetry Fluorescein angiography 
Rod  Cone 
Phenotype  
1 10034 77 M 69 0.3 0.5 Soft drusen maculopathy. No abnormalities. 1996: mild atrophic changes 
in the macula. 1997: 
parafoveal choroidal 
neovascularisation. 
NL NL AMD 
2 24481 68 M 60 0.1 0.6 Geographic atrophic 
changes in the posterior 
pole surrounded by 
pisciform yellow flecks. 
Decreased 
sensitivity of the 
central visual 
field. 
Hyperfluorescence in the 
posterior pole surrounded 
by small hyperfluorescent 
dots. 
NL NL Late-onset 
FFM 
3 
 
15168 52 M 15 0.1 0.1 Yellow pisciform flecks in the 
posterior pole extending in 
periphery. 
Relative central 
scotomas. 
Obscuration of choroidal 
background fluorescence. 
NL NL FFM 
4 19504 40 F 14 0.1 0.05 Discrete number of yellow 
flecks surrounding the 
macula, mild atrophic 
changes. 
Relative central 
scotomas. 
Obscuration of choroidal 
background fluorescence. 
Central confluent 
hyperfluorescent spots. 
1987: NL 
1996: NL 
1987: NL 
1996: NL 
STGD1 
5 11302 16 F 10 0.05 0.05 Age 10: abnormal macular 
reflex. Yellow flecks in the 
posterior pole extending to 
the midperiphery. Age 14: 
the flecks have 
disappeared, atrophy of the 
macula. 
Central scotoma. Extreme obscuration of 
choroidal background 
fluorescence. Numerous 
hyperfluorescent spots 
extending beyond the 
vascular arcades. 
NR  STGD1 with 
progression 
to CRD 
(early stage) 
6 7608 75 F 20 HM HM Age 54: atrophy mainly in the 
posterior pole. Age 75: 
widespread atrophy 
throughout retina. 
1960: central 
scotomas of 15º  
2003: impossible 
to perform. 
Age 38: central 
hyperfluorescence 
surrounded by 
hyperfluorescent dots. 
Blocking of choroidal 
background fluorescence. 
1967: NL 
1970:  
2004: NR 
1967: NL 
1970:  
2004: NR 
STGD1 with 
progression 
to CRD  
(late stage) 
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Visual 
acuity 
ERG                 Case ID Age 
(yrs) 
Sex Age of 
onset 
(yrs) 
OD OS 
Ophthalmoscopy Perimetry Fluorescein angiography 
Rod  Cone 
Phenotype  
7 15680 52 F 20-25 HM HM Bull’s eye maculopathy, 
retinal vasculature of 
normal size. 
Very small 
central island 
(3º). Large 
absolute 
ringscotoma 
(30º). 
Hypofluorescent ring 
surrounding 
hyperfluorescent macular 
centre, hyperfluorescent 
dots in periphery. 
1994:  
2003:  
1994:  
2003:  
CRD 
8 12608 41 M 12 HM HM Age 17: Macular pigment 
alterations, atrophic spots 
in retinal periphery. Age 40: 
extensive, central and 
midperipheral atrophy, 
attenuated vessels. 
Large, absolute 
central 
scotomas of 
60º. Nasal 
constriction.  
Age 17: numerous 
hyperfluorescent spots 
throughout retina. Age 27: 
central hyperfluorescent 
area due to confluent spots.  
1980:  
1986: NR 
2003: NR 
1980: NL/ 
1986:  
2003: NR 
CRD with 
extensive 
atrophy 
9 11366 58 M 7 HM LP Extensive atrophy, irregular 
bone spicule pigmentations, 
severely attenuated 
vessels.  
Temporal rescent 
shaped islands. 
Confluent, circular areas of 
atrophy of retina and 
underlying choriocapillaris. 
NR NR RP 
 
M, male; F, female; LP, light perception; HM, hand movements; LP, light perception; AMD, age-related macular degeneration; FFM, fundus flavimaculatus; 
STGD1, autosomal recessive Stargardt disease; CRD, cone-rod dystrophy; RP, retinitis pigmentosa. ERG recordings: , decreased; , severely decreased; NL, 
normal; NR, nonrecordable. 
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Figure 1. Fundus photographs of the patients in this study. Case 1 (1-A): Age-related macular 
degeneration at age 70, superotemporal from the macula early signs of choroidal 
neovascularisation can be seen. Case 2 (1-B): late-onset fundus flavimaculatus (FFM) at age 69. 
Case 3 (1-C): FFM phenotype at age 27. Case 4 (1-D): Stargardt disease (STGD1) phenotype at 
age 27. Case 5 (1-E): FFM phenotype (age 10) which will soon progress to a CRD phenotype. 
Case 6 (1-F): Final stage of a STGD1 phenotype with progression to cone-rod dystrophy (CRD) 
at age 70. 
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Figure 1 –  (cont.).  Case 7 (1-G): typical CRD with bull’s eye maculopathy at age 51. Case 8 (1-
H): fluorescein angiogram in the early stage of CRD at age 17. Case 8 (1-I): Final stage CRD in 
the same patient as in figure 1-H at age 41. Case 9 (1-J): Retinitis pigmentosa at age 56, the hazy 
spot in the centre of the image is caused by anterior polar cataract. 
 
 
 
Discussion 
 
Various combinations of mutations in the ABCA4 gene are the underlying cause of the retinal 
dystrophies presented in this study. Case 1 (patient 10034), displaying the combination of 
AMD and a heterozygous G1961E mutation, is an exception in the sense that a causal relation 
may be disputed. The assumption that certain heterozygous ABCA4 mutations are associated 
with AMD is primarily founded on the observation that a 3- to 5-fold elevated risk of AMD 
exists for carriers of the D2177N and G1961E variants.9,10,30 This finding, however, could not 
be confirmed by smaller-sized mutation screening studies,11-14 and neither could most of the 
cosegregation studies in AMD patients and their relatives.31-34  Additional support for the 
involvement of ABCA4 in AMD can be found in the studies of transgenic mice. 
Histopathologic studies of mice carrying heterozygous ABCA4 null mutations demonstrated 
accumulation of a major lipofuscin component (A2-E) in a manner resembling the formation 
of drusen in AMD.18  
Several authors mention a subtype of fundus flavimaculatus that is characterized by a later 
age of onset, up to the age of 70.14,35,36 Case 2 (patient 24481) is an example of such a late-
G H
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onset FFM and clearly exhibits overlapping features with AMD.  The areas of geographic 
atrophy as well as the yellow lipofuscin deposits, although shaped differently than soft 
drusen, bear resemblance with the dry form of AMD.  
In the past, typical features such as yellow flecks scattered around the posterior pole 
extending out to the midperiphery and an overall milder course have been used to distinguish 
FFM from STGD1.37-39 Presently, most authors use the terms FFM and STGD 
interchangeably in view of the observed similarities in phenotype and genotype.40-42 
Moreover,  a recent study associated the presence of midperipheral flecks, especially early in 
life, with a poorer visual prognosis for patients with Stargardt disease than when disease is 
limited to the macula.43 The close relation between FFM and STGD1 is also demonstrated by 
case 3 (patient 15168) and his sister. Although this patient demonstrated typical FFM, his 
sister, carrying the same set of ABCA4 mutations, developed STGD1. 
A similar overlap in phenotypes has also been observed between STGD1 and CRD. Although 
the functional abnormalities in most STGD1 patients remain limited to the macular region, it 
has long been known that a subset of patients develop additional photoreceptors loss in the 
peripheral retina.41,44 This condition, sometimes referred to as “STGD with peripheral 
involvement”, is represented by case 5 (patient 11302) and case 6 (patient 7608). Such a 
progression may not be a rare finding; in a recent study we evaluated 18 ABCA4-associated 
CRD patients and found that 3 patients (17%) initially had received the diagnosis STGD1.5 
The final stages of this phenotype may differ dramatically from the atrophic macular scar 
usually found in older STGD1 patients. This is exemplified by the very low visual acuity, the 
severely affected visual fields and the extensive chorioretinal atrophy in case 6. This 
progression of the STGD1 phenotype in this patient, despite the normal ERG recordings at 
age 38, are not in accordance with the observation by Lois et al that STGD1 patients with an 
initial normal ERG will always preserve a normal ERG.45 This finding is an important aspect 
in counselling STGD1 patients as to their long-term prognosis. The transgression from 
FFM/STGD1 to CRD may be swift, as demonstrated by case 5. In a period of only six years, 
the yellowish flecks in this patient have virtually disappeared, an ERG at that time already 
revealed severe abnormalities in a cone-rod pattern of photoreceptor degeneration. The 
fluorescein angiogram is virtually identical with that of case 8 at the same age (Fig. 1-H). The 
numerous hyperfluorescent dots in these patients resemble the more centrally located dots 
observed in many STGD1 patients. This typical involvement of the peripheral retina on 
fluorescein angiography is found in many of our patients with ABCA4-associated retinal 
disease involving the peripheral retina. These peripheral hyperfluorescent dots were not only 
observed in the early fluorescein angiograms of cases 5 and 8, but also in cases 6 and 7, and 
may be an early indication of involvement of the peripheral retina.  
Mutations in the ABCA4 gene may also underlie more typical arCRD (CORD3) phenotypes, 
as demonstrated in case 7 (patient 15680) and, to a lesser extent, case 8 (patient 12608). In 
fact, from molecular genetic studies analyzing cohorts of arCRD patients, it can be estimated 
that ABCA4 mutations are involved in approximately 60% of the arCRD patients.4,6-8,46 
Clinical evaluation of these ABCA4-associated CRDs demonstrated a surprising diversity in 
age of onset and fundoscopic abnormalities, as well as rate and extent of progression.6,8,46 
This variability is also seen when the CRD phenotypes of case 7 and 8 are compared. 
Whereas case 7 demonstrated the typical bull’s eye maculopathy, the final stage of the retinal 
dystrophy in case 8 is characterized by extensive atrophy that resembles the ABCA4-
associated RP phenotype.  
Case 9 represents the typical arRP phenotype associated with ABCA4 mutations. To the best 
of our knowledge 16 unrelated patients with this type of RP (RP19) have been 
described.2,3,5,6,47-52 As in case 9, the majority of these patients demonstrate a highly 
progressive, severe phenotype with extreme atrophy and an early age of onset. In our 
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experience, central and peripheral pathology seem to arise almost at the same time in these 
patients.2,48,49 This would explain why some of these patients initially experience a loss of 
visual acuity, rather than night blindness. ABCA4 mutations have also been described in a 
limited number of patients with a ‘classic’ RP that features a more characteristic inward 
progression of the retinal dystrophy and limited atrophy.5,6 In our opinion, pathologic 
involvement of the ABCA4 gene in these patients remains doubtful. First, most ABCA4-
associated RP patients with early loss of visual functions and severe atrophy carry 
homozygous null (function) mutations in the ABCA4 gene, whereas in patients with ‘classic’ 
RP mostly heterozygous ABCA4 mutations have been found. In itself, this is not uncommon 
in ABCA4-associated retinal disease, but a coincidental finding can not be ruled out in view of 
the high carrier frequency of approximately 5% for ABCA4 mutations. Second, the pathologic 
ABCA4 variants identified in these ‘classic’ RP patients are commonly associated with STGD 
and not with RP, since they do not represent null mutations. And third, longstanding 
preservation of central vision with simultaneous degeneration of the retinal periphery is in 
contrast with the observed disease sequence in other patients with ABCA4-associated retinal 
dystrophies. 
 Comparison of the ABCA4 mutations with the resulting retinal dystrophy has led to the 
proposition of a genotype-phenotype model.2,3,23,24 In this model the severity of the ABCA4 
mutations is correlated with the rate and extent of photoreceptor cell death. A combination of 
mutations that results in a moderate dysfunction of the ABCR protein leads to STGD1. A 
more severe impairment of ABCR results in a CRD phenotype, whereas complete absence of 
function causes RP. This model is undoubtedly a simplified reflection of reality, and although 
mutation analysis data largely seem to concur with such a model,23,53 exceptions have been 
reported.54,55  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Functional implications of missense and splice site mutations. 
 
 
The functional consequences of the ABCA4 mutations in this study – that is, ABCR protein 
expression, ATP binding and ATPase activity – are summarized in Table 3. In 4 patients only 
one ABCA4 gene mutation was identified. Patient 10034 (case 1) with AMD carries the 
G1961E variant; the heterozygous presence of this ABCA4 sequence variation has previously 
been associated with AMD.10 Patient 24481 (case 2), with a late-onset variant of FFM, is 
heterozygous for the 768G→T mutation. This splice site mutation invariably leads to a 
nonfunctional ABCR protein.28 It is altogether possible that this patient carries a second 
unidentified ABCA4 mutation, given the fact that with the currently employed mutation 
detection techniques approximately 40% of the mutations will not be identified.28,29,31,35,55 
Others  proposed that heterozygous mutations leading to truncation of ABCR may also result 
Mutation Type of 
mutation 
Predicted effect on ABCR function  
768G>T Splice site No protein 28   
G683A/G863 Missense Decreased ATPase activity56,57 
R943Q Missense Decreased ATPase activity56 
IVS38-10T>C Splice site Variant in linkage disequilibrium with unknown 
mutation35 
IVS40+5G>A Splice site Some residual ABCR function35 
G1961E Missense Decreased ATP binding and ATPase activity57 
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in the late-onset variant of FFM.36 In patient 11302 (case 5, FFM progressing to CRD) and 
patient 15680 (case 7, CRD) only one ABCA4 mutation could be identified. 
In the remaining 5 patients two ABCA4 mutations were identified. The combinations of 
ABCA4 mutations in patients 15168 (case 3, FFM), 19504 (case 4, STGD1) and 11366 (case 
9, RP) are compatible with the resulting retinal dystrophies according to the genotype-
phenotype model. In patient 12608 (CRD), genotype-phenotype correlation is not possible 
since this patient is homozygous for IVS38-10T→C, a sequence variant that is presumed to be 
in linkage equilibrium with an unknown ABCA4 mutation.35 Patient 7608 (case 6 with STGD1 
progressing to CRD) carries the same combination of mutations as patient 15168 (case 3 with 
STGD). It is unclear why the retinal phenotype in patient 7608 is more severe than in patient 
15168. It is possible that patient 7608 carries another unidentified pathologic ABCA4 
mutation that contributes to the retinal phenotype. On the other hand, the proposed genotype-
phenotype model, though applicable in many patients, must be considered an 
oversimplification of reality. Obviously, other factors besides these ABCA4 mutations are of 
influence on the resulting phenotype. Besides the presence of undetected pathologic ABCA4 
variants, other genes and/or environmental factors may contribute to the expression of the 
ABCA4 genotype.58 Such factors may also explain the phenotypic variability that is 
sometimes encountered in patients with identical mutations, as demonstrated by patients 7608 
and 15168, as well as by patient 15168 and his sister.55   
 With very few exceptions, therapeutic options are nonexistent for patients with 
inherited retinal disorders. Insights in the underlying genetic and biochemical mechanisms in 
STGD1 and other ABCA4-associated disorders have improved our chances of developing 
rational therapeutic regimes. A therapeutic option that is currently under investigation 
involves isotretinoin (13-cis-retinoic acid, Roaccutane/Accutane), a drug used in the treatment 
of severe acne. Isotretinoin is thought to reduce all-trans-retinal levels in the discs of the rod 
outer segments.59 In transgenic mice without functional ABCR protein, treatment with 
isotretinoin was successful in suppressing the formation of A2-E.60,61 Although these results 
are encouraging, potential drawbacks related to the therapeutic effect on human ABCA4-
associated retinal disorders and the substantial side-effects of isotretinoin may exist.  
Another concern in patients with ABCA4-associated retinal disease is exposure to light. There 
are two reasons why these patients, at least on theoretical grounds, should avoid excessive 
light exposure. First, the accumulation of the toxic A2-E in the RPE ultimately depends on the 
level of all-trans-retinal that is formed by the isomerization of 11-cis-retinal following light 
exposure. This corresponds with the finding that A2-E formation was completely inhibited 
when transgenic mice without functional ABCR transport protein were raised in complete 
darkness.17 A second reason is related to evidence that mutations in the ABCA4 gene facilitate 
photooxidative damage of the retina and the RPE in several ways.62,63 
 In this study we have described 9 patients that illustrate the existence of a continuum 
of ABCA4-related phenotypes. This spectrum ranges from dystrophies primarily affecting the 
central retina, such as (late-onset) FFM, STGD1 and perhaps selected cases of AMD, to 
panretinal dystrophies like arCRD and arRP. Atypical phenotypes representing overlapping or 
intermediate forms may be encountered. Similar ABCA4-associated retinal dystrophies may 
progress quite differently during the course of the disease. On the other hand, different 
phenotypes may converge to a similar end stage, characterized by massive atrophy. Improved 
insights in the mechanisms underlying ABCA4-associated retinal dystrophies have allowed us 
to conceive and test the first rational treatment modalities in transgenic mouse models. In the 
prospect of future therapeutic approaches, early recognition of patients with ABCA4-
associated retinal disorders by the general ophthalmologist becomes increasingly important.  
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Summary 
 
 
 
In the past seven years, the ABCA4 gene has emerged as one of the most prominent genes in 
ophthalmology. Following the report in 1997 that mutations in the ABCA4 gene are the cause 
of autosomal recessive Stargardt disease, this gene was implicated in several other retinal 
disorders. Pathogenic ABCA4 mutations were found in patients with autosomal recessive 
retinitis pigmentosa and shortly thereafter in patients with autosomal recessive cone-rod 
dystrophy. Moreover, specific heterozygous alterations in this gene have been detected in a 
statistically significant higher number of patients with age-related macular degeneration 
(AMD) when compared to control groups. However, this putative role of ABCA4 in the 
development of AMD has been disputed by others and therefore remains a topic of ongoing 
debate.  
 Research has mainly been focused on three areas. The large majority of studies have 
addressed the spectrum of ABCA4 sequence variations that are involved in the associated 
disorders, including age-related macular degeneration. A second field of interest involves the 
elucidation of the pathophysiology underlying these disorders. Finally, a limited number of 
clinical studies have described the various phenotypes in ABCA4-associated retinal disease. 
 The ABCA4 gene is expressed in cone and rod photoreceptors and encodes the ABCR 
or rim protein, an ATP-binding cassette (ABC) transporter. The localisation of ABCR in the 
rim of the disc membrane in the photoreceptor outer segment suggests that this protein acts as 
a retinoid transporter. Two studies independently identified the substrate of the ABCR protein 
as all-trans-retinal or the complex of all-trans-retinal and phosphatidylethanolamine (PE), a 
substance known as N-retinylidene-PE.  
Mutation analysis studies revealed that the allelic diversity of the ABCA4 gene is very 
high. Furthermore, a substantial diversity in type and distribution has been reported between 
ethnic study populations. This makes it difficult to establish, on statistical grounds, whether a 
particular mutation is pathogenic or neutral. An alternative can be found in a functional assay 
to determine the effect of ABCA4 mutations on the functionality of ABCR as outward directed 
flippase for all-trans-retinal or N-retinylidene-PE. 
 In 1998, a genotype-phenotype correlation model for ABCA4 mutations was 
suggested. This model proposed an inverse relationship between the presumed residual ABCR 
protein function and the severity of the retinal phenotype. The combination of a mild and a 
severe ABCA4 mutation will most likely result in Stargardt disease, whereas a moderate and a 
severe mutation will cause cone-rod dystrophy. Finally, two null ABCA4 mutations will lead 
to a complete absence of functional ABCR protein and result in the retinitis pigmentosa 
phenotype. It must be kept in mind, though, that this model is a simplified reflection of reality 
and does not take into account the effects of the genetic background and/or environmental 
factors. 
 The majority of the studies aimed at elucidating the pathophysiology of human 
ABCA4-associated retinal disease used the Abcr-/- knockout mouse model. It was shown that 
ABCR dysfunction leads to increased levels of all-trans-retinal in the rod outer segment. 
Through various intermediates, all-trans-retinal is degraded into A2-E, a major component of 
lipofuscin. Following phagocytosis of the rod outer segment, this toxic compound 
accumulates in the retinal pigment epithelium (RPE). Accumulation of A2-E eventually leads 
to apoptosis of the RPE cells and subsequent death of the overlying photoreceptors. 
 These insights in the pathophysiology argue against excessive light exposure in 
patients with ABCA4-associated photoreceptor dystrophies, since light induces the formation 
of all-trans-retinal. On similar theoretical grounds, supplementation of vitamin A should be 
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discouraged. Several rational therapeutic approaches might be conceived, including the 
insertion of a functional copy of the ABCA4 gene in photoreceptor cell DNA. At present, the 
most promising option seems the reduction of A2-E formation by inhibiting 11-cis-retinol 
dehydrogenase by isotretinoin. Once a therapeutic option will become available, early 
recognition of the ABCA4 retinal phenotypes by the general ophthalmologist, as well as fast 
and reliable ABCA4 mutation screening techniques, will be crucial. 
 
The papers in this thesis, joined in the six appendices, address the clinical findings in ABCA4 
retinal dystrophies and attempt to correlate these findings with the underlying genetic 
abnormalities. In addition, the importance of ABCA4 gene mutations in autosomal recessive 
retinitis pigmentosa and cone-rod dystrophies is evaluated. 
 Appendix 1 contains the first detailed description of the clinical findings in patients 
with cone-rod dystrophy and retinitis pigmentosa caused by ABCA4 gene mutations. Both 
phenotypes were encountered in a consanguineous family. Family members carrying 
homozygous ABCA4 null function mutations develop retinitis pigmentosa. This phenotype is 
characterized by an early and virtual complete loss of visual functions, extensive retinal 
atrophy, and nonrecordable photopic and scotopic electroretinograms (ERGs). Patients 
carrying compound heterozygous ABCA4 mutations, on the other hand, develop a phenotype 
that resembles cone-rod dystrophy. The visual symptoms in these patients tend to occur later 
in life and initially affect central vision. The fundoscopic abnormalities include retinal atrophy 
and are mainly located in the posterior pole. ERG recordings, however, demonstrate rod-cone 
patterns of photoreceptor degeneration and we classified the retinal disorder in these patients 
therefore as an atypical cone-rod dystrophy.  
 A subsequent study (Appendix 2) was performed to evaluate the involvement of the 
ABCA4 gene in autosomal recessive cone-rod dystrophy. Twenty patients with autosomal 
recessive or isolated cone-rod dystrophy were analyzed for mutations in the ABCA4 gene. A 
total of 19 ABCA4 pathogenic mutations could be identified in 13 of 20 patients (65%). In 6 
patients we identified mutations in both ABCA4 alleles; in 7 patients mutations were detected 
in one allele. These results strengthened the role of ABCA4 in inherited retinal dystrophies. 
Besides its role in autosomal recessive Stargardt disease, mutations in the ABCA4 gene 
seemed responsible for the majority of the cases of autosomal recessive cone-rod dystrophy.  
 Appendix 3 describes the clinical findings in twelve patients with ABCA4-associated 
cone-rod dystrophy. A remarkable variability in the retinal phenotype was observed, despite 
the similarities in the underlying genetic cause. Although all patients met the standard criteria 
for cone-rod dystrophy, differences were observed in fundoscopic abnormalities and ERG 
recordings that could not be attributed to the stage of disease progression. This lead to the 
conclusion that detailed clinical subclassifications are difficult and may not be very useful at 
this moment, given the wide clinical spectrum of ABCA4-associated cone-rod dystrophy. 
 In Appendix 4 three families are demonstrated that harbour patients with Stargardt 
disease as well as cone-rod dystrophy or retinitis pigmentosa. The occurrence of different 
ABCA4-associated phenotypes in one family may not be as uncommon as once thought. As a 
matter of fact, the genotype-phenotype model and the relative high carrier frequency of 
disease-causing ABCA4 variants implicitly predict the occurrence of such families. Therefore, 
when the ophthalmologist encounters an ABCA4-associated dystrophy, specific inquiries 
should be made to exclude the presence of other ABCA4-associated retinal disorders in the 
family. 
 In Appendix 5 the ABCR400 microarray (gene chip) is used to estimate the 
contribution of causative ABCA4 gene mutations to autosomal recessive retinitis pigmentosa 
and cone-rod dystrophy. At least one ABCA4 sequence variant was found in 5 (5.6%) of 90 
patients with retinitis pigmentosa and in 18 (33%) of 54 cone-rod dystrophy patients. Taking 
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into account the mutation detection efficiency (about 60%), the severity of the mutations and 
the characteristics of the retinal dystrophies, it can be estimated that causative ABCA4 
mutations will be present in approximately two-third of the autosomal recessive cone-rod 
dystrophy cases and less than 5% of the cases with autosomal recessive retinitis pigmentosa. 
Furthermore, this study has demonstrated that the ABCA4 mutation chip is an efficient first 
screening tool for autosomal recessive cone-rod dystrophy. 
 Appendix 6 describes the continuum of ABCA4-associated retinal dystrophies, 
exemplified by nine well-documented patients. The mild end of the spectrum consists of 
retinal dystrophies that mainly affect the central retina, such as age-related macular 
degeneration, (late-onset) fundus flavimaculatus and Stargardt disease. These last two 
dystrophies may show progression to a panretinal dystrophy, thus demonstrating overlap with 
the cone-rod dystrophy phenotype. In patients with cone-rod dystrophy a variable amount of 
peripheral pathology may be encountered, as demonstrated by the amount of retinal atrophy 
and the full-field ERG tracings. Overlap with the retinitis pigmentosa phenotype may be 
observed in the end stage. The majority of ABCA4-associated retinitis pigmentosa patients 
demonstrate a highly progressive phenotype with extreme atrophy and an early age of onset. 
In our experience, the central and the peripheral photoreceptor pathology arise almost 
simultaneously in this type of retinitis pigmentosa. 
Thus, a spectrum of ABCA4-associated retinal disease arises that includes both typical and 
intermediate forms. With the prospect of future therapeutic approaches, early recognition of 
these phenotypes by the general ophthalmologist will become increasingly important.  
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Samenvatting 
 
 
 
In de afgelopen zeven jaar is het ABCA4 gen uitgegroeid tot één van de belangrijkste genen in 
de oogheelkunde. Na de ontdekking in 1997 dat het ABCA4 gen gemuteerd was bij de 
autosomaal recessieve vorm van de ziekte van Stargardt, bleek dat dit gen ook was betrokken 
bij andere erfelijke netvliesaandoeningen. Zowel bij patiënten met autosomaal recessieve 
retinitis pigmentosa, als bij patiënten met autosomaal recessieve kegel-staaf dystrofie werden 
pathologische ABCA4 mutaties gevonden. Bovendien werden bepaalde heterozygote mutaties 
in dit gen vaker teruggevonden bij patiënten met leeftijdsgebonden maculadegeneratie dan bij 
controle groepen. Deze veronderstelde rol van het ABCA4 gen bij leeftijdsgebonden 
maculadegeneratie wordt overigens betwist en is nog steeds onderwerp van discussie.  
 Studies op het gebied van het ABCA4 gen hebben zich voornamelijk op een drietal 
terreinen gericht. De meerderheid van de studies onderzoekt het spectrum van ABCA4 
mutaties bij de diverse geassocieerde aandoeningen, met inbegrip van leeftijdsgebonden 
maculadegeneratie. Een ander deel van de studies tracht de pathofysiologie van deze 
aandoeningen te ontrafelen. Een relatief gering aantal studies, ten slotte, brengt de klinische 
verschijnselen van ABCA4-gerelateerde aandoeningen in kaart.  
 Het ABCA4 gen komt tot expressie in kegeltjes en staafjes en codeert het ABCR eiwit. 
Dit is een transporteiwit dat behoort tot de groep van “ATP-binding cassette (ABC) transport” 
eiwitten. De lokalisatie van ABCR in de rand van het membraanschijfje in het buitensegment 
van staafjes suggereert een rol in het transport van retinoïden. Twee studies kwamen 
onafhankelijk van elkaar tot de conclusie dat hetzij all-trans-retinal, hetzij het complex dat 
all-trans-retinal vormt met fosfatidylethanolamine (PE), N-retinylideen-PE, het substraat is 
van het ABCR transport eiwit.  
 Bij het ABCA4 gen worden zeer veel verschillende allelen gevonden. Bovendien 
bestaan er aanzienlijke verschillen in type en distributie van de diverse allelen tussen de 
etnische onderzoekspopulaties. Dit maakt het moeilijk om, op statistische gronden, vast te 
stellen of bepaalde ABCA4 varianten pathologisch zijn dan wel neutraal. Een alternatief is een 
functionele test op de gevolgen van specifieke ABCA4 mutaties op de transportfunctie van het 
ABCR eiwit.  
 In 1998 werd een genotype-fenotype model voor ABCA4 mutaties voorgesteld. Dit 
model veronderstelt een rechtstreekse relatie tussen het functieverlies van het ABCR eiwit en 
de ernst van de retinale aandoening. Eenvoudig gesteld leidt de combinatie van een milde en 
ernstige mutatie meestal tot het Stargardt fenotype, terwijl de combinatie van een matige en 
ernstige mutatie kegel-staaf dystrofie veroorzaakt. De combinatie van twee ernstige (nul) 
mutaties in het ABCA4 gen leidt ten slotte tot retinitis pigmentosa. Hierbij moet aangetekend 
worden dat dit model een vereenvoudigde weergave van de werkelijkheid is en bijvoorbeeld 
geen rekening houdt met de invloed van andere modificerende genen en omgevingsfactoren.  
 De meeste studies die de pathofysiologie van ABCA4-gerelateerde aandoeningen 
onderzochten, deden dit met behulp van het Abcr-/- transgene muis model. Zoals verwacht, 
bleek dysfunctie van het ABCR eiwit te leiden tot een verhoogde concentratie all-trans-retinal 
in het buitensegment van het staafje. All-trans-retinal wordt vervolgens in diverse stappen 
afgebroken tot A2-E, een belangrijke component van lipofuscine. Na fagocytose van het 
buitensegment accumuleert deze toxische stof in het retinaal pigment epitheel (RPE). 
Uiteindelijk veroorzaakt de accumulatie van A2-E apoptosis van de RPE cel, gevolgd door 
dood van de er boven gelegen fotoreceptor cellen.  
 Met de aldus verkregen inzichten lijkt het zinvol patiënten met ABCA4-gerelateerde 
netvliesaandoeningen te adviseren om blootstelling aan overmatig licht te vermijden. De 
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vorming van all-trans-retinal is immers afhankelijk van licht. Om dezelfde reden zouden 
voedingssupplementen met vitamine A moeten worden afgeraden. 
Er kunnen diverse therapeutische opties worden bedacht voor deze aandoeningen, waaronder 
de insertie van een functionerend ABCA4 gen in het DNA van de fotoreceptor cel. Op dit 
moment lijkt de meest levensvatbare optie de remming van A2-E accumulatie door de 
inhibitie van 11-cis-retinol dehydrogenase met isotretinoïne. Wanneer een dergelijke therapie 
ter beschikking komt, zullen vroegtijdige herkenning van de ABCA4-gerelateerde fenotypes 
door de algemene oogarts, evenals snelle en betrouwbare ABCA4 mutatie screening 
technieken een cruciale rol spelen. 
 
De artikelen in dit proefschrift, samengebracht in de zes appendices, hebben grotendeels 
betrekking op de klinische bevindingen bij ABCA4-gerelateerde netvliesaandoeningen en de 
correlatie hiervan met de onderliggende genetische afwijkingen. Daarnaast wordt een 
schatting gemaakt van het aandeel van ABCA4 mutaties bij autosomaal recessieve vormen van 
retinitis pigmentosa en kegel-staaf dystrofie.  
 Appendix 1 bevat de eerste gedetailleerde beschrijving van de klinische afwijkingen 
bij patiënten met ABCA4-gerelateerde kegel-staaf dystrofie en retinitis pigmentosa. Beide 
netvliesaandoeningen werden aangetroffen in een consanguine familie. Patiënten die 
homozygoot waren voor een nul (functie) ABCA4 mutatie ontwikkelden retinitis pigmentosa. 
Dit fenotype werd gekenmerkt door vroegtijdig verlies van centrale en perifere visuele 
functies, uitgebreide retinale atrofie en een vlak fotopisch en scotopisch elektroretinogram 
(ERG). Patiënten met verschillende mutaties in beide ABCA4 allelen (samengesteld 
heterozygoot) ontwikkelden echter een beeld dat het meest leek op kegel-staaf dystrofie. De 
klachten ontstonden bij deze patiënten over het algemeen op wat latere leeftijd en bestonden 
vooral uit een daling van de gezichtsscherpte. De fundoscopische afwijkingen, waaronder een 
uitgesproken retinale atrofie, waren voornamelijk gelokaliseerd in de achterpool. Het 
scotopisch ERG was vreemd genoeg ernstiger gestoord dan het fotopisch ERG, om deze 
reden werden deze patiënten geclassificeerd als een atypische kegel-staaf dystrofie. 
 In een vervolgstudie (Appendix 2) werd de rol van het ABCA4 gen in kegel-staaf 
dystrofie onderzocht. Twintig patiënten met autosomaal recessieve of geïsoleerde kegel-staaf 
dystrofie werden bekeken op mutaties in het ABCA4 gen. In totaal werden 19 ABCA4 mutaties 
gevonden bij 13 van de 20 patiënten (65%). Bij 6 patiënten bevonden zich ABCA4 mutaties in 
beide allelen; bij 7 patiënten kon een mutatie in één van beide allelen worden vastgesteld. 
Deze bevindingen versterken de rol van ABCA4 gen mutaties op het gebied van de erfelijke 
netvliesaandoeningen. Naast de rol van het ABCA4 gen bij de autosomaal recessieve ziekte 
van Stargardt, blijken mutaties in dit gen ook verantwoordelijk voor het merendeel van de 
gevallen van autosomaal recessieve kegel-staaf dystrofie. 
 Appendix 3 gaat in op de klinische bevindingen bij twaalf patiënten met een ABCA4-
gerelateerde kegel-staaf dystrofie. Al deze patiënten voldeden aan de standaard criteria voor 
kegel-staaf dystrofie. Ondanks het overeenkomstig genetisch defect waren er aanzienlijke 
verschillen in de fundus afwijkingen en de ERG afleidingen die niet toegeschreven konden 
worden aan het stadium van de aandoening. Een gedetailleerde klinische subclassificatie is 
daarom lastig bij deze aandoening en lijkt, gezien de aanzienlijke klinische verschillen, op dit 
moment niet zinvol. 
 In Appendix 4 worden drie families beschreven waarin zowel patiënten met de ziekte 
van Stargardt voorkomen als patiënten met kegel-staaf dystrofie of retinitis pigmentosa. Dit 
verschijnsel, waarbij meerdere ABCA4-gerelateerde fenotypes voorkomen binnen één familie, 
is wellicht niet zo ongewoon als lang werd aangenomen. Feitelijk kan het bestaan van 
dergelijke families al worden voorspeld uit het genotype-fenotype model en de relatief hoge 
dragerfrequentie van pathologische ABCA4 mutaties. Het is daarom van belang dat, wanneer 
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een oogarts een ABCA4-gerelateerde aandoening diagnosticeert, hij informeert naar het 
voorkomen van dergelijke aandoeningen bij andere leden van de familie. 
 In Appendix 5 wordt de ABCR400 microarray (gen chip) gebruikt om het aandeel 
oorzakelijke ABCA4 mutaties te bepalen bij patiënten met autosomaal recessieve kegel-staaf 
dystrofie en retinitis pigmentosa. Tenminste één ABCA4 mutatie werd gevonden bij 5 van de 
90 (5.6%) patiënten met retinitis pigmentosa en bij 18 van de 54 (33%) patiënten met kegel-
staaf dystrofie. Dit betekent dat mutaties in het ABCA4 gen verantwoordelijk zijn voor 
tweederde van de gevallen van autosomaal recessieve kegel-staaf dystrofie en minder dan 5% 
van de autosomaal recessieve retinitis pigmentosa gevallen. Bij deze schatting wordt rekening 
gehouden met de efficiëntie van de gebruikte mutatie detectietechnieken (ongeveer 60%), het 
type van de mutatie en de kenmerken van het retinale fenotype. 
Tevens toont deze studie aan dat met de ABCA4 gen chip een efficiënte eerste mutatie 
screening bij autosomaal recessieve kegel-staaf dystrofie mogelijk is.  
 Appendix 6 beschrijft het continuüm van ABCA4-gerelateerde netvliesaandoeningen 
aan de hand van negen uitvoerig gedocumenteerde patiënten. Aan de milde kant van dit 
spectrum worden retinale dystrofieën gevonden die vooral het centrale netvlies treffen, zoals 
leeftijdsgebonden maculadegeneratie, (laat optredende) fundus flavimaculatus en de ziekte 
van Stargardt. Deze laatste twee netvliesaandoeningen kunnen zich ook uitbreiden naar de 
perifere retina, en vertonen dan een overlap met kegel-staaf dystrofie. Pathologie van de 
perifere retina wordt in wisselende mate gevonden bij ABCA4-gerelateerde kegel-staaf 
dystrofie, zoals blijkt uit de mate van retinale atrofie en de Ganzfeld ERG afleidingen. In het 
eindstadium wordt soms overlap met het retinitis pigmentosa fenotype gevonden. De 
meerderheid van de ABCA4-gerelateerde retinitis pigmentosa patiënten vertonen al op vroege 
leeftijd een zeer ernstig, progressief fenotype met uitgebreide atrofie van de retina. Onze 
ervaring is dat de centrale en de perifere fotoreceptor pathologie vrijwel gelijktijdig ontstaan 
bij deze vorm van retinitis pigmentosa. 
Zo blijkt er dus een spectrum van ABCA4-gerelateerde netvliesaandoeningen te bestaan dat 
niet alleen typische maar ook intermediaire vormen bevat. Met het uitzicht op therapeutische 
opties voor deze groep patiënten, wordt vroegtijdige herkenning van deze beelden door de 
algemene oogarts steeds belangrijker. 
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Woord van dank 
  
 
 
Vaak leest men in het dankwoord van een proefschrift dat het schrijven van een proefschrift 
een eenzaam gebeuren is, ver van familie en vrienden. En zo is het ook. Met mijn voorliefde 
voor dramatiek en mijn aangeboren gevoel voor zelfmedelijden heb ik de tijd van mijn leven 
gehad. Toch valt niet te ontkennen dat zonder de hulp van mijn omgeving geen artikel de 
drukpers zou hebben gehaald. Ook zou ik niet hebben geweten hoe men het woord 
“polimorfisme” spelt, en is het niet ondenkbaar dat ik op dit moment, krabbend aan een 
verluisde baard, daklozenkrantjes stond te venten voor het centraal station. Om deze en vele 
andere redenen wil ik iedereen, mijn co-auteurs op de eerste plaats, bedanken die heeft 
meegeholpen aan de totstandkoming van dit proefschrift.  
Een aantal mensen wil ik bij naam noemen. Frans Cremers was mijn goeroe op moleculair 
genetisch gebied en zijn geest is dan ook alom aanwezig in dit werk. Ik heb zijn 
ondersteuning buitengewoon gewaardeerd: vanaf de eerste opzet tot aan het verplaatsen van 
de laatste komma (pagina 64, regel 40). Ook August Deutman was onmisbaar voor dit 
proefschrift. Samen met Fred Pinckers (†) heeft hij een patiëntenbestand opgebouwd dat van 
onschatbare waarde blijft voor het ophthalmogenetisch onderzoek in Nijmegen. Carel Hoyng 
wil ik bedanken voor zijn ideeën, zijn enthousiasme en het eindeloos aandragen van nieuwe 
patiënten en families. Tevens moet ik hem mijn excuses aanbieden voor mijn opmerking van 
vele jaren geleden dat het zoeken naar genen geen enkel praktisch doel dient. Alessandra 
Maugeri was ook een grote steun in de moleculaire genetica en bovendien onvermoeibaar in 
haar speurtocht naar nieuwe mutaties in het uitgestrekte ABCA4 gen.  
Farida was onmisbaar vanwege haar fraaie structuurformules, baka bana’s, wetenschappelijke 
adviezen, visballetjes en haar liefdevolle ondersteuning in het algemeen. Bir wordt bedankt 
voor zijn filosofische begeleiding.  
Ten slotte wil ik een grotendeels anonieme, maar zeer belangrijke groep bedanken: de 
patiënten en familieleden, zonder wiens medewerking we geen stap verder zouden zijn 
gekomen.  
Ik hoop dat ik degenen die dit dankwoord uitsluitend doorlazen om vast te stellen of ze 
werden genoemd, niet heb teleurgesteld. Indien iemand er niet in voorkomt, is dat niet omdat 
ik hem of haar bewust heb weggelaten, maar omdat een woord van dank ergens moet 
eindigen. 
 
 
 
 
 
 
